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1 Summary 
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by a 
progressive loss of dopaminergic neurons in the substantia nigra pars compacta. The 
etiology of sporadic PD remains poorly understood, however the recent identification of 
causative gene mutations responsible for monogenic familial variants of PD has 
provided significant new insights into the molecular mechanisms underlying the 
neuronal degeneration. So far, six genes have been associated with monogenic familial 
variants of PD, such as α-synuclein and LRRK2 for autosomal dominant PD and 
parkin, PINK1, DJ-1 and ATP13A2 for autosomal recessive PD. The parkin gene 
(PARK2) seems to play a prominent role, accounting for the majority of autosomal 
recessive PD. The modular structure of parkin suggests that it acts as a RING-type E3 
ubiquitin ligase. 
Endoplasmic reticulum (ER) stress has been implicated in the pathogenesis of 
PD. In this study I show that parkin plays an important role in the cellular ER stress 
response. Under ER stress parkin is significantly up-regulated on the mRNA and 
protein level due to the binding of the unfolded protein response (UPR)-specific 
transcription factor, ATF4, to a cis-acting element within the parkin promoter region. 
Interestingly, another transcription factor, c-Jun, can bind to the same regulatory 
region, but acts as a transcriptional repressor of parkin gene expression. Moreover, 
increased expression of parkin protects cells against ER stress-induced cell death, 
while cells lacking endogenous parkin are highly vulnerable to an imbalance in ER 
homeostasis. Interestingly, we could show that the protective activity of parkin is 
independent of the proteasome, indicating that parkin mediates non-degradative 
ubiquitylation. Moreover, we could provide evidence that the protective activity of parkin 
is associated with the regulation of cell survival/death pathways, like the JNK or the 
NF-κB pathway. The latter one is activated by parkin-mediated non-degradative 
ubiquitylation. In addition, parkin is able to suppress mitochondrial dysfunction and 
damage induced by ER stress, indicating an important role for parkin in the 
interorganellar crosstalk between the ER and mitochondria to promote cell survival 
under stress. 
In the second part of my thesis I studied the transcriptional regulation of PD-
associated genes under stress conditions playing a role in the pathogenesis of PD, such 
as mitochondrial stress, ER stress and oxidative stress. This study revealed that parkin 
is transcriptionally up-regulated in response to all stress conditions tested, while the 
other genes only were responsive to ER stress, emphasising the significance of ER 
stress in the pathogenesis of PD. 
  Introduction 
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2 Introduction 
 
2.1 PARKISON’S DISEASE 
Idiopathic Parkinson’s Disease (PD) is the most common movement disorder 
and the second most common neurodegenerative disorder after Alzheimer’s disease 
(AD). In 2005, the number of people suffering from PD worldwide was estimated 
between 4,1 and 4,6 million with the tendency to be doubled in 2030 (Dorsey et al., 
2007). The disease is characterized by the progressive loss of dopaminergic (DA) 
neurons in the substantia nigra pars compacta (SNpc), and the subsequent lack of 
dopamine in the corpus striatum, responsible for the major PD motor symptoms. The 
symptoms of the disease can be ameliorated by medication, but medication cannot 
cure the disease. To develop more effective treatments, it is necessary to shed light on 
the complex and virtually unexplored molecular basis of the disease. Research on 
genetic cases of PD can increase the understanding of the molecular mechanism 
behind the symptoms of PD and may serve as a future basis for the development of 
drugs which could delay, or even halt the disease’s progression. 
 
2.1.1 History 
In 1817, the clinical symptoms of Parkinson’s disease (PD) were first described 
by the British physician James Parkinson in his script: “An Essay on the Shaking Palsy” 
(Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: First description of Parkinson’s Disease written by James Parkinson, 1817. On the 
left: James Parkinson (1755-1824) (source: http://www.parkinsonsinjury.info); on the right: title 
page of his monograph “An Essay on the Shaking Palsy” from 1817 (source:  
www.pdmdcenter.com). 
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He systematically characterized the medical history of six individuals and 
concludes his work with following disease symptoms: “Involuntary tremulous motion, 
with lessened muscular power, in parts not in action and even when supported; with a 
propensity to bend the trunk forwards, and to pass from a walking to a running pace: 
the senses and intellect being uninjured”. With this he had already described the 
cardinal symptoms of Parkinson’s disease: tremor, akinesis and postural instability. 
Rigor, another cardinal symptom of PD was described 67 years later, by the French 
neurologist Jean-Martin Charcot. Charcot also recognized the disease as a uniform 
assembly of symptoms and named it after the man who had first documented it, James 
Parkinson. The discovery of pathological changes in the brain took place more than a 
century later. The starting point of this was the work of the Swedish scientist Arvid 
Carlsson, who discovered dopamine as a neurotransmitter in the mammalian brain. 
Neurons in the SNpc were then found to be lost in PD patients resulting in the 
consecutive lack of dopamine in the corpus striatum, which is believed to induce the 
classical clinical motor deficits seen in PD patients (Ehringer and Hornykiewicz, 1960; 
Sourkes and Poirier, 1965). It was this discovery that lead to the first effective medical 
treatment of the disease. In 1967 the drug levodopa (L-3,4-dihydroxyphenylalanine, L-
DOPA), the precursor of dopamine, entered clinical practice and the first large study 
reporting improvements in patients with PD resulting from treatment with L-DOPA was 
published in 1968. Although the discovery of L-DOPA revolutionized the treatment of 
PD, and it certainly diminishes PD symptoms neither this, nor any other medication 
available at present is able to halt or retard dopaminergic neuron degeneration.  
 
2.1.2 Neuropathological characteristics 
The neuropathological hallmark of PD is the widely selective degeneration of 
dopaminergic neurons in the SN and the loss of projections to the corpus striatum 
putamen. The striatal dopaminergic nerve terminals are suggested to be the primary 
target of the degenerative process and the neuronal cell death is the following 
consequence (Bernheimer et al., 1973). Dopaminergic neurons contain conspicuous 
amounts of the dark-brown pigment neuromelanin (Marsden, 1983), a catabolism 
product of dopamine. The loss of these neurons results in depigmentation of the SN, 
which can be observed in the post mortem brains of PD patients (Fig. 2).  
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To understand the possible therapeutic treatments of PD, it is useful to pay 
attention to the neuropathological changes in the basal ganglia circuits. The loss of 
nigrostriatal projections in the striatum produces an imbalance within both the direct 
pathway (striatum to the Globus pallidus internus, GPi) as well as the indirect pathway 
(striatum to the GPi via GP externus and Subthalamic nucleus), leading to a reduced 
activation of the direct pathway and a reduced inactivation of the indirect pathway. The 
balance between these circuits allows smooth coordinated movement behaviour. The 
net-effect of the non-equilibrium present in PD is an increased inhibitory output activity 
of the GPi neurons to the thalamus, resulting in reduced motor cortex activity and 
clinically in a reduced regulation of movements.  
Apart from the degeneration of dopaminergic neurons in the SN, neuronal cell 
death occurs also in the noradrenergic (locus coeruleus), serotonergic (raphe nucleus), 
and cholinergic (nucleus basalis of Meynert, dorsal motor nucleus of vagus) systems of 
the brain as well as in the cerebral cortex, olfactory bulb and autonomic nervous 
systems (Dauer and Przedborski, 2003; Forno, 1996).  
Another pathological feature of sporadic and some familial PD forms (detailed 
explanation in chapter “Familial forms of PD and their genetics”) is the occurrence of 
intraneuronal, cytoplasmatic, eosinophilic inclusions, so called Lewy bodies, and 
dystrophic neuritis, so called Lewy neurites, present in the remaining intact nigral 
Fig. 2: Schematic representation of the nigrostriatal projections. (A) Normal nigrostriatal 
pathway between the SNpc and the putamen/caudate nucleus (solid red line). The photograph 
demonstrates the normal pigmentation of the SNpc due to the production of neuromelanin 
within the dopaminergic neurons. (B) Degenerated nigrostriatal pathway in PD. The loss of 
dopaminergic neurons that project to the putamen is more severe (dashed red line) than the 
loss of dopaminergic neurons that project to the caudate (thin red solid line). The photograph 
demonstrates depigmentation of the SNpc due to the marked loss of dopaminergic neurons. 
From (Dauer and Przedborski, 2003). 
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neurons (Dickson et al., 1991). Lewy bodies are composed of numerous proteins, for 
example neurofilaments, ubiquitin, α-synuclein, molecular chaperones and parkin 
(Forno, 1996; Spillantini et al., 1998; Spillantini et al., 1997). Immunohistochemical 
staining reveals an organized structure with a dense round core surrounded by a clear 
halo with a diameter of about 15 µm (Fig. 3) (Pappolla, 1986). Nevertheless, Lewy 
bodies are not specific for PD and also other diseases exhibit Lewy-body pathology 
such as dementia with Lewy bodies (DLB) or multiple system atrophy (MSA). These 
diseases are collectively termed “α-synucleinopathies” (Duda et al., 2000). The role of 
Lewy bodies and Lewy neurites in the pathogenesis of PD is widely controversial.  
 
 
 
 
 
 
 
 
 
 
 
2.1.3 Symptoms and therapeutic approaches 
Although the age of onset of the cardinal symptoms of PD does vary across 
patients and can occur prior to the age of 40 in early-onset PD, most cases generally 
occur in patients over 55 years. Prevalence of PD increases from approximately 1%-
2% of those over age 60 to about 4% of those over age 80 (de Lau and Breteler, 2006). 
The disease prevalence rises markedly with age and will expand due to the expected 
increased average life-expectancy of the population, giving PD more and more 
relevance in an aging society. 
 The major clinical PD symptoms are resting tremor, muscle rigidity, slowness or 
absence of voluntary movements without paralysis (bradykinesia, akinesia), postural 
instability, paucity of normal facial expression (hypomimia), decreased voice volume 
(hypophonia), drooling (failure to swallow without thinking about it), decreased size and 
speed of handwriting (micrographia), decreased stride length and freezing (inability to 
begin a voluntary movement) (Hughes et al., 1991; Lang, 1998; Lang and Lozano, 
1998). Olfactory and autonomic nervous system dysfunction (Herting et al., 2008), 
adverse effects in the visual system (Bodis-Wollner, 1990), psychological symptoms 
like depression, slowness of cognitive processes and also dementia typically develop 
Fig. 3: Immunohistochemical staining of Lewy bodies in a SNpc dopaminergic neuron. 
Left panel: Immunostaining against α-synuclein; right panel: Immunostaining against ubiquitin. 
From (Dauer and Przedborski, 2003). 
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as the disease progresses and often become a major cause of disability (Aarsland et 
al., 1996; Cummings, 1992). The non-nigral lesions are considered to account for the 
main cognitive aspects of PD. A growing number of clinical results speak for an 
etiologically heterogenic syndrome rather than a homogenous disease. When the first 
cardinal symptoms of the disease appear, 50-60% of DA neurons in SNpc have 
already been lost and the dopamine release in the striatum has been reduced by more 
than 80%, indicating that the brain is able to compensate deficits in the nigro-striatal 
dopaminergic system for quite a long time. 
 For diagnosis of the disease the brain of PD patients can be examined by 
imaging methods such as by a positron emission tomography (PET) scan. During such 
a scan the uptake of [18F]-Fluoro-L-Dopa by the presynaptic dopaminergic terminals is 
monitored. The uptake differs between a normal individual and an individual suffering 
from PD (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The therapeutic approaches mainly focus on compensating the lack of 
dopamine and the consequent imbalance of neurotransmitters. The basis of therapy is 
the prescription of L-DOPA, the precursor of dopamine, as dopamine is not able to 
pass the blood-brain barrier. L-DOPA is taken up into the central nervous system and 
is converted into dopamine in dopaminergic neurons by the DA (dopamine) 
decarboxylase. In addition to L-DOPA, an inhibitor of peripheral DA decarboxylase, e.g. 
carbidopa is administered, which increases the L-DOPA concentrations that reach the 
brain, decreases the dosage, which is needed and inhibits the premature degradation 
of L-DOPA (Fig. 5). Further, dopaminergic agonists can be used to directly stimulate 
dopamine receptors. Another possibility of treatment is the inhibition of the dopamine 
Fig. 4: Comparison of PET (positron emission tomography) scans from a normal 
individual with one from a PD patient, demonstrating the massive dopaminergic neuron 
loss that occurs in PD. Left: Control brain of a healthy individual has a normal uptake of 18F-
DOPA into the striatum. Right: Brain of a PD patient shows a reduced uptake of 18F-DOPA. 
From G. Leger and A. Dagher, Montreal Neurological Institute, Mc Gill University.  
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catabolism: The monoamine oxidase B (MAO-B) inhibitor prevents the conversion of 
dopamine to DOPAC (3,4-Dihydroxyphenyl acetic acid). It is mostly used to treat mild 
symptoms of PD. The catechol-O-methyl-transferase (COMT) inhibitor reduces the 
dopamine methylation to 3-methoxytyramine. MAO-B and COMT inhibitors can also be 
prescribed in combination with L-DOPA, to prolong the action of dopamine. 
Anticholinergics are only given in some tremor cases, as they cause severe side 
effects. Medical surgery by introducing microelectrodes in specific regions of the basal 
ganglia (deep brain stimulation) is mainly carried out in patients who cannot be treated 
conventionally. All available treatments are merely ameliorating the symptoms of PD, 
however they are not able to modify the disease process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Current pharmacologic therapies for PD and their potential sites of action on the 
central nervous system. Red: site of drug action. COMT: Catechol-O-methyl-transferase; 
MAO-B: Monoamine oxidase-B. (Adapted from parkinsonsdiseasecme.com/cme-
modules/neuroprotection-parkinsons-disease/introduction.html.) 
 
 
 
) 
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2.1.4 Etiology 
No familiar accumulation can be observed in about 80% of the PD cases. As 
the reason for the loss of dopaminergic neurons is broadly unclear, they are referred to 
as idiopathic or sporadic PD cases. About 10% of the cases are familiar forms of the 
disease with autosomal dominant or recessive inheritance. The remainder (10% of 
cases) are associated with the symptomatic Parkinson syndrome also known as 
secondary Parkinson syndrome. This inhomogenous group of disorders can have 
multiple possible causes, for example drug- or toxin-induced parkinsonism, 
inflammation, metabolic dysfunctions, tumours, ischemia or traumata (Dauer and 
Przedborski, 2003). Further, atypical parkinsonism can also occur in other 
neurodegenerative diseases such as dementia with Lewy bodies (DLB), progressive 
supranuclear palsy (PSP), MSA and corticobasal degeneration (CBD) (Fig. 6). 
For the majority of individuals with sporadic PD the cause of the disease 
remains unclear. Aging seems to be the major risk factor. The difference in the age of 
onset may relate to the combination of risk factors underlying an individual’s particular 
disease, a combination of environmental influences and genetic predisposition is 
suggested. An example for an environmental toxin induced destruction of dopaminergic 
neurons is the accidental intoxication of young drug addicts with MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine), resulting in the development of a syndrome nearly 
identical to PD (Langston et al., 1983). Human epidemiological studies revealed an 
elevated risk of developing PD symptoms for people who live in rural environments and 
have exposure to herbicides and pesticides (Tanner, 1992). Examples of herbicides 
and pesticides, which are under suspicion of inducing PD, are paraquat and rotenone, 
both shown to inhibit like MPTP complex I of the mitochondrial respiratory chain. Also 
endogenous toxins are suspected to be responsible for PD neurodegeneration. 
Inherited differences or environmental toxins might distort the normal metabolism, 
creating toxic substances; e.g. the normal dopamine metabolism, which generates 
reactive oxygen species (ROS) (Cohen, 1984). Thirteen different loci are described for 
familial forms of PD, showing all a mendelian pattern of inheritance.  
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2.2 FAMILIAL FORMS OF PD AND THEIR GENETICS 
The identification of genes responsible for the rare familial forms of PD 
dramatically improved our understanding of the molecular mechanisms underlying the 
pathogenesis of PD. Since 1997, linkage data has identified at least 13 loci associated 
with PD. Currently the genes are known for 8 of them (Table 1). Their discovery 
opened new and exciting research opportunities to track the molecular pathways 
involved in the disease pathophysiology and provided new opportunities to generate 
cell culture or animal models for the disease. The typical and extremely consistent 
phenotype of both sporadic and hereditary PD suggests a common molecular 
mechanism for the disease (Thomas and Beal, 2007). Consequently, new insights into 
the pathomechanism of idiopathic PD will also facilitate a better understanding of 
sporadic PD and will help to develop novel therapies for this common and so far 
incurable neurodegenerative disorder. In the following some PD-associated genes will 
be described in detail.  
 
 
 
 
Fig. 6: Etiology of Parkinson’s Disease. MSA: multiple systems atropy; DLB: dementia with 
Lewy bodies; PSP: progressive supranuclear palsy. 
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gene 
locus 
map position gene product Inheritance 
pattern 
putative 
function 
A. Loci and genes implicated in PD with conclusive evidence from genome-wide 
linkage screens 
PARK1/4 4q21-q23/4p15 
(duplication/triplications) 
α-synuclein 
(SCNA) 
AD vesicle trafficking 
/ synaptic 
plasticity 
PARK2 6q25-q27 parkin AR E3 ubiquitin 
ligase 
PARK6 1p36-p35 PINK1 AR mitochondrial 
kinase 
PARK7 1p36 DJ-1 AR cytosolic redox- 
sensitive protein 
PARK8 12p11-q13 LRRK2 AD MAPKK kinase 
PARK9 1p36 ATP13A2 AR lysosomal 
ATPase 
B. Further loci identified in genome-wide linkage screens 
PARK3 2p13 unknown (SPR?) AD  
PARK10 1p32 unknown unclear  
PARK11 
 
2q36-q37 unknown 
(GIGYF2?) 
unclear  
PARK12 Xq unknown unclear  
C. Genes proposed to be implicated in PD etiology in studies adapting a 
candidate-gene approach 
PARK5 4p14 UCHL1 AD? ubiquitin 
carboxy-terminal 
hydrolase 
PARK13 2p12 HtrA2/omi unclear mitochondrial 
protease 
 
Table 1: Catalogue of genes and loci for parkinsonism. AR: autosomal recessive; AD: 
autosomal dominant; PINK1: phosphatase and tensin (PTEN)-induced kinase 1; LRRK2: 
leucine-rich repeat kinase 2; SPR: sepiapterin reductase; GIGYF2: GBR10 interacting GYF 
protein-2; HtrA2/omi: high temperature requiring protein A 2/omi (Bonifati, 2007; Gasser, 2009). 
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2.2.1 Autosomal-dominant genes 
2.2.1.1 α-synuclein (PARK1 and PARK4) 
α-Synuclein (SCNA) was the first gene to be described in the context of familial 
PD (Polymeropoulos et al., 1997). An autosomal dominant mutation (A53T) was found 
in the α-synuclein gene of a small number of Greek/Italian families. Up to the present 
two more dominant mutations have been identified: A30P and E46K (Kruger et al., 
1998; Zarranz et al., 2004). Subsequently, a genomic duplication or triplication at the α-
synuclein locus, resulting in an increase of the gene dosage was also reported to 
cause autosomal dominant PD (Farrer et al., 2004; Singleton et al., 2003). The natively 
unfolded relatively small (140 aa) α-synuclein protein contains three regions: First, an 
N-terminal region taking up a α-helical confirmation after binding to membranes, and 
characterized by repetitive imperfect repeats (Davidson et al., 1998; Eliezer et al., 
2001), second, a central hydrophobic NAC-domain (non-amyloid component of 
plaques) responsible for the aggregation potential of α-synuclein (Bodles and Irvine, 
2004; Giasson et al., 2001), and third an acidic C-terminal region, containing several 
phosphorylation sides and being able to give the protein a chaperone like activity 
(Okochi et al., 2000; Park et al., 2002). Normally, α-synuclein is an abundant soluble 
neuronal cytoplasmic protein, predominantly localized to pre-synaptic terminals in close 
association with synaptic vesicles (Maroteaux et al., 1988). The function of α-synuclein 
is not well understood, but its localization to synaptic membranes implicates a role in 
the regulation of vesicle dynamics and neuronal plasticity (Abeliovich et al., 2000; 
Sidhu et al., 2004). Interestingly, α-synuclein is known to be a major constituent of 
Lewy bodies (LBs), therefore providing the most obvious link between sporadic and 
familial PD (Spillantini et al., 1997). In vitro the α-synuclein protein tends to aggregate 
in a concentration-dependent manner to form fibrils similar to those observed in LBs 
(Conway et al., 2000; Serpell et al., 2000). Moreover, for the pathogenic mutations an 
increased propensity to self-assembly and fibrillization was described (Greenbaum et 
al., 2005). Further, the genomic multiplication of the α-synuclein loci, and the resulting 
enhanced expression of α-synuclein, fosters insoluble α-synuclein aggregation (Miller 
et al., 2004). In addition, α-synuclein protofibrils were shown in vitro to build up ring-like 
structures able to permeabilize vesicles by acting like pores (Volles and Lansbury, 
2003). These findings point to the ongoing debate, whether the oligomeric 
intermediates, the protofibrils, or the fibrils (formed later in the aggregation process) are 
the toxic species for the cell. Studies of PD patient-derived brain tissue demonstrated 
an increased phosphorylation of α-synuclein at serine 129 in the C-terminal domain in 
LBs (Anderson et al., 2006; Okochi et al., 2000). However, this posttranslational 
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modification was recently shown to reduce the α-synuclein induced toxicity (Gorbatyuk 
et al., 2008), further demonstrating the controversy in the field. 
 
2.2.1.2 LRRK2 (PARK8) 
Leucine-rich repeat kinase 2 (LRRK2), also named Dardarin, was recently 
discovered to play a role in the context of PD (Funayama et al., 2002; Paisan-Ruiz et 
al., 2005; Zimprich et al., 2004). The LRRK2 gene is a very large protein with a 
molecular mass of 285 kDa. It consists of multiple domains: an N-terminal ankyrin 
domain, a leucin-rich repeat, a GTPase/ROC (ras of complex proteins) domain, a COR 
(C-terminal of ROC domain), a kinase domain and a WD40 domain (Taylor et al., 
2006). LRRK2 mutations are the most common cause of familial PD, typically 
associated with late onset. Until now there are about twenty known mutations, with the 
G2019S located in the kinase domain being the most frequent one. Mutations in the 
kinase domain and also in other domains appear to increase the kinase activity, which 
suggests a toxic gain of function mechanism (Brice, 2005; West et al., 2007). However, 
mutations in the LRRK2 gene give rise to diverse, widespread neuropathological 
features and the physiological function of LRRK2 is still unclear.  
 
2.2.2 Autosomal-recessive genes 
2.2.2.1 Parkin (PARK2) 
Parkin was the first identified recessive gene involved in PD. In 1998, Kitada 
and colleagues described mutations in the parkin gene as the cause of recessive PD 
with juvenile onset in a Japanese family (Kitada et al., 1998). A broad spectrum of 
parkin mutations have since been described, accounting for the majority of autosomal 
recessive Parkinsonism and pointing to a prominent role among the other PD-
associated genes. For a detailed description of parkin see section “Parkin-associated 
Parkinson’s Disease”. 
 
2.2.2.2 PINK1 (PARK6) 
In 2004, PTEN (phosphatase and tensin)-induced kinase 1 (PINK1) mutations 
were found to be associated with PARK6 autosomal recessive PD in a large Sicilian 
family (Valente et al., 2004). PINK1 is a 581 amino acid protein and contains a 
mitochondrial-targeting motif at the N-terminus, and there is evidence that PINK1 is 
targeted to mitochondria (Beilina et al., 2005; Silvestri et al., 2005; Valente et al., 
2004). In addition, PINK1 contains a conserved serine/threonine kinase domain. The 
kinase activity was shown by autophosphorylation in vitro (Beilina et al., 2005; Silvestri 
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et al., 2005), and additionally for two putative substrates, TRAP1 (TNFR-associated 
protein 1; Hsp75), a mitochondrial localized chaperone (Pridgeon et al., 2007) and 
HtrA2/omi in vivo (Plun-Favreau et al., 2007). Increased PINK1 expression in neurons 
protects from oxidative and proteasomal stress and staurosporine induced apoptosis 
(Haque et al., 2008; Petit et al., 2005; Valente et al., 2004), whereas loss of PINK1 
function increases the vulnerability of the cell for stress (Deng et al., 2005a; Wood-
Kaczmar et al., 2008). Recently, published data from Drosophila and cell culture 
demonstrate a major function of PINK1 in maintaining mitochondrial integrity and 
dynamics (Clark et al., 2006; Exner et al., 2007; Gandhi et al., 2009; Gegg et al., 2009; 
Marongiu et al., 2009; Morais et al., 2009; Park et al., 2006; Poole et al., 2008). 
Evidence exists that parkin is functionally linked to PINK1 and that they act in a 
common cellular pathway with PINK1 upstream of parkin (Clark et al., 2006; Exner et 
al., 2007; Lutz et al., 2009; Yang et al., 2006a).  
To date, approximately 20 pathogenic mutations, mainly missense and 
nonsense mutations, but also whole gene deletions have been described (Marongiu et 
al., 2007). PINK1 mutations are the second most frequent cause for autosomal 
recessive, early onset parkinsonism (Bonifati, 2007). Most pathogenic mutations occur 
in the kinase domain of PINK1, and were shown to affect its activity, essential for the 
neuroprotective potential of PINK1. Yet no neuropathological data from patients with 
PINK1 mutations have been reported.  
 
2.2.2.3 DJ-1 (PARK7) 
Mutations in the DJ-1 gene are the least common among the known cases of 
early onset autosomal recessive parkinsonism (Bonifati et al., 2003). The first 
mutations identified were a deletion mutant (exon 1-5) in a Dutch family and a 
missense mutation (L166P) in an Italian family, indicating that the loss of DJ-1 function 
can cause parkinsonism (Bonifati et al., 2004). The DJ-1 gene encodes a ubiquitously 
expressed 189 amino acids protein found to be localized in the cytoplasma and 
nucleus as well as within mitochondria (Junn et al., 2009; Zhang et al., 2005). It was 
first identified as an oncogene (Nagakubo et al., 1997), and diverse cellular functions 
have been attributed to it. The most commonly held view might implicate a role in the 
response to oxidative stress. In several cell culture and animal models DJ-1 was shown 
to be protective against oxidative stress-induced cell death (Canet-Aviles et al., 2004; 
Kim et al., 2005; Yokota et al., 2003). The mechanism behind this protective effect is 
still unclear. DJ-1 could have intrinsic chaperone-like activity as structural studies 
demonstrated similarities with the bacterial chaperone Hsp13 (Lee et al., 2003; 
Shendelman et al., 2004) and/or serve as an antioxidant and/or a stress sensor for 
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oxidative stress, since it can be oxidized at the cysteine residue C106 (Canet-Aviles et 
al., 2004; Mitsumoto et al., 2001). Notably, this residue was demonstrated to be 
essential for the protective activity of DJ-1 (Taira et al., 2004; Waak et al., 2009; Yokota 
et al., 2003) Additionally, DJ-1 could have an impact on stress-signalling pathways: 
The pro-apoptotic ASK (apoptotic signal-regulating kinase1)-pathway was inhibited and 
the anti-apoptotic Akt-pathway was shown to be activated by DJ-1 (Gorner et al., 2007; 
Junn et al., 2005; Yang et al., 2005). Of note, DJ-1 does not seem to be part of the 
PINK1/parkin-pathway as it was not able to compensate for mitochondrial alterations in 
parkin or PINK1 deficient cells (Exner et al., 2007; Yang et al., 2008).  
Some evidence exists that the inactivation of DJ-1 can also lead to 
Parkinsonism. Extensive oxidation was shown to damage DJ-1 (Zhou et al., 2006), 
supported by the finding of oxidatively damaged DJ-1 in brains of sporadic PD patients 
(Choi et al., 2006). Further, the pathogenic L166P mutant impairs the functional dimer 
formation of DJ-1, leading to a very unstable protein, which is rapidly degraded by the 
proteasome (Miller et al., 2003; Olzmann et al., 2004). 
 
2.2.2.4 HtrA2/omi (PARK13) 
Mutations in the high temperature requirement protein A2 (HtrA2/omi) encoding 
gene were implicated with PD etiology. In PD patients a heterozygous mutation 
(G399S) and a polymorphismn (A141S) of HtrA2/omi were proposed to be responsible 
for PD pathology (Bogaerts et al., 2008; Strauss et al., 2005). However, the genetic 
proof of pathogenicity is still lacking as the linkage evidence from large families is 
missing (Bonifati, 2007; Gasser, 2009). However, loss-of-function mice show 
neurodegeneration with a parkinsonian phenotype (Jones et al., 2003; Martins et al., 
2004).  
HtrA2/omi is a mitochondrially located serine protease and is assumed to play 
an important role in apoptosis. Upon apoptotic stimuli it is released from the 
mitochondrial intermembrane space into the cytosol where it interacts with IAPs 
(inhibitor of apoptosis proteins), thus inducing caspase activity, and also mediating 
caspase- independent death through its own protease activity. However, its functional 
role may be context-dependent as HtrA2/omi mutations result in a defective activation 
of their protease activity, which leads to mitochondrial dysfunction and increased 
susceptibility to apoptosis (Hegde et al., 2002; Martins et al., 2002). On the contrary, 
phosphomimetic HtrA2/omi mutants showed an increase in protease activity and 
enhanced the protection capacity of the cell for rotenone -or 6-OHDA-induced stress, 
presuming a neuroprotective function for HtrA2/omi. Furthermore, HtrA2/omi was 
shown to interact with PINK1, which phosphorylates HtrA2/omi on serine 142 in 
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dependency of p38 (Plun-Favreau et al., 2007). It seems therefore likely that HtrA2/omi 
functions in a similar manner to that of its bacterial homologues DegP and DegS, which 
are involved in transducing stress response signals and protection against cell stress 
(Clausen et al., 2002; Schlieker et al., 2004).  
 
 
2.3 PATHOGENESIS OF PD AND ITS ASSOCIATED CELLULAR PROCESSES 
The molecular mechanisms responsible for the degeneration of dopaminergic 
neurons remain very difficult to pinpoint. However, the findings from familiar forms of 
PD coupled with those from toxin-induced PD models implies a multifactorial cascade 
of deleterious factors for the pathogenesis of PD. In this cascade mitochondrial 
dysfunction, accumulation of oxidative stress, protein aggregation, impairment of the 
ubiquitin-proteasome system (UPS), increased ER stress, and activation of stress 
kinase signalling pathways are involved. These aspects are described in detail below.  
 
2.3.1 Mitochondrial dysfunction and oxidative stress 
Mitochondrial dysfunction has long been implicated in PD pathogenesis. The 
primary function of mitochondria is the generation of cellular energy in the form of ATP 
by oxidative phosphorylation. In addition, they play a role in metabolism of e.g. amino 
acids and lipids, as well as calcium homeostasis, signalling pathways and apoptosis.  
The mitochondrial electron transport chain is composed of five multi-subunit 
complexes. Electrons are fed from NADH (derived from the Krebs cycle) to complex-I 
in the electron transport chain and transported via ubiquinone (coenzyme Q) to 
complex-III (FADH2 directly transfers its electrons to ubiquinone). From there the 
electrons are transferred to cytochrome C and passed to complex-IV. The transport of 
electrons down the respiratory chain produces energy, which is used to pump protons 
across the inner mitochondrial membrane by the complex-I, -III and -IV, thus creating a 
proton and electrochemical gradient. This gradient forms the basis for the mitochondrial 
membrane potential and is used by complex-V to drive ATP synthesis by reducing 
oxygen to water. However, 2% of electrons passing through the electron transport 
chain, mostly at complex-I and complex-III, react with molecular oxygen to superoxide 
anion (O2-) (Beal, 2003), which is the precursor of most other reactive oxygen species 
(ROS) (Turrens, 2003), such as the highly reactive hydroxyl radicals (⋅OH) or the stable 
molecular oxidant hydrogen peroxide (H2O2). These reactive species can be 
inactivated by a network of antioxidative systems, consisting of glutathione (GSH), and 
glutathione peroxidases, catalases and superoxide dismutases (SOD). A very delicate 
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equilibrium exists between the formation and the elimination of ROS and a disturbance 
can have disastrous effects for the cell. Increased formation of ROS or the defective 
removal can lead to oxidative damage of proteins, DNA and lipids (Raha and 
Robinson, 2000). The damage can also affect mitochondrial constituents such as the 
mtDNA or components of the mitochondrial electron transport chain, in particular 
because of their proximity to ROS production. In turn, the damage of the electron 
transport chain again increases oxidative stress producing a vicious cycle. As time 
goes on oxidative alterations accumulate, resulting in further mitochondrial dysfunction 
and finally to cell death, pointing to the fact that increasing age is the most consistent 
risk factor for sporadic PD (Wallace, 2005).  
A possible reason why in particular dopaminergic neurons are affected in PD is 
their exposure to high oxidative stress levels due to their dopamine metabolism. 
Dopamine is degraded enzymatically by monoaminoxidase (MAO) or catechol-O-
methyl-transferase (COMT) or non-enzymatically by autooxidation. The degradation by 
MAO or COMT results besides the formation of the desaminated metabolites 3,4-
dihydroxyphenyl acetic acid (DOPAC), homovanillic acid (HVA) and 3-methoxytyramine 
(3-MT) also in reactive hydrogen peroxide (H2O2) (Maker et al., 1981) (Fig. 7). The 
autooxidation of dopamine leads to the production of toxic quinones and semi-
quinones, able to damage proteins with their cysteine residues (Stokes et al., 1999). 
Further, also the production of neuromelanine by oxidative polymerisation of dopamine 
leads to the release of free radical species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Enzymatic degradation of dopamine. (source: http://en.wikipedia.org/wiki/dopamine) 
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Several studies support the hypothesis that mitochondrial dysfunction, 
increased ROS production and oxidative stress at least contribute to dopaminergic cell 
death in the SN. Concretely, post-mortem brain analysis of PD patients showed a 
strong reduction of complex-I activity in the SNpc (Schapira et al., 1990). Low activity of 
complex-I leads to an energy deficit for the cell, while oxidative stress is increased 
(Chan et al., 1991). Furthermore, the SN of patients showed an increase in oxidative 
modifications of lipids, proteins and DNA (Dexter et al., 1989; Giasson et al., 2000; 
Jenner, 2003; Zhang et al., 1999), as well as reduced amounts of the antioxidative 
GSH (Sian et al., 1994) and increased ROS. Animal models support the thesis of a 
dysfunction of mitochondria in PD. Thus the treatment of mice or primates with 
mitochondrial complex-I inhibitor MPTP results in a specific loss of dopaminergic 
neurons, and PD-like pathology (Bloem et al., 1990; Dauer and Przedborski, 2003). 
Additional, also the fish poison rotenone and the herbicide paraquat, were shown in 
animal models to reduce complex-I activity (Betarbet et al., 2000; Brooks et al., 1999; 
McCormack et al., 2002; Sherer et al., 2003). Conclusively, mitochondrial dysfunction 
and oxidative stress play a major role in the pathogenesis of PD, whether they are the 
cause or the consequence is still unclear.  
It is notable that ROS are not always harmful or toxic for the cell and increasing 
evidence shows that they are also important as signalling molecules for the regulation 
of diverse cellular pathways such as the JNK (c-Jun N-terminal-kinase) pathway and 
the NF-κB (nuclear factor kappa enhancer binding protein) pathway (Shen and Liu, 
2006; Yoon et al., 2002).  
 
2.3.2 Mitochondria-induced apoptosis 
Besides ATP production, mitochondria are important regulators of Ca2+ 
signalling. Mitochondria respond actively and sensitively to a local increase of Ca2+ 
concentration by a transient and massive uptake of the ion into the organelle (Rizzuto 
et al., 1999). This uptake can affect various cellular processes ranging from the 
induction of mitochondrial ATP production, regulation of subcellular processes by Ca2+-
dependent enzymes, control of mitochondrial movement but also the induction of 
apoptosis. Specially, for the latter case mitochondria play an integral role. The trigger 
for apoptosis can be mitochondrial complex inhibition, increased ROS production or 
misfolded proteins for example (Bredesen et al., 2006). Apoptosis is executed via two 
main pathways. Firstly, the death receptor (or extrinsic) pathway, which is initiated by 
the activation of cell-surface death receptors, for example Fas, and secondly, the 
mitochondrial (or intrinsic) pathway characterized by the release of mitochondrial pro-
apoptotic factors. The permeabilization of the outer mitochondrial membrane plays a 
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key role in this process. This effect can occur via two mechanisms: the first one 
involves the opening of the mitochondrial permeability transition pore and the second 
one is dependent on the inactivation or activation of Bcl-2 (B-cell leukaemia/lymphoma 
2) family members, being anti- (like Bcl-2 and Bcl-xL) or pro-apoptotic (like Bid (BH3-
interacting domain death agonist), Bax (Bcl-2 associated X protein) and Bak (Bcl-2 
antagonist/killer), respectively. Upon permeabilization of the mitochondrial membrane, 
several intermembrane space proteins are released, such as cytochrome c, apoptosis 
inducing factor (AIF), endonuclease G, HtrA2/omi and second mitochondria-derived 
activator of caspases  (Smac). Cytochrome c release leads to the formation of the 
protein complex known as the apoptosome, together with apoptosis protease-activating 
factor 1 (Apaf1) and procaspase 9 (pro cysteine-aspartic protease 9). The formation of 
the complex results in the activation of caspase 9, which then triggers the activation of 
caspase 3 and other caspases in an amplification cascade, ultimately causing cell 
death. Inhibitors of apoptosis (IAPs) are able to halt activated caspases, however, they 
are deactivated by Smacs and HtrA2/omi. The two proteins AIF and endonuclease G 
translocate to the nucleus and induce chromatin condensation and DNA fragmentation 
independent of caspase activation (Fig. 8).  
 The JNK pathway is also implicated in the execution of apoptosis in response to 
different stress stimuli by catalyzing the phosphorylation of anti- and pro-apoptotic Bcl-
2 family members (Davis, 2000; Schroeter et al., 2003) (see Fig. 11). 
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2.3.3 Protein aggregation and dysfunction of the ubiquitin proteasome system 
 Protein aggregates are characteristic for many age-related neurodegenerative 
diseases. It is uncertain whether the presence of these aggregates per se, or a loss of 
normal protein function due to the sequestering is associated with their toxicity. 
However, new studies suggest that it is not the aggregates themselves that are toxic, 
but the oligomeric intermediates (e.g. α-synuclein, Aβ, poly-Q-huntingtin), associated 
with them. Moreover, aggregates may also occur as a result of attempts by neurons to 
protect themselves from toxic proteins, indicating a protective potential for the cell, 
rather than a toxic one (Ciechanover and Brundin, 2003). In PD protein aggregates 
occur as cytosolic Lewy-bodies (see also the section “Neuropathological 
characteristics” of PD).  
 One reason for an accumulation of proteins to aggregates could be their 
impaired degradation. Normally, short-lived, mislocalized, misfolded, mutated or 
damaged proteins are degraded by the ubiquitin-proteasome system (UPS) (Sherman 
and Goldberg, 2001). This degradational process is a highly complex and tightly 
regulated multistep mechanism, catalyzed by several specific enzymes (Ciechanover 
and Brundin, 2003). In a first step the protein to be degraded is tagged covalently by a 
ubiquitin chain to be recognized by the proteasome. This process is catalysed by three 
enzymatic steps: (1) formation of an ATP-dependent thioester bond between the C-
terminus of ubiquitin and a reactive cysteine of the activating enzyme E1; (2) transfer of 
the activated ubiquitin to a cysteine residue of a ubiquitin-carrier enzyme E2; and (3) 
attachment of ubiquitin to a target protein through an isopeptide bond between a C-
terminal glycine of ubiquitin and a specific ε-amino group of a lysine residue within the 
Fig. 8: Extrinsic and intrinsic pathways of apoptosis. The extrinsic pathway is mediated by 
cell-surface death receptors. Following interaction with death receptor ligand, the cytoplasmic 
death domains of death receptors undergo trimerization and recruit a set of adaptor proteins 
and initiator caspases (caspase-8 and -10), forming a death-inducing signalling complex 
(DISC). Initiator caspases are activated by homodimerization and when released from the DISC 
into the cytoplasm they cleave effector pro-caspases to generate active effector caspases 
(caspase-3, -6, -7), which cleave a large number of cytoplasmic and nuclear substrates to 
induce morphological and biochemical features of apoptosis. The intrinsic pathway is dependent 
on the mitochondrial permeability transition pore and inactivation or activation of anti- or 
proapoptotic Bcl2 family members (e.g. Bcl2 (B-cell leukaemia/lymphoma) or Bcl2-XL). Upon 
induction of apoptosis the outer mitochondrial membrane is permeabilized and several 
intermembrane space proteins are released. Cytochrom c (cyto c), Apaf1 (apoptosis protease 
factor 1), and pro-caspase 9 form a complex, which leads to the activation of caspase 9 and to 
the generation of active effector caspases. IAPs (inhibitor of apoptosis) inhibit activated 
caspases, however they are deactivated by Smac (second mitochondria-derived activator of 
transcription) and HtrA2/omi (high temperature requiring enzyme A2). AIF (apoptosis inducing 
factor) and Endo G (endonuclease G) translocate to the nucleus and induce chromatin 
condensation and DNA fragmentation independent of caspase activation. Ca2+ plays a major 
role for the induction of apoptosis. Modified from (Gupta et al., 2006). 
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Fig. 9: Ubiquitylation of proteins. 1. Formation of an ATP-dependent thioester bond between 
the C-terminus of ubiquitin and a reactive cysteine of E1 (ubiquitin-activating enzyme), 2. 
Transfer of the ubiquitin to a cysteine residue of E2 (ubiquitin-conjugating enzyme), 3. 
Formation of an isopeptide bond between a C-terminal glycine of ubiquitin and the ε-amino 
group of a lysine residue within the substrate in the presence of E3 (ubiquitin ligase). Ub: 
ubiquitin. Modified from (Winklhofer, 2006). 
substrate in the presence of an E3 ubiquitin-protein ligase. Target specificity is dictated 
by the functional interaction between the E2/E3 complex and its substrate (Fig. 9). 
 Three E3 ubiquitin ligase families have been identified: RING (Really Interesting 
New Gene), U-box E3s and HECT (homologous to the E6-AP C-terminus) E3s. The 
first two facilitate conjugation by acting as bridging factors, whereas the latter directly 
catalyzes the final attachment of ubiquitin to the substrate, by first forming a thiol ester 
intermediate with ubiquitin. In multiple rounds additional ubiquitin moieties may then be 
attached to the first ubiquitin, leading to the generation of polyubiquitin chains. The 76 
amino acid residue protein ubiquitin contains seven lysine residues that in principle can 
all engage in the formation of polyubiquitin chains. Typically, ubiquitin linkage via Lys48 
(K48) targets a protein for proteasomal degradation (at least four ubiquitin molecules 
must be attached) (Hershko and Ciechanover, 1998; Hershko et al., 2000), whereas 
the linkage via K63 is implicated in various regulatory processes, such as endocytosis, 
autophagy, protein trafficking, DNA-repair or signal transduction (Hicke, 2001; Pickart, 
2001; Pickart and Fushman, 2004). Additionally, a substrate can be monoubiquitylated 
at one or several lysine residues, also leading to the regulation of different cellular 
processes including endocytosis, membrane trafficking, histone regulation and DNA 
repair. 
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The 26S proteasome is a large multiprotein complex, consisting of two 
subcomplexes, one barrel-like 20S catalytic core, and two 19S regulatory cap 
structures binding on each side of the 20S core openings. The 20S core contains four 
stacked rings creating a central pore. The inner two rings consist of β-subunits 
comprising of proteolytic activity located at the interior surface of the pore to degrade 
the entered polypeptides. The outer two rings are built up of α-subunits, which gate the 
polypeptides for the entry into the pore. The 19S complex recognizes the polyubiquitin 
chains of the substrates, regulates their unfolding and deubiquitylation, and thereby 
initiates their degradation. The degradational products are small peptides (4-9 amino 
acids), which are further hydrolyzed by cellular peptidases to their amino acids 
(Baumeister et al., 1998). The ubiquitin chains are decomposed by ubiquitin carboxy 
terminal hydrolases (like UCH-L1) into ubiquitin monomers (Healy et al., 2004). 
It is speculated that an impairment of the UPS is implicated in the pathogenesis 
of PD. In fact, several familiar forms of PD are thought to be associated with the UPS: 
On the one hand parkin and UCH-L1 are components of the system, which interfere 
with the processes that normally recognize or process misfolded proteins. On the other 
hand modified or/and mutated α-synuclein and DJ-1 are targets of the UPS, which 
induce abnormal and possibly toxic protein conformations, able to disrupt proteasomal 
function (Chen et al., 2006; Miller et al., 2003; Petrucelli et al., 2002; Shimura et al., 
2001; Stefanis et al., 2001; Tanaka et al., 2001). Also in the sporadic form of PD, 
indication for a role for the UPS in the pathogenesis of the disease is given. A reduced 
level and activity of a proteasomal subunit was observed in the SNpc of PD patients, 
suggesting that components of the UPS may be sequestered into aggregates 
(McNaught et al., 2003; McNaught et al., 2002). On the other hand protein aggregates 
were shown to directly block the UPS (Bence et al., 2001). In addition, experiments 
with toxin-induced animal models also showed an involvement of the UPS. MPTP 
infusion in mice was shown to interfere with proteasomal function (Fornai et al., 2005) 
and an in vitro model showed that rotenone impaired the proteasome (Betarbet et al., 
2006; Wang et al., 2006). Further, treatment of rats with a proteasomal inhibitor 
resulted in a progressive loss of dopaminergic neurons, α-synuclein-positive 
aggregates and development of PD-like symptoms, however subsequent studies failed 
to reproduce this effect (McNaught and Olanow, 2006; McNaught et al., 2004).  
Presumably, the ability of the cell to cope with oxidative stress decreases with 
aging. Oxidative stress leads to decreased mitochondrial activity, resulting in energy 
deficiency for the ATP-dependent proteasomal degradation. In addition, the function of 
the heat shock proteins Hsp70 and Hsp40 is ATP-dependent. Oxidised proteins 
accumulate, provoking a vicious cycle by increasing ROS production and damage of 
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the mitochondria. The fact that the capability of the cell to handle misfolded proteins 
also decreases with age enhances the toxic result (Abou-Sleiman et al., 2006; Sullivan 
et al., 2004). 
 
2.3.4 Endoplasmic Reticulum (ER) stress  
A second reason for increased accumulation of aggregated proteins in PD 
patient brain could be a dysfunction of the folding machinery. Unfolded proteins are 
characterized by a high number of hydrophobic surface patches, making them prone to 
interaction and aggregation with other unfolded proteins in the crowded environment of 
the cell (Stevens and Argon, 1999). To circumvent this interaction and to ensure 
correct folding of the proteins, molecular chaperones promote productive protein 
folding by preferentially interacting with hydrophobic surface patches on unfolded 
proteins. In the Endoplasmic Reticulum (ER) protein folding is even more complex, as 
post-translational modifications of nascent polypeptide chains e.g. N-linked 
glycosylation and formation of disulfide bonds, additionally take place. Besides the 
capability of the cell to extract properly folded proteins from the ER it is also essential 
for a functional protein folding machinery that slowly folding or incompletly folding 
polypeptide chains are also extracted and targeted for proteolytic degradation, a 
process called ER-associated protein degradation (ERAD) (Ellgaard and Helenius, 
2003). A balance between the influx of newly synthezised, completely unfolded 
polypeptide chains into the ER, and the sum of the effluxes of correctly folded proteins 
to the Golgi complex and unfolded proteins targeted for degradation, is necessary to 
ensure homeostasis of protein folding in the ER. Various different insults lead to the 
disruption of this sensitive homeostasis such as glucose/energy deprivation, ischemia, 
redox changes, viral infections, perturbations in calcium homeostasis, elevated 
secretory protein synthesis, altered glycosylation, and mutations that impair correct 
protein folding (Kaufman et al., 2002). Alteration in ER homeostasis consequently 
disrupts protein folding and leads to the accumulation of unfolded proteins and protein 
aggregates, resulting in ER stress. As a consequence, the cell has evolved various 
protective strategies, collectively termed the unfolded protein response (UPR). This 
coordinated adaptive response regulates the expression of numerous genes, which 
lead to a reduction in the protein load into the ER and up-regulates the protein folding 
and degradation pathways of the cell. However, if these mechanisms fail to restore 
normal ER homeostasis, signalling switches from pro-survival to pro-apoptotic.  
 
The UPR is mediated through three ER transmembrane receptors: double-
stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK), activating 
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transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1). In unstressed 
cells, all three ER stress receptors remain inactive through their binding to the ER 
chaperone BiP (binding immunoglobulin protein; also named GRP78 [glucose related 
protein 78]). Upon accumulation of unfolded proteins in the ER, BiP dissociates from 
the three receptors resulting in their activation. The activation occurs sequentially, with 
PERK being the first, rapidly followed by ATF6, with IRE1 being activated last.  
When BiP binding to PERK is disrupted, PERK homodimerizes and 
phosphorylates itself on its threonine kinase domain, thereby generating an active 
kinase. Activated PERK phosphorylates the eukaryotic initiation factor 2α (eIF2α) at 
Ser51, which inhibits the guanine exchange factor eIF2B that normally recycles eIF2α 
to its active, GTP-bound from. Lower levels of active eIF2α result in lower levels of 
translation initiation, globally reducing new protein synthesis, thereby decreasing the 
load of nascent proteins arriving at the ER. However, this attenuation of translation is 
not absolute; genes carrying certain regulatory sequences in their 5’-untranslated 
regions are only translated under these conditions, among them activating transcription 
factor 4 (ATF4) (Lu et al., 2004). ATF4 translocates to the nucleus and induces the 
transcription of genes regulating amino acid metabolism, redox reactions, stress 
response and protein secretion (Harding et al., 2003). However, pro-apoptotic genes 
are also induced, such as the transcription factor C/EBP homologous protein (CHOP). 
Notably, also several other signalling pathways unrelated to ER stress are triggered by 
amino-acid starvation, double-stranded RNA accumulation or haem depletion converge 
on eIF2α phosphorylation and activate a common set of target genes.  
Dissociation of BiP from ATF6 leads to ATF6’s translocation to the Golgi 
apparatus, where it is proteolytically cleaved by site-1 and site-2 proteases, resulting in 
an active transcription factor (Ye et al., 2000). ATF6 mainly regulates the expression of 
ER chaperones and XBP-1 (x-box binding protein-1).  
After the dissociation of BiP, IRE1, like PERK, homodimerizes and 
autophosphorylates itself. Activated IRE1 cleaves the mRNA of XBP-1 with its 
endoribonuclease domain to remove a 26 nucleotide intron, generating a translational 
frameshift. The frameshift in the XBP-1 mRNA leads to the translation of an active 
stable transcription factor. XBP-1 has several targets, including ER chaperones, 
proteins involved in protein degradation and p58IPK, which provides a negative feed 
back loop to PERK (Fig. 10).  
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 In case too excessive and/or prolonged ER stress occurs, pro-apoptotic 
pathways are activated. Among these downstream pro-apoptotic proteins are JNK and 
CHOP. Both JNK, activated by the IRE1-TRAF2-ASK1 branch of the UPR (Nishitoh et 
al., 2002; Urano et al., 2002; Urano et al., 2000) and CHOP, transcriptionally regulated 
by ATF4, are able to suppress the anti-apoptotic effect of Bcl-2. CHOP blocks the 
expression of Bcl-2 (Matsumoto et al., 1996; McCullough et al., 2001), whereas JNK 
phosphorylates it. Additionally, JNK can phosphorylate the pro-apoptotic protein Bim, 
leading to its release from its inhibitory association with the cytoskeleton and to its 
activation (Lei and Davis, 2003). Altogether, these alterations lead to the activation of 
Bax and Bak, resulting in caspase activation and ultimately to cell death. Furthermore, 
caspases (caspase-12) were reported to be directly activated at the ER membrane 
through interaction with IRE1 and TRAF2 (Nakagawa et al., 2000; Rao et al., 2002; 
Szegezdi et al., 2003; Yoneda et al., 2001). However, caspase-12 is only expressed in 
Fig. 10: The unfolded protein response. Upon aggregation of unfolded proteins, BiP (binding 
immunoglobulin protein) translocates from the three ER stress receptors, PERK (PKR-like ER 
kinase), ATF6 (activating transcription factor 6), IRE1 (inositol requiring enzyme 1) allowing their 
activation. Upon translocation of BiP PERK dimerizes and autophosphorylates itself, leading to 
its activation. Activated PERK phosphorylats eIF2α (eucaryotic initiation factor 2), resulting in a 
general protein synthesis block. However, ATF4 (activating transcription factor 4) is only 
translated in case of phosphorylated eIF2α. Translated ATF4 transclocates to the nucleus and 
induces the transcription of genes for example to restore ER homeostasis. After its translocation 
from the ER ATF6 is activated by limited proteolysis by site1 or site2 proteases (s1P, s2P) in 
the Golgi apperatus. Cleaved ATF6 translocates into the nucleus and drives transcription of 
target genes. Upon dimerization and autophosphorylation, resulting in the activation of IRE1, 
IRE1 splices the XBP1 mRNA (sXBP1; x-box binding protein 1), which leads to the translation 
of the active transcritpition factor XBP1. XBP1 transclocates to the nucleus and controls the 
transcription of target genes. 
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rodents, the human homologue carries several functional mutations. Caspase 4 has 
been proposed to fulfil the function of caspase-12 in humans, but this is still under 
debate (Fig. 11).  
The potential clinical relevance of ER stress in PD was supported by the finding 
that several ER stress markers were found to be up-regulated in brain of sporadic PD 
patients by a post mortem analysis, such as phospho-PERK, phospho-eIF2α and 
caspase-4 (Hoozemans et al., 2007; Moran et al., 2007). In addition, neurotoxins used 
as model compounds to mimic the disease process, such as MPTP, 6-OHDA and 
rotenone were shown to trigger ER stress both in cell culture and in vivo models (Conn 
et al., 2004; Ghribi et al., 2003; Holtz and O'Malley, 2003; Holtz et al., 2006; Holtz et 
al., 2005; Ryu et al., 2005; Ryu et al., 2002; Yamamuro et al., 2006). Gene profiling 
revealed an up-regulation of ER chaperones and other components of the UPR such 
as CHOP, in addition to the phosphorylation of IRE1 and PERK (Ryu et al., 2002). One 
possible reason for the induction of ER stress by these mitochondrial toxins could be 
their effect on mitochondrial respiration, causing damaged oxidized proteins to 
accumulate in the cell, resulting in ER stress. Alternatively, oxidative stress can directly 
compromise proteasomal components or the folding machinery of the ER (Friedlander 
et al., 2000; Reinheckel et al., 2000). Also for the familial form of PD ER stress is 
implicated to play a role in the pathogenesis of the disease. Parkin as a proposed E3 
ligase is suggested to ubiquitylate proteins for degradation. In case of parkin 
dysfunction some substrates accumulate and could cause neurotoxicity. One substrate 
for parkin has been described as the Pael-receptor (parkin-associated endothelin 
receptor-like receptor; Pael-R). The folding of the multipass G protein-coupled 
transmembrane protein proves a massive challenge for the cell and when 
overexpressed in cell culture Pael-R was reported to become unfolded and insoluble. 
Accumulation of Pael-R was shown to induce ER stress. Parkin suppresses Pael-R 
induced toxicity by ubiquitylation and promoting the degradation of the protein (Imai et 
al., 2001). In a Drosophila model from the same group parkin was shown to suppress 
Pael-R-induced dopaminergic neuronal loss (Yang et al., 2003). Experiments with 
overexpressed Pael-R in parkin null mice revealed conflicting data about the induction 
of ER stress in these mice, however an increased death of dopaminergic neurons of 
SNpc was observed (Dusonchet et al., 2009; Kitao et al., 2007; Wang et al., 2008). 
Furthermore, ER stress induces up-regulation of parkin mRNA per se, and cells 
overexpressing parkin, but not pathogenic parkin mutants, are particularly resistant to 
unfolded protein-induced stress (Imai et al., 2000). In addition, also DJ-1 was shown to 
play a role in the protection from ER stress. DJ-1-deficient cells were more vulnerable 
to ER stress-induced cell death than wild-type cells (Canet-Aviles et al., 2004). In 
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contrast, α-synuclein was reported to cause ER stress. Several studies reported that 
overexpression of α-synuclein mutants, but also α-synuclein wild-type induces ER 
stress (Cooper et al., 2006; Smith et al., 2005a; Sugeno et al., 2008). Interestingly, 
parkin was shown to suppress the α-synuclein-induced toxicity (Yang et al., 2003). In 
addition, α-synuclein was reported to block ER to Golgi vesicular trafficking in different 
model systems, leading to ER stress (Cooper et al., 2006).  
 Conclusively, the involvement of ER stress in the familial forms and sporadic 
forms of PD, coupled with the evidence from the neurotoxin models raises the 
possibility of wide spread involvement of ER stress-mediated cell death in the 
pathogenesis of PD.  
 
2.3.5 Interaction of ER and mitochondria 
Interestingly, the ER and mitochondria physically and functionally interact with 
each other to allow the exchange of metabolites and determine the efficiency of Ca2+ 
signalling and regulation of apoptotic pathways (Hayashi et al., 2009; Pizzo and 
Pozzan, 2007). Ca2+ seems to be the most important key molecule in this interaction. 
The ER is the principal internal store of calcium ions. The binding of IP3 (inositol 1,4,5-
trisphosphate) to the IP3 receptor (IP3R) or the binding of cyclic adenosine diphosphate 
ribose (cADPr) to the ryanodine receptor (RyR) stimulates a rapid efflux of Ca2+ from 
the ER into the cytoplasm, where the Ca2+ concentration is significantly lower (about 
100 µM in the ER and about 100 nM in the cytosol). However, the speed of Ca2+ 
diffusion is slow, leading to the formation of high concentrated Ca2+ patches, so called 
microdomains. Strategic location of the mitochondria close to the opening Ca2+ 
channels is the key to rapid and regulated Ca2+ uptake by the mitochondria (Rizzuto 
and Pozzan, 2006). As already mentioned above, the Ca2+ uptake into mitochondria 
triggers several cellular pathways, including cell death pathways. In the context of 
apoptosis it should be mentioned that several proteins of the Bcl-2 family with pro-and 
anti-apoptotic features are located on the ER membrane, influencing among other 
things the Ca2+ concentration in the ER, again indicating that the two organelles act in 
concert in this key process (Kim et al., 2008a; Oakes et al., 2006) (Fig. 11) 
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2.3.6 Pathways implicated in neuronal survival and cell death 
2.3.6.1 NF-κB pathway 
 The nuclear factor kappa enhancer binding protein (NF-κB) is a key 
transcription factor, which controls various biological processes, including immunity, 
differentiation and apoptosis (Baeuerle and Henkel, 1994; Barnes, 1997; Ghosh and 
Karin, 2002). It regulates the expression of a broad spectrum of target genes (Pahl, 
1999), which is achieved by the existence of five diverse NF-κB family members: RelA 
(p65), RelB, c-Rel, p50 and p52 (p50 and p52 are derived from the larger precursors 
p105 and p100, respectively, through proteolytic processing). For functional diversity 
and specificity, these five NF-κB proteins form hetero- and homodimers and interact 
with different co-factors in a cell type- and/or promoter-specific manner (Hayden and 
Ghosh, 2004). All NF-κB proteins contain a highly conserved REL-homology domain 
that is responsible for DNA binding, dimerization, nuclear translocation and interaction 
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Fig. 11: ER stress triggers apoptosis. Upon prolonged ER stress caspase-12 is activated 
through interaction with IRE1 and TRAF2. Activated caspase-12 cleaves effector pro-caspases 
to active caspases. The activated IRE1/TRAF2 complex recruits ASK1 and JNK. Activated JNK 
phosphorylates Bcl-2, resulting in its inactivation, and Bim, leading to its release from its 
inhibitory association with the cytoskeleton and to its activation. Upon stimulation of the UPR 
CHOP is expressed, leading to the reduction of Bcl-2 expression (not illustrated here). 
Altogether, suppression of Bcl-2 and phosphorylation of Bim lead to the activation of the pro-
apoptotic proteins Bax and Bak in the mitochondrial membrane and to the induction of the 
mitochondrial apoptotic pathway. ER and mitochondria are in close contact. Ca2+ signalling from 
the ER to the mitochondria through IP3R (IP3 receptor) or RyR (ryanodine receptor; not 
illustrated here) can induce mitochondrial toxicity events, including mitochondrial membrane 
depolarization, increased production of free oxygen radicals and release of cytochrom c, which 
triggers the activation of caspases. Modified from (Gupta et al., 2006). 
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with the IκB (inhibitor of NF-κB) protein. The IκB proteins, including IκBα, β and ε, bind 
to NF-κB and block its nuclear import by sequestering it in the cytoplasma and thereby 
inhibit its transcriptional activity (Baldwin, 1996; Ghosh et al., 1998). Various stimuli can 
induce NF-κB translocation through distinct upstream pathways that converge at the 
IκB-kinase-complex (IKK), composed of two catalytic subunits IKKα and IKKβ, and a 
regulatory subunit NEMO (NF-κB essential modifier, also known as IKKγ). The most 
predominant NF-κB signalling pathway is the canonical pathway, stimulated by 
treatment with cytokines, like the tumour necrosis factor-α (TNF-α) or interleukin 1 (IL-
1) as well as with bacterial antigens, like lipopolysaccharide (LPS) (Hayden and Ghosh, 
2004). Upon activation of the IKK-complex, IKKβ mediates the phoshporylation of IκBα 
at two N-terminal serine residues (Ser32 and Ser36), which targets the inhibitor for 
ubiquitylation and subsequent proteasomal degradation. The NF-κB molecules are 
thereby released from their inhibitors and translocate due to their now uncovered 
nuclear signal sequence into the nucleus, where they are further modified 
(phosphorylation, acetylation) for transcriptional regulation of target genes (Delhase et 
al., 1999; Karin, 1999a; Karin, 1999b). Among these target genes are genes coding for 
c-IAPs (cellular inhibitors of apoptosis), anti-oxidative enzymes such as MnSOD 
(manganese superoxide dismutase) and proteins of the Bcl-2 family (Karin and Lin, 
2002; Mattson et al., 2000). The regulatory subunit IKKγ/NEMO is crucial for the 
activation of the IKK-complex. At the beginning of the canonical pathway, activating 
stimuli induce the regulatory ubiquitylation (via K63) of several signal molecules, like 
TRAF2 (TNFR-associated factor 2) and TRAF6 (TNFR-associated factor 6). These 
activated upstream regulators in turn ubiquitylate IKKγ/NEMO (also via K63). This 
ubiquitylation mediates the interaction of the IKK-complexes with kinases, resulting in 
the phosphorylation of IKKβ, and its activation as IκB kinase (Chen, 2005; Haglund and 
Dikic, 2005; Krappmann and Scheidereit, 2005; Ravid and Hochstrasser, 2004) (Fig. 
12).  
 The transcriptional activity of NF-κB is regulated by a negative feed back loop. 
NF-κB induces the expression of IκBα, which binds to deacetylated RelA and mediates 
nuclear export of NF-κB. Thus, the transcriptional activity is stopped and the pool of 
inactive NF-κB complexes in the cytosol restored (Arenzana-Seisdedos et al., 1995; 
Arenzana-Seisdedos et al., 1997).  
 NF-κB is present throughout the whole nervous system, and accumulating 
evidence indicates that it plays a central role in neuronal integrity and synaptic plasticity 
(Karin and Lin, 2002). Recent cell culture and animal models demonstrated that NF-κB 
is able to protect neuronal cells from apoptosis induced by oxidative stress, 
excitotoxicity or glucose deprivation (Kaltschmidt et al., 2005; Mattson et al., 2000). 
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These observations suggest a possible involvement of NF-κB in neurodegenerative 
diseases, in particular PD. And indeed, increased NF-κB activation was found in 
mesencephalic neurons from sporadic PD patients (Hunot S 1997). In addition, parkin 
along with proteins associated with the NF-κB pathway was observed to be up-
regulated in the lateral SN of PD patients (Moran et al., 2007).  
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Fig. 12: Canonical NF-κB pathway. Activating stimuli like TNFα, IL-1 or LPS induce the 
regulatory ubiquitylation via K63 of several signal molecules like TRAF2 or TRAF6, which in turn 
ubiquitylate IKKγ/NEMO (also via K63). The ubiquitylation of the IKK-complex (consisting of the 
subunits IKKα and IKKβ and the regulatory subunit IKKγ/NEMO) mediates the interaction with 
kinases, resulting in the phosphorylation of IKKβ. The activated IKK-complex in turn 
phosphorylates IκB, leading to its ubiquitylation and subsequent proteasomal degradation. The 
NF-κB molecules are thereby released from their inhibitor and translocate into the nucleus, 
where they induce the transcription of the appropriate target genes. 
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2.3.6.2 JNK pathway 
 The NF-κB pathway has been implicated in crosstalks to other signalling 
pathways, and in particular to the JNK (c-Jun N-terminal kinase) pathway at various 
levels (Papa et al., 2004). JNK, or stress-activated protein kinase (SAPK), is an 
important member of the mitogen-acitvated protein kinase (MAPK) superfamily, which 
also includes ERK and p38 MAP kinases. The JNK family includes three isoforms: 
JNK1, JNK2 and JNK3. JNK1 and 2 are ubiquitously expressed, while JNK3 is 
primarily found in the brain, heart and testes. The JNK pathway is activated by various 
environmental stimuli, including UV radiation, heat shock, oxidative stress, ER stress, 
cell death ligand Fas-L and proinflammatory cytokines, like TNF-α or IL-1. Similar to 
other members of the MAPK family, JNK activation is mediated by the MAPK cascade 
comprising MAP kinase kinase kinase (MAPKKK), MAP kinase kinase (MAPKK) and 
MAPK. Activated JNK phosphorylates and activates besides the transcription factor 
AP1 (mainly c-Jun, JunB, and ATF-2) other transcription factors, such as p53 or c-myc 
(Davis, 2000; Minden and Karin, 1997) as well as other non-transcription factors, such 
as Bcl-2 family members. The functional specificity and diversity is achieved by 
phosphorylation and functional modification of these molecular targets in stimuli- and 
cell type-dependent manners.  
 A large number of studies implicated a role for the JNK pathway in the 
mediation of neuronal cell death in neurodegenerative diseases (Bogoyevitch et al., 
2004; Peng and Andersen, 2003; Waetzig and Herdegen, 2004) and in particular in 
PD, as a very potent stimulus for JNK activation is oxidative stress. Thus, post mortem 
brain samples from PD patients showed an increased JNK activity (Hunot et al., 2004; 
Teismann et al., 2003). In mouse models JNK was activated in nigrostriatal 
dopaminergic neurons upon treatment with the neurotoxins paraquat and MPTP (Hunot 
et al., 2004; Peng et al., 2004; Saporito et al., 2000), and it was suggested that the JNK 
pathway is an obligatory signalling pathway utilized by these neurotoxins to selectively 
induce apoptosis (Peng et al., 2004). Subsequently, the use of a JNK inhibitor 
(CEP1347), which inhibits MLK (mixed lineage kinase; a MAPKKK) protected MPTP-
treated mice against dopaminergic cell death (Maroney et al., 2001; Saporito et al., 
1999). Notably, because of the promising effects in mice and primates, CEP1347 has 
recently been tested in a clinical trial, which unfortunately failed to detect favourable 
effects in PD patients. Another JNK inhibitor, which directly targets JNK (SP600125) 
was shown to protect dopaminergic neurons in MPTP models (Wang et al., 2004b; Xia 
et al., 2001). In Drosophila the loss of parkin was determined to result in an up-
regulation of JNK, and a dominant negative form of JNK was able to rescue the 
phenotype of impaired dopaminergic neurons. In the same study the authors showed 
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that parkin overexpression inhibited JNK activation in human neuroblastoma cells (Cha 
et al., 2005), indicating a role for parkin as an upstream physiological inhibitor for the 
pro-apoptotic JNK pathway. 
 
 
2.4 PARKIN-ASSOCIATED PARKINSON’S DISEASE 
2.4.1 Clinical and neuropathological characteristics of parkin-associated PD 
 Mutations in the parkin gene account for the majority of known autosomal 
recessive PD cases (Kitada et al., 1998). The patients have either homozygous or 
compound heterozygous (different mutations in each allele) mutations of parkin. It is 
currently under discussion, whether heterozygous carriers bear an increased risk of 
developing PD and exhibit an earlier age of onset (Farrer et al., 2001; Foroud et al., 
2003; Khan et al., 2003), however for some cases it is also possible that a 
complementary mutation at the other allele, perhaps within the promoter or an intron, 
has been overlooked. 
 The clinical phenotype is characterized by early onset parkinsonism with the 
vast majority of patients manifesting the disease before the age of 40 (Klein et al., 
2000) and a good and prolonged response to levodopa (Lohmann E 2003). Relatively 
little is known about the neuropathology of molecularly confirmed parkin associated 
cases. A severe and selective degeneration of dopaminergic neurons and gliosis in the 
SNpc, and to a somewhat lesser degree in the locus coeruleus has been reported 
(Mori et al., 1998; Takahashi et al., 1994; van de Warrenburg et al., 2001). Initially, it 
was described that patients with parkin mutation do not harbour Lewy body pathology. 
In addition, in sporadic PD cases parkin was found to localize to Lewy bodies, giving 
rise to the hypothesis that functional active parkin is essential for Lewy body formation 
(Schlossmacher et al., 2002). However, several parkin-linked cases with Lewy body 
formation were discovered recently (Farrer et al., 2001; Pramstaller et al., 2005; Rawal 
et al., 2003), suggesting that the neuropathological changes are influenced by 
additional genetic or environmental factors and possibly depend upon the age of the 
patient and the type of parkin mutation. Interestingly, a lack of Lewy bodies was also 
reported in LRRK2 patients (Gaig et al., 2007), raising the question of whether Lewy 
bodies are necessary for the definition of PD or not. 
 
2.4.2 Molecular genetics and cell biology of parkin 
Parkin is with 1.3 Mb of genomic DNA one of the largest genes in the genome. 
The gene has 12 exons with a super-expanded intronic structure encoding a 465 amino 
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acid protein with an approximate molecular mass of 52 kDa (Kitada et al., 1998). The 
parkin locus on chromosome 6q25.2-q27 lies adjacent to the 6q telomere and within 
FRA6E, the third most common fragile site in tumor tissue (Denison et al., 2003), 
however a possible additional role of parkin in cancer is not yet determined. The core 
promoter of parkin is 204 bp long (Asakawa et al., 2001; West et al., 2001). Parkin 
shares it with the parkin co-regulated gene (PACRG), which is transcribed on the 
opposite strand in an opposite orientation (Fig. 13).  
 
 
 
 
 
 
 
 
 
 
Given their physical proximity and common transcription factor binding sites, a 
co-regulation of both genes to some degree may occur (West et al., 2003a). For parkin 
a possible enhancing element between -890 and -1500 bp and between -2280 and -
4500 bp was observed. A silencing element may exist between -1500 and -2280 bp 
(West et al., 2001). Several binding sites of transcription factors were described for the 
core promoter such as SP-1, AP-4, AP-1/CREB and NF-1. In addition, the promoter 
contains several CpG islands but no TATA box, which would be typical for a 
housekeeping gene (Asakawa et al., 2001; West et al., 2001). To date, no single 
mutation or small deletion located in the parkin promoter has been found. Only a 
complete deletion of the parkin/PACRG promoter resulted to early-onset Parkinsonism 
(Lesage et al., 2007). In addition, a single nucleotide polymorphismen (-258T/G) was 
reported to influence the transcriptional regulation of parkin and increases the risk 
factor in elderly PD patients (Sutherland et al., 2007; Tan et al., 2005; West et al., 
2002).  
 The expression of parkin is ubiquitous with high expression levels in the brain, 
heart, skeletal muscle and testis. In the brain the expression levels vary between 
different regions, curiously in the SNpc parkin is only weakly expressed (Kitada et al., 
1998). In the cell, parkin is mainly localized to the cytoplasma (Shimura et al., 1999), 
but also an association with the trans-Golgi-network (Kubo et al., 2001), actin- and 
tubulin-filaments (Ren et al., 2003), synaptic vesicles (Fallon et al., 2002; Kubo et al., 
Fig. 13: Schematic model of the parkin and PACRG promoter. Parkin and PACRG share 
the same promoter, but are transcribed on opposite strands in opposite direction. The promoter 
region between the two genes is 204 bp long. 
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2001) as well as mitochondria was described (Darios et al., 2003; Kuroda et al., 2006; 
Stichel et al., 2000). 
 Parkin consists of several structural domains: An ubiquitin-like domain (UBL) at 
the N-terminus and a RING box close to the C-terminus. The RING box consists of two 
RING (Really Interesting Gene) finger motifs, which are separated by a cysteine-rich in-
between RING domain (IBR) (Fig. 14). The N-terminal UBL domain comprises the 
amino acids 1-76 and is to 62% homologues to human ubiquitin (Kitada et al., 1998). It 
is suggested that the N-terminus plays a functional role in the control of parkin 
expression (Finney et al., 2003), substrate recognition (Shimura et al., 2000) and 
interaction with the Rpn10 subunit (protein of the 19S complex) of the 26S proteasome 
(Sakata et al., 2003). The C-terminal RING box implicates an E3 ligase activity for 
parkin, which mediates the interaction between substrate and E2 ubiquitin conjugating 
enzyme, leading to the covalent attachment of ubiquitin to lysine residues of specific 
substrates (Joazeiro and Weissman, 2000). 
 
 
 
 
 
 
 
 
 
2.4.3 Parkin mutations 
To date more than 100 parkin mutations have been described in PD cases of 
different ethnic groups worldwide. All types of mutations were identified, including 
missense mutations leading to amino acid exchanges, nonsense mutations resulting in 
premature termination of translation and exonic rearrangements (deletions, 
duplications and triplications) (Lucking et al., 2000). The mutations are distributed over 
almost the whole coding region of parkin, but hot spots are in particular the functional 
domains, suggesting the importance of these regions for function (Fig. 15). The 
localization of mutation and the identification and characterization of amino acids 
essential for the function of parkin can provide insights into the role of parkin for the 
pathogenesis of Parkinsonism. Genetic and biochemical studies demonstrated that 
pathogenic parkin mutations induce a loss of function. Mutations may either impair the 
catalytical E3 activity of parkin or its interaction with substrates, with E2 ubiquitin 
enzymes or with other proteins of functional complexes. Interaction analyzes revealed 
Fig. 14: Modular structure of the parkin protein. Parkin consists of 465 amino acids and has 
a molecular mass of 52 kDa. It comprises different structural domains: a N-terminal UBL domain 
and a C-terminal RING-box domain, which consists of two RING-finger motifs, separated by an 
IBR domain. UBL: ubiquitin-like; RING: really interesting new gene; IBR: in-between RING. 
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that mutations in the RING box are able to interfere with the binding of E2-enzymes 
and/or substrates (Chung et al., 2001; Hershko et al., 2000; Imai et al., 2000; Shimura 
et al., 2001; Zhang et al., 2000). However, increasing evidence indicates that the 
majority of parkin mutations are characterized by misfolding and aggregation, leading 
to non-functional parkin (Cookson et al., 2003; Gu et al., 2003; Henn et al., 2005; 
Schlehe et al., 2008; Sriram et al., 2005; Wang et al., 2005a; Wang et al., 2005b; 
Winklhofer et al., 2003).  
 
 
 
 
 
 
2.4.4 Putative parkin substrates 
A variety of putative parkin substrates have been reported by different 
approaches, however these proteins are highly diverse and so far have not contributed 
to understanding the physiological role of parkin. Due to its RING box parkin is 
suggested to act as an E3 ubiquitin ligase. Recent evidence indicated that ubiquitin, in 
addition to its traditional role in proteasomal degradation can also have a regulatory 
function (Winklhofer, 2007). 
 
2.4.4.1  Parkin-mediated ubiquitylation for proteasomal degradation 
Consistent with its assumed function, parkin was shown to interact with several 
E2 ubiquitin conjugating enzymes, including UbcH7 and UbcH8 (Imai et al., 2000; 
Shimura et al., 2000; Shimura et al., 2001; Zhang et al., 2000) and the ER-associated 
E2 enzymes Ubc6 and Ubc7 (Imai et al., 2001). It was postulated that the E2/E3 
enzyme complex catalyzes the ubiquitylation via K48, and thus targets the substrates 
for proteasomal degradation. 
The association of parkin to the proteasome system and the knowledge that 
pathogenic mutation lead to a loss of parkin function gave rise to the hypothesis that an 
accumulation of parkin substrates leads to toxicity for the cell, resulting in dopaminergic 
Fig. 15: Missense and nonsense mutations in the parkin gene. Schematic representation of 
parkin with its functional domains. Localization of pathogenic missense and nonsense mutations 
in the parkin gene are indicated by arrows. Stop mutations are marked with an asterisk. UBL: 
ubiquitin-like; RING: really interesting new gene; IBR: in-between RINGs. (Kindly provided by 
Iris Henn.) 
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neuronal cell death. Using Yeast-two-hybrid and pull-down approaches a long list of 
putative parkin substrates were identified, however these substrates show a wide 
functional diversity and do not fit into a common pathway: Proteins with a vesicular and 
synaptic function such as CDCrel-1a (cell division and control-related protein) (Zhang 
et al., 2000), CDCrel-2a (Choi et al., 2003), synaptotagmin XI (Huynh et al., 2003), O-
glycosylated α-synuclein (αSp22) (Shimura et al., 2001), the α-synuclein-interacting 
protein synphillin-1 (Chung et al., 2001) and the dopamine transporter (DAT) (Jiang et 
al., 2004), control proteins of the cell cycle such as cyclin E (Staropoli et al., 2003), 
proteins of the protein synthesis, for example aminoacyl-tRNA synthetase-subunit 
p38/JTV-1 (Corti et al., 2003; Ko et al., 2005), transcription factors such as FBP1 (far 
upstream sequence element-binding protein 1) (Ko et al., 2006), nuclear export 
proteins like RanBP2 (Um et al., 2006), proteins involved in cell death pathways, for 
example PDCD2-1 (programmed cell death 2 isoform 1) (Fukae et al., 2009), and 
signal transduction proteins like Pael-R (parkin associated endothelin-like receptor) 
(Imai et al., 2001). 
The relevance and authenticity of most of the mentioned substrates has still not 
been proven consistently. For some (αSp22, Pael-R, cyclin E, CDCrel-1, CDCrel2a, 
FBP1 and p38/JTV-1, PDCD2-1) a possible accumulation of their non-ubiquitylated 
forms could be shown in brain tissue from parkin-linked PD cases. Only for p38/JTV-1 
and FBP1 also a mild accumulation in the brain of parkin-deficient mice and in sporadic 
PD cases could be observed (Ko et al., 2006; Ko et al., 2005), increasing the evidence 
for authentic substrates. However, the pathophysiological relevance for these findings 
remains unclear.  
 
2.4.4.2 Parkin-mediated regulatory ubiquitylation 
Recent research has also revealed a proteasome-independent ubiquitylation 
function for parkin. An in vitro approach showed the interaction of parkin with the 
heterodimeric E2-ubiquitin-conjugating enzyme Ubc13/Uev1a (Doss-Pepe et al., 2005; 
Matsuda et al., 2006). This enzyme was reported to catalyze ubiquitylation via K63 and 
not via the conventional K48 (McKenna et al., 2001). Furthermore, a direct K63 linked 
ubiquitylation by parkin was observed for synphilin-1, besides the already known K48 
linkage (Lim et al., 2005). Fallon and colleagues showed that parkin is able to mono-
ubiquitiylate PICK1, a scaffold protein that regulates the activity of acid sensing ion 
channels (ASIC), which contribute to excitotoxicity in neurons (Fallon et al., 2002). The 
same group also reported a regulatory mono-ubiquitylation of Eps-15, resulting in the 
delay of EGF receptor internalization and degradation, and the promotion of the 
PI3K/Akt signalling (Fallon et al., 2006). In addition, parkin can also mediate the 
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multiple mono-ubiquitylation of several lysine residues of p38/JTV-1 and HSP70 
(Hampe et al., 2006; Moore et al., 2005a), and in vitro ubiquitylation experiments 
revealed the capability of parkin to mediate its own multiple mono-ubiquitylation 
(Matsuda et al., 2006). 
Conclusively, it seems that under experimental conditions parkin can catalyze 
all modes of ubiquitylation (K48, K63 as well as multiple mono-ubiquitylation), however, 
the physiological role of parkin-mediated regulatory ubiquitylation is still largely 
unknown. In summary, it could be speculated that either an accumulation of toxic 
substrates and/or the loss of the regulatory E3 function of parkin could be the reason 
for dopaminergic cell death.  
 
2.4.4.3  Other parkin interacting proteins 
In addition to the E2 enzymes and the putative substrates of parkin, which have 
already been mentioned, several other parkin-interacting proteins have been identified. 
For example, parkin has been proposed to be a functional component of a larger ligase 
complex, the Skp1-Cullin-F-box (SCF) complex (Staropoli et al., 2003). Further, it was 
reported to be in a complex together with the chaperones CHIP (Carboxyl terminus of 
the Hsc70-interacting protein) or Hsp70 (Imai et al., 2001). The interaction between the 
scaffold protein CASK (Ca2+-calmodulin-dependent serine protein kinase) suggests that 
parkin is part of a complex, which co-localizes with postsynaptic membranes and lipid 
rafts in the brain (Fallon et al., 2002). In addition, further interactions of parkin with 
following proteins were described: proteins of the cytoskeleton like α/β-tubulin (Ren et 
al., 2003), actin filaments (Huynh et al., 2000), γ-tubulin (Zhao et al., 2003), and 
HDAC6 (histone deacetylase 6) (Jiang et al., 2008), proteasomal proteins such as 
Rpn10 α4 (Dachsel et al., 2005; Sakata et al., 2003), other PD-associated genes like 
LRRK2 (Smith et al., 2005b), DJ-mutants (Moore et al., 2005b), PINK1 (Moore, 2006; 
Shiba et al., 2009; Um et al., 2009), and PACRG (Imai et al., 2003). 
Furthermore several proteins were reported to influence the E3 ligase activity of 
parkin. For example PINK1 was proposed to control mitochondrial localization of parkin 
through direct phosphorylation (Kim et al., 2008b), also casein kinase-1 and protein 
kinase A and C as well as cyclin-dependent kinase 5 (Cdk5) were reported to 
phosphorylate parkin and thereby reduce parkin E3 activity (Avraham et al., 2007; 
Yamamoto et al., 2005). HtrA2/omi was described to inactivate parkin function by 
cleaving parkin (Park et al., 2009a), the co-chaperone BAG5 (Bcl-2 associated 
anthogene 5) (Kalia et al., 2004) and 14-3-3η, a chaperone-like protein (Sato et al., 
2006b) were shown to interact with parkin, both leading to the down-regulation of its E3 
activity.  
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2.4.5 Parkin-deficient animal models 
Parkin is highly conserved during evolution. It exists not only in vertebrates such 
as human, mouse and rat, but also in invertebrates, for example Caenorhabditis 
elegans, Drosophila melanogaster and Danio rerio (zebra fish). A comparison of the 
amino acid sequence of parkin in vertebrates and invertebrates reveals a high 
homology between the different species (Haywood and Staveley, 2004) e.g. mouse or 
rat parkin orthologues show a 82% or 83% homology to human parkin, respectively. 
Interestingly, the functional domains are especially highly conserved.  
Parkin knockout mice were generated by deletion of several exons in the 
murine parkin gene: exon 2, corresponding to the UBL domain (Perez and Palmiter, 
2005; Sato et al., 2006a), exon 3, the most common deletion of parkin-linked PD 
(Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004) or exon 7, corresponding 
to the RING1 of the RBR domain (von Coelln et al., 2004). All deletions lead to the 
complete loss of parkin protein.  
As with other knockout mouse models of PD-associated genes, none of the 
published parkin knockout mice showed any significant pathological phenotype, in 
particular the loss of dopaminergic neurons or nigrostriatal degeneration, which is a key 
pathological feature of PD, was not apparent. The strains carrying the exon 2 deletion 
of parkin have been described to have no phenotype at all (Perez and Palmiter, 2005). 
The other strains show various, but not very pronounced phenotypes. Mild alterations 
of dopaminergic neurotransmission, and of the DA metabolism were observed in 
addition to subtle deficits in behaviour. The behavioural phenotype, such as reduced 
explorative behaviour, indicates a disturbance of the nigrostriatal pathway, but 
neuropathologically a loss of dopaminergic neurons or nigrostriatal degeneration was 
not detected (Fleming et al., 2005; Goldberg et al., 2003; Itier et al., 2003; Kitada et al., 
2009a). The proteomic analysis of the ventral midbrain revealed a slight decrease in 
the abundance of proteins involved in mitochondrial function (in particular complex-I 
and -VI of the respiratory chain) and protection from oxidative stress (Palacino et al., 
2004). Subsequently, dopaminergic neurons from knockout mice show a higher 
sensitivity to oxidative stress induced by rotenone compared to wild-type animals 
(Casarejos et al., 2006). Another parkin knockout model has its cause in a 
spontaneous deletion of a 1,17 Mb region, encompassing the complete parkin 
promoter, the first 5 exons of parkin, PACRG and the promoter of the quaking gene. 
The loss of the quaking gene leads to the dysmyelination of the central nervous system 
(Sidman et al., 1964). Additionally, the mice are characterized by a slight change in 
their DA-metabolism, which might be due to the loss of parkin, but no 
neurophatological feature was detected (Lockhart et al., 2004; Lorenzetti et al., 2004; 
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Nikulina et al., 1995). Of note, also the recently published parkin/DJ-1/PINK1 triple 
knockout mice did not show any nigral degeneration (Kitada et al., 2009b). 
In conclusion, parkin knockout mice do not recapitulate the human phenotype of 
PD, they only exhibit mild defects. One explanation for this could be a compensatory 
mechanism of other E3 ubiquitin ligases for the loss of parkin function. 
By contrast, Drosphila melanogaster appears more susceptible to PD-type 
pathology. Parkin deficient flies show a marked phenotype, which includes reduced life 
span, male infertility, locomotor deficits, and flight muscle degeneration. This indicates 
some of the functional aspects of parkin and points to a problem of energy demanding 
tissues and the involvement of mitochondria. Indeed, mitochondrial dysfunction was 
confirmed to play a role in parkin null mutants (Clark et al., 2006; Park et al., 2006) and 
was underlined by the discovery of swollen mitochondria and disintegrated cristae 
(Greene et al., 2003; Wang et al., 2007a). However, here the loss of parkin did not lead 
to dopaminergic neuronal degeneration either. Strikingly, the parkin null flies showed a 
phenotype with marked similarities to that observed in PINK1-deficient flies. In a 
genetic interaction study parkin was able to compensate the PINK1 loss-of function 
phenotype but not vice versa, suggesting that parkin functions downstream of PINK1 in 
the same molecular pathway (Clark et al., 2006; Park et al., 2006; Yang et al., 2006a).  
Subsequent studies suggested a role of PINK1 and parkin in modulating 
mitochondrial morphology and dynamics. Key regulator proteins that decrease 
mitochondrial fusion and increase mitochondrial fission were able to suppress the 
PINK1/parkin flight muscle phenotype (Deng et al., 2008; Park et al., 2009b; Poole et 
al., 2008; Yang et al., 2008).  
 
2.4.6 Parkin has a neuroprotective potential 
Parkin can protect cells against a remarkably broad spectrum of toxic or stressful 
agents. In a variety of cell culture systems and animal models, parkin was shown to 
protect from apoptosis induced by mitochondrial toxins such as MPTP (Hyun et al., 
2005; Paterna et al., 2007), 6-OHDA (Manfredsson et al., 2007; Vercammen et al., 
2006) and rotenone (Casarejos et al., 2006; Rosen et al., 2006), kainic acid-induced 
excitotoxicity (Staropoli et al., 2003), endoplasmic reticulum stress (Imai et al., 2000; 
Takahashi and Imai, 2003), proteasomal inhibition (Muqit et al., 2004; Petrucelli et al., 
2002), treatment with sphingolipide ceramide (Darios et al., 2003), dopamine (Jiang et 
al., 2004), H2O2 (Hyun et al., 2005) or manganese (Higashi et al., 2004), and 
overexpression of parkin substrates or other proteins, for example Pael-R (Imai et al., 
2001; Yang et al., 2003), p38/JTV-1 (Corti et al., 2003; Ko et al., 2006), α-synuclein (Lo 
Bianco et al., 2004; Petrucelli et al., 2002; Yang et al., 2003), LRRK2 G2019S mutant 
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(Ng et al., 2009), mutant tau (Menendez et al., 2006), β-amyloid (Aβ) (Burns et al., 
2009; Rosen et al., 2009; Rosen et al., 2006), Ataxin-2 (Huynh et al., 2007) or 
expanded polyQ ataxin-3-fragment (Tsai et al., 2003) (all listed in Table 2).  
 
Obviously, parkin seems to play a central role for neuronal integrity in response 
to stress. Moreover, dopaminergic neurons are in particular exposed to a high oxidative 
stress burden, due to their dopamine metabolism. The mechanism behind this broad 
protective role of parkin is still not known.  
There is evidence that parkin could play a general role in the pathogenesis of 
sporadic PD based on the fact that severe oxidative stress can induce misfolding of 
native parkin (Henn et al., 2005; Winklhofer et al., 2003). Indeed, misfolded parkin was 
found in the substantia nigra of sporadic PD patients (LaVoie et al., 2005). This 
concept is supported by the discovery that parkin is also inactivated by nitrosative 
stress and correspondingly, S-nitrosylated parkin was found in the brains of sporadic 
PD patients (Chung et al., 2004; Yao et al., 2004). In addition, dopamine was shown to 
covalently modify and functionally inactivate parkin (LaVoie et al., 2005). These 
observations suggest that the protective properties of parkin might be lost over time, 
contributing to sporadic PD. 
In line with this central role of parkin in maintaining neuronal viability, parkin 
gene expression is up-regulated in various stress paradigms such as after induction of 
ER stress (Imai et al., 2000; Koch et al., 2009; Ledesma et al., 2002; Oda et al., 2008; 
Wang et al., 2007b) and treatment with rotenone (Koch et al., 2009), H2O2 (Tan et al., 
2005), dopamine (Yang et al., 2006b) or MPP+ (Hyun et al., 2005; Yang et al., 2006b).  
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parkin mediates neuroprotection 
from 
model system citation 
mitochondrial toxins: 
MPTP, 6-OHDA, rotenone 
 
• parkin knock out mice 
• cell culture (NT-2 and 
SK-NMC) 
• primary skeletal muscle 
cells 
• mouse model (viral gene 
transfer) 
• rat model (viral gene 
transfer) 
(Casarejos et al., 2006) 
(Hyun et al., 2005) 
 
(Rosen et al., 2006)  
 
(Paterna et al., 2007)  
 
(Manfredsson et al., 
2007; Vercammen et al., 
2006) 
kainic acid induced excitotoxicity • primary murine neurons 
(viral overexpression) 
(Staropoli et al., 2003) 
endoplasmatic reticulum stress 
induced cell death 
• cell culture (SH-SY5Y) (Imai et al., 2000) 
proteasomal inhibition • primary murine neurons 
(viral overexpression) 
• cell culture (SH-SY5Y) 
(Petrucelli et al., 2002) 
 
(Muqit et al., 2004) 
ceramide induced cell death • cell culture (PC12) (Darios et al., 2003) 
dopamine induced apoptosis • cell culture (SH-SY5Y) (Jiang et al., 2004) 
H2O2 induced oxidative stress • cell culture (NT-2 and 
SK-N-MC) 
(Hyun et al., 2005) 
manganese induced toxicity • cell culture (SH-SY5Y) (Higashi et al., 2004) 
Toxicity induced by overexpression 
of parkin substrates or other 
proteins: 
  
Pael-R • cell culture (SH-SY5Y) 
• Drosophila model 
(Imai et al., 2001) 
(Yang et al., 2003) 
P38/JTV-1 • cell culture (SK-N-MC, 
SH-SY5Y) 
(Corti et al., 2003; Ko et 
al., 2005) 
α-synuclein • mouse primary neurons 
• rat model (viral gene 
transfer) 
• Drosophila model 
(Petrucelli et al., 2002) 
(Lo Bianco et al., 2004) 
 
(Ng et al., 2009; Yang et 
al., 2003) 
LRRK2 G2019S mutant  • Drosophila model (Ng et al., 2009) 
tau (mutant) • transgenic mice (parkin-/-
/tauVLW) 
• rat-model (viral gene 
transfer) 
(Menendez et al., 2006) 
 
(Klein et al., 2006) 
Aβ • primary skeletal muscle 
cells 
• cell culture (M17; viral 
overexpression) 
• cell culture (SH-SY5Y) 
• primary neuronal cells 
(Rosen et al., 2006) 
 
(Burns et al., 2009) 
 
(Rosen et al., 2009) 
Ataxin-2 • cell culture (PC12) (Huynh et al., 2007) 
expanded polyQ ataxin 3 fragment • cell culture (N18) (Tsai et al., 2003) 
 
Table 2: Neuroprotective potential of parkin against various stressors. TauVLW: Tau with a 
triple FTDP-mutation (G272V, P301L and R406W); FTDP-17: Frontotemporal dementia with 
parkinsonism-17.
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3 Results 
 
3.1 PARKIN IS A TARGET OF THE UNFOLDED PROTEIN RESPONSE AND PROTECTS 
CELLS FROM ER STRESS-INDUCED MITOCHONDRIAL DAMAGE 
3.1.1 Parkin is up-regulated in response to ER stress  
 Previous studies showed a possible transcriptional up-regulation of parkin in 
response to ER stress (Imai et al., 2000; Ledesma et al., 2002). To reproduce and 
extend these studies, we incubated human neuroblastoma-derived SH-SY5Y cells with 
the ER Ca2+-ATPase inhibitor thapsigargin or with the N-glycosylation inhibitor 
tunicamycin. Parkin-specific mRNA levels were analyzed by quantitative RT-PCR. Both 
ER stressors significantly increased the level of parkin-specific mRNA with a maximum 
at 12 hours after drug treatment (Fig. 16A). Notably, the increase in parkin mRNA in 
response to ER stress was translated into elevated parkin protein levels (Fig. 16B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 16: Parkin gene expression is up-regulated in response to ER stress. (A) Parkin 
mRNA levels are increased under ER stress induced by thapsigargin or tunciamycin. SH-SY5Y 
cells were incubated with 1 µM thapsigargin (TG) or 2 µg/ml tunicamycin (TM) for the indicated 
time. Cells were harvested and total cellular RNA was isolated and subjected to quantitative 
RT-PCR using parkin-specific primers. The amount of RNA of each sample was normalized 
with respect to the endogenous housekeeping gene β-actin. Shown is the fold increase of 
parkin-specific mRNA compared to untreated control cells. (B) Expression of endogenous 
parkin after treatment of SH-SY5Y cells with TG or TM for 12 h was analyzed by Western 
blotting using the anti-parkin mAb PRK8. Loading was controlled by re-probing the blots for β-
actin. The Western blot image for TM was re-arranged by excluding one line, as indicated by a 
white line; all samples originate from one gel. 
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In addition to SH-SY5Y cells, human embryonic kidney (HEK293T) cells (Fig. 17A), 
mouse embryonic fibroblasts (MEFs) (Fig. 17B) and primary neuronal cultures (Fig. 
17C) prepared from mouse cortex also showed a robust up-regulation of parkin mRNA 
in response to thapsigargin or tunicamycin treatment. (MEF cells were kindly prepared 
by Anita Schlierf and primary neuronal cultures were provided by Carsten Culmsee.) 
 
 
 
 
 
 
 
 
 
 
 
3.1.2 Parkin as target of the unfolded protein response (UPR)  
 The previous experiments showed an up-regulation of parkin in response to ER 
stress. Transcription/translation of proteins after ER stress is mainly mediated by the 
UPR. The UPR comprises three pathways: the PERK (protein kinase-like ER kinase), 
the ATF6 (activating transcription factor 6) and the IRE1 (inositol requiring kinase 1) 
pathway. They all lead to the induction of various transcription factors, helping the cell 
to restore cell homeostasis. Thus, we wondered if the parkin promoter contains a cis-
acting element for one of the activated transcription factors.  
 The promoter analysis of the human parkin gene (TFSEARCH: Searching 
Transcription Factor Binding Sites, http://www.rwcp.or.jp/papia; (Heinemeyer et al., 
1998)) revealed a putative CREB/ATF site at position –168 to position –162. Further 
in-depth analysis identified this binding site as a possible binding sequence for ATF4 
(activating transcription factor 4). Of note, the transcription factor ATF4 is activated by 
the PERK pathway. To test whether this ATF4-binding site in the parkin promoter is 
responsible for the up-regulation of parkin after ER stress, a reporter construct was 
Fig. 17: Parkin mRNA is up-regulated upon ER stress in HEK293T cells, mouse 
embryonic fibroblasts and mouse primary cortical neurons. (A-C) HEK293T cells were 
incubated with 1 µM TG for 14 h (A), mouse embryonic fibroblasts (B) or primary cortical 
neurons derived from embryonic mouse brain (C) were incubated with 1 µM TG or 2 µg/ml TM 
for 12 h and then analyzed as described in Fig. 16. The amount of RNA of each sample was 
normalized with respect to the endogenous housekeeping gene β-actin. Shown is the fold 
increase of parkin-specific mRNA compared to untreated control cells. ***p<0.001, 
**p<0.01,*p<0.05. 
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cloned containing the putative ATF4-binding site in triplicate in front of a sequence 
coding for luciferase (park-luc). As a control, a reporter construct was cloned, 
comprising an already confirmed ATF4-binding site from the insulin growth factor 
binding protein 1 (IGFBP1) promoter in triplicate in front of a luciferase gene 
analogously to the park-luc construct. This control construct was termed ATF4RE-luc 
(ATF4 response element-luc) (Fig. 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The park-luc construct as well as the control construct (ATF4RE) were tested 
under ER stress conditions. Both constructs showed to a similar extent an increase in 
luciferase expression after treatment with thapsigargin in comparison to the vector 
control, lacking a binding site for ATF4 (Fig. 19A). The experiment was performed in 
HEK293T as well as in SH-Y5Y cells (data not shown). In addition, the park-luc 
construct was also tested after treatment with tunicamycin. This treatment resulted 
likewise in an induction of luciferase activity (Fig. 19B). 
 
 
 
 
ATF4RE-luc:
ATTTACATCA
luc
ATTTACATCA ATTTACATCA
park-luc:
TGACGTAAG TGACGTAAGTGACGTAAG
luc
5’-TGACGTAAG-3’
3’-ACTGCATTC-5’
putative ATF4 binding site within the parkin promoter:
consensus ATF4 binding site:
TTT
A
C
G
C TCA
T
G
A
G
A
Fig. 18: Schematic representation of the consensus ATF4-binding site, the putative 
ATF4-binding site within the parkin promoter and the luciferase reporter constructs 
cloned for the analysis. The letters written one upon the other for the consensus ATF4-
binding site are alternatively used. Of note, the putative binding site for ATF4 within the parkin 
promoter is located on the complementary strand in 5’→3’ direction. The luciferase constructs 
are described in the following: park-luc contains the putative ATF4-binding site of the parkin 
promoter in triplicate in front of a luciferase gene and ATF4RE-luc contains the confirmed 
ATF4-binding site of the insulin growth factor binding protein 1 (IGFBP1) promoter in triplicate in 
front of a luciferase gene. 
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 To test whether ATF4 itself is responsible for the up-regulation of parkin, ATF4 
was co-expressed together with the park-luc reporter construct. Indeed, overexpression 
of ATF4 stimulated the induction of the park-luc construct. In parallel, the control 
construct ATF4RE-luc was likewise induced. Additionally, the overexpression of PERK, 
the kinase located upstream of ATF4, showed an increase in luciferase expression of 
the park-luc construct as well as of the control construct. Notably, the activated 
transcription was higher for the park-luc construct than for the ATFRE control construct 
(Fig. 20). The experiment was performed in HEK293T as well as in SH-Y5Y cells (data 
not shown). 
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Fig. 19: The park-luc reporter construct is induced after ER stress. (A, B) HEK293T cells 
were transfected with either the control luciferase reporter construct PGL3-luc, the ATF4RE-luc 
construct containing the confirmed ATF4-binding site or the park-luc construct. 8 h after 
transfection cells were incubated with 1 µM TG (A) or with 2 µg/ml TM (B) and harvested after 
additional 14 h. Shown is the fold induction of luciferase activity in stressed cells compared to 
non-stressed control cells based on triplicates of at least three independent experiments. *** p < 
0.001; ** p < 0.01. 
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 In line with these findings, the transient expression of a dominant negative 
mutant of ATF4, ATF4ΔN, lacking the transcriptional activation domain located at the 
N-terminus, failed to induce the park-luc construct and consistently decreased the 
activation of the park-luc after ER stress (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 To confirm the data that ATF4 binds to the parkin promoter, an electromobility 
shift assay (EMSA) using the putative ATF4-binding site of the parkin promoter as a 
probe (park oligo) was established. As a positive control the ATF4RE oligo was used, 
comprising the confirmed ATF4 binding site of the IGFBP1 promoter. The park oligo 
was radiolabeled and incubated with nuclear extract from HEK293T cells treated with 2 
µM thapsigargin for 3 hours (Fig. 22A). Upon treatment with thapsigargin, a DNA-
protein complex appeared (lane 2), which could be supershifted by an anti-ATF4 
antibody (lane 7), but not with a polyclonal antibody against TRAF6 (tumor necrosis 
factor (TNF) receptor associated factor 6; lane 8). Furthermore, this complex was 
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Fig. 20: Increased expression of ATF4 or upstream PERK induces transcription from the 
park-luc reporter construct. HEK293T cells were co-transfected with either the ATF4RE-luc 
reporter plasmid or the park-luc reporter plasmid and ATF4 or PERK or GFP (as a control). 8 h 
after transfection cells were incubated with 1 µM TG for 14 h. Shown is the fold induction of 
luciferase activity compared to GFP-expressing control cells based on triplicates of at least 
three independent experiments. Expression levels of AFT4 and PERK were analyzed by 
immunoblotting using the anti-ATF4 pAb C-20 or the anti-myc mAb 9E10 (right panels). Notably, 
TG treatment (1 µM, 14 h) induced the increased expression of endogenous ATF4. The cells 
were lysed in urea lysis buffer. Loading was controlled by re-probing the blots for β-actin. 
Fig. 21: A dominant negative mutant of ATF4 (ATF4ΔN) fails to activate the park-luc 
reporter construct. HEK293T cells were co-transfected with the park-luc reporter plasmid and 
ATF4 or ATF4ΔN or GFP (as a control). 8 h after transfection cells were incubated with 1 µM 
TG for 14 h. Shown is the fold induction of luciferase activity in comparison to GFP-expressing 
control cells based on triplicates of at least three independent experiments. Expression levels of 
ATF4 and ATF4ΔN were analyzed by immunoblotting using the anti-ATF4 pAb C-20. The cells 
were lysed in urea lysis buffer. Loading was controlled by re-probing the blots for β-actin (right 
panel). *** p < 0.001. 
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competed out by a 100-fold excess of homologous unlabeled park oligo (lane 3) or a 
100-fold excess of cold ATF4RE oligo (lane 4). In contrast, the complex was not 
displaced by an oligonucleotide mutated at the ATF4 composite sequence of the parkin 
promoter (park mut; lane 5) or by an oligonucleotide that binds the octamer binding 
transcription factor 1 (Oct1; lane 6), suggesting specific binding of ATF4 (Fig. 22A). In 
addition, cells expressing ATF4 showed likewise the appearance of the same DNA-
ATF4 complex under non-stress conditions (Fig. 22B). Next, we compared the park 
oligo to the ATF4RE oligo (Fig. 22A). The ER stress-induced ATF4RE oligo-protein 
complex migrated similarly to the complex observed with the park oligo (lane 10) and 
could be supershifted in the presence of the anti-ATF4 antibody (lane 13). The complex 
of DNA and protein could be competed out by a 100-fold excess of cold ATF4RE oligo 
(lane 11) as well as with a 100-fold excess of cold park oligo (lane 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22: ATF4 binds to the to the putative binding site within the parkin promoter. (A) ER 
stress induces ATF4 binding to the parkin promoter. HEK293T cells were incubated with 2 µM 
TG and harvested after 3 h. Nuclear extracts were prepared and tested for binding to a 32P-
labeled oligonucleotide comprising the putative ATF4-binding site of the parkin promoter (park 
oligo; lanes 1-8) by an electrophoretic mobility shift assay (EMSA). As a positive control a 32P-
labeled oligonucleotide comprising the confirmed ATF4-binding site of the IGFBP1 promoter 
(ATF4RE oligo; lanes 9-13) was used. The labelled oligonucleotides were incubated with 
nuclear extracts in the absence or presence of a 100-fold excess of unlabelled park oligo (lanes 
3 and 12), ATF4RE oligo (lanes 4 and 11), mutated park oligo (lane 5), or Oct1 oligo (lane 6) to 
test for competition with the binding reaction. For supershift assays, the anti-ATF4 pAb C-20 
(lanes 7 and 13) or the anti-TRAF6 pAb H-274 (lane 8) was added to the binding reaction. (B) 
Overexpressed ATF4 binds to the parkin promoter. HEK293T cells were transfected with ATF4 
(lanes 3 and 4) followed by treatment with 2 µM TG for 3 h one day later (lanes 2 and 4) and 
EMSA was performed as described above.  
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 To further confirm our results that ATF4 mediates the transcriptional up-
regulation of parkin under ER stress in vivo, an ATF4 knockdown approach was 
established. SH-SY5Y cells were reversely transfected with siRNA against ATF4 or 
control siRNA. Two days later the cells were again transfected, to interfere with the up-
regulation of ATF4 mRNA after induction of ER stress. As expected, the mRNA level of 
parkin in the control transfected cells was increased after ER stress. However, in the 
ATF4-deficient cells the ER stress-induced up-regulation of parkin mRNA was 
significantly decreased (about 69%) (Fig. 23A) The knockdown of ATF4 was verified on 
the mRNA as well as on the protein level (Fig. 23B). The same result was obtained with 
a second siRNA targeted against ATF4 (data not shown). 
 As a positive control the mRNA levels of the ATF4-regulated gene CHOP 
(C/EBP homologue protein) was examined. In the ATF4 knockdown cells the response 
of CHOP mRNA to ER stress was decreased to a similar extent than for the parkin 
mRNA, about 69%, compared to control transfected cells (Fig. 23C). 
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 To increase experimental evidence for an in vivo interaction of ATF4 with the 
parkin promoter during ER stress, chromatin immunoprecipitation (ChIP) assays were 
performed using an ATF4-specific antibody. A rabbit polyclonal antibody against 
chicken IgG was used as non-specific control. After isolation of cross-linked chromatin 
from cells incubated with or without 300 nM thapsigargin, immunoprecipitated DNA was 
analyzed by real time PCR. The ChIP analysis revealed binding of ATF4 to the parkin 
promoter after 2 and 8 hours of thapsigargin treatment (Fig. 24). (The ChIP was done 
in cooperation with Jixiu Shan in the group of Michael S. Kilberg.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Notably, also starvation of SH-SY5Y cells with L-histidinol resulted in the up-
regulation of parkin protein (Fig. 25). L-histidinol is a histidine analogue which blocks 
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Fig. 23: ER stress-induced up-regulation of parkin is impaired in ATF4-deficient cells. (A-
C) SH-SY5Y cells were reversly transfected with ATF4-specific or control siRNA duplexes. 2 
days later cells were transfected again with siRNA duplexes and then incubated with 1 µM TG 
for 16 h. The cells were harvested and analyzed as described in Fig. 16 for quantitative RT-
PCR using parkin-specific (A), ATF4-specific (B) or CHOP-specific primers (C). The amount of 
RNA of each sample was normalized with respect to β-actin. (A) Shown is the fold increase of 
parkin mRNA in response to TG treatment. (B) The efficiency of ATF4 downregulation was 
determined by quantitative RT-PCR and Western blotting using the anti-ATF4 pAb C-20. Cells 
were lysed in urea lysis buffer. Loading was controlled by re-probing the blots for β-actin. (C) 
Shown is the fold increase of CHOP mRNA in response to TG treatment. ** p < 0.01; *** p < 
0.001.  
 
Fig. 24: ATF4 binds to the parkin promoter in vivo. HEK293T cells incubated with or without 
300 nM TG for 2 and 8 h were used to perform a ChIP analysis using a pAb specific for ATF4 in 
comparison to a non-specific rabbit IgG. For the final real time PCR step, primers specific for 
the parkin promoter region were used. *** p < 0.001. (This experiment was kindly done by Jixiu 
Shan.) 
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charging of the histidyl-tRNA synthetase, thus mimicing histidine deprivation. Amino 
acid deprivation in general leads to an increase in uncharged tRNA, which binds to and 
activates the eIF2α kinase GCN2 (general control non-derepressible-2). GCN2 
specifically phosphorylates eIF2α, which results in the activation of ATF4 but no other 
UPR branch, indicating a specific regulation of parkin by ATF4.  
 
 
 
 
 
 
3.1.3 c-Jun represses the ER stress-induced transcriptional activation of parkin 
 The EMSAs performed with the park oligo showed in addition to the ATF4–park 
complex another protein complex, with reduced electrophoretic mobility behaviour. This 
protein complex was also very specifically increased after ER-stress (Fig. 26A; lane 2). 
It has been described previously that ATF4 can form heterodimers with other ATF 
family members as well as with c-Jun family members. Therefore different antibodies 
were tested for their potential to supershift the upper band. By using a specific antibody 
against c-Jun a supershift for the larger protein-DNA complex but not the smaller 
ATF4-park-DNA complex could be observed (lane 3). Additionally, the respective band 
could be competed out by an excess of unlabeled park oligo (lane 5). Further 
experiments using the AP1 (activator protein 1) site, the common binding site of c-Jun 
as probe, revealed that thapsigargin was able to induce a c-Jun/AP1 complex (lane 2) 
which could be competed out by a 100-fold excess of cold AP1 oligo (lane 3; Fig. 26B). 
The same band also appeared after PMA (phorbol 12-myristate 13-acetate) treatment, 
a specific stimulus for JNK/c-Jun activation (lane 2; Fig. 26C). This complex could be 
competed out with a 100-fold excess of cold park oligo, supporting the hypothesis of c-
Jun binding to the park oligo (lane 4). Cells expressing c-Jun showed likewise the 
appearance of the same band for the AP1 oligo (lane 2; Fig. 26D) as well as for the 
park oligo (lane 5). Of note, increasing amounts of c-Jun expression in HEK293T cells 
resulted in an increasing signal for the c-Jun/park oligo complex (Fig. 26C).  
 
 
L-histidinol
!-parkin
!-actin
Fig. 25: Starvation leads to the up-regulation of parkin protein expression. SH-SY5Y cells 
were treated with 2 mM L-histidinol in cell culture medium containing 10% dialysed FCS for 16 h 
and expression of endogenous parkin was analyzed by Western blotting using the anti-parkin 
mAb PRK8. Loading was controlled by re-probing the blots for β-actin. (With experimental help 
of Vincenza Palmisano.) 
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Fig. 26: c-Jun binds to the parkin promoter. (A) ER stress induces c-Jun binding to the 
parkin promoter. HEK293T cells were incubated with 2 µM TG and harvested after 3 h. Nuclear 
extracts were prepared and tested for binding to the 32P-labeled oligonucleotide comprising the 
putative ATF4-binding site of the parkin promoter (park oligo; lanes 1-5) by an electrophoretic 
mobility shift assay (EMSA). The labelled oligonucleotides were incubated with nuclear extracts 
in the absence or presence of a 100-fold excess of unlabeled park oligo (lane 5) to compete 
with the binding reaction. To test for supershift activity, the anti-c-Jun pAb (N) sc-45 X (lane 3) 
or the anti-ATF4 pAb C-20 (lane 4) was added to the binding reaction. (The EMSA was kindly 
performed by Anita Schlierf.) (B) c-Jun binds to the AP1 site in response to ER stress. EMSA 
with TG-treated HEK293T cells (lane 2) was performed as described above. As 32P-labeled 
oligonucleotide the common c-Jun binding site AP1 was used. To show the specificity of the 
bands, a 100-fold excess of unlabeled AP1 oligo (lane 3) was added. (C) PMA-stimulated 
binding of c-Jun to the AP1 site is competed by an excess of cold park oligo. HEK293T cells 
were incubated with 10 ng/ml PMA for 45 min (lanes 2-5) and prepared as described above. 
The labelled AP1 oligonucleotide was incubated with nuclear extracts with a 100-fold excess of 
unlabeled AP1 oligo (lane 3), park oligo (lane 4) or unspecific Oct1 (lane 5). (D) Overexpressed 
c-Jun binds to the parkin promoter. HEK293T cells were transcfected with His-tagged c-Jun 
(lane 2 and lane 5) or treated with 10 ng/ml PMA for 45 min (lane 3 and 6). Cells were 
harvested and the EMSA was performed as described above by incubation with labelled park 
oligo (lanes 4-6).  As a control nuclear extracts were incubated with labelled AP1 oligo  instead 
of the park oligo (lanes 1-3) The image was re-arranged by excluding one line, as indicated by a 
white line; all samples originate from one gel. (E) Increasing amounts of c-Jun expression result 
in a stronger binding to the parkin promoter. Nuclear extracts of HEK293T cells transfected with 
0.1 µg (lane 2), 0.5 µg (lane 3), 1 µg (lane 4), 2 µg (lane 5) c-Jun DNA were incubated with 
labelled park oligo.  
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 To better understand the role of c-Jun in the transcriptional regulation of parkin 
expression, c-Jun was co-transfected together with the park-luc construct. As 
expected, upon thapsigargin treatment the transcription of the park-luc construct was 
induced. However, in cells overexpressing c-Jun the luciferase expression was 
remarkably reduced under basal as well as under ER stress conditions (Fig. 27A). 
Moreover, the overexpression of c-Jun together with ATF4, resulted in a suppression of 
ATF4-mediated activation of the park-luc construct under non-stress conditions as well 
as under ER stress conditions, indicating a dominant negative effect of c-Jun on ATF4 
(Fig. 27B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 For further in vivo evidence that c-Jun suppresses the up-regulation of parkin 
expression under ER stress conditions a c-Jun knockdown approach was established. 
c-Jun specific siRNA duplexes were reversely transfected into SH-SY5Y cells. One day 
Fig. 27: c-Jun decreases transcription from the park-luc reporter after ER stress. (A) 
HEK293T cells were co-transfected with the park-luc reporter plasmid and c-Jun or GFP (as a 
control). 8 h after transfection, the cells were treated with 1 µM TG for 14 h. Shown is the fold 
induction of luciferase activity in c-Jun-expressing cells in comparison to GFP-expressing 
control cells based on triplicates of at least three independent experiments. Expression levels of 
c-Jun were analyzed by immunoblotting using the anti-c-Jun pAb (N) sc-45. Loading was 
controlled by re-probing the blots for β-actin (lower panel). (B) c-Jun suppresses the ATF4-
mediated activation of the park-luc construct. HEK293T cells were co-transfected with the park-
luc reporter plasmid and either GFP, ATF4 or ATF4 plus c-Jun. 8 h after transfection, the cells 
were treated with 1 µM TG for 14 h. Shown is the fold induction of luciferase activity in ATF4-
expressing cells in comparison to ATF4- and c-Jun-expressing cells based on triplicates of at 
least three independent experiments. Expression levels of ATF4 and c-Jun were analyzed by 
immunoblotting using the anti-ATF4 pAb C-20 or the anti-c-Jun pAb (N) sc-45. Cells were lysed 
in urea-lysis buffer. Loading was controlled by re-probing the blots for β-actin (lower panel). *** 
p < 0.001. 
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later the cells were again transfected with siRNA, to interfere with the up-regulation of 
c-Jun mRNA after the induction of ER stress. The knockdown efficiency was controlled 
by real-time RT PCR, revealing a reduction of c-Jun mRNA of about 87% under basal 
conditions and of about 69% under ER stress conditions. In parallel, the knockdown 
efficiency was also controlled on the protein level (Fig. 28B). Already under normal 
conditions c-Jun knockdown cells showed a slightly higher parkin mRNA expression 
than control cells. Notably, under ER stress conditions parkin mRNA was significantly 
stronger induced in c-Jun-deficient cells compared to control transfected cells (Fig. 
28A). The same result was obtained with a second siRNA targeted against c-Jun (data 
not shown). As a control for specific effect of c-Jun on parkin gene expression, the 
mRNA levels of the pro-apoptotic protein CHOP (Fig. 28C) and the PD-associated 
protein PINK1 (Fig. 28D) was examined in c-Jun deficient cells. The mRNA levels of 
both, CHOP and PINK1 were increased after ER stress, however the knockdown of c-
Jun had no significant influence on the level of induction. 
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 To get more insight into the binding behaviour of ATF4 and c-Jun on the parkin 
promoter, recombinant proteins were tested in an EMSA. c-Jun and ATF4 were either 
incubated alone or together with the park oligo for 30 min on ice. As expected, 
increasing amounts of protein resulted in more protein bound to the park oligo (c-Jun: 
lane 1-4; ATF4: lane 9-11) (Fig. 29). Remarkably, the binding properties of the two 
proteins were changed when first ATF4 was incubated with the park oligo and after 15 
min c-Jun was added to the reaction. The bound ATF4 was able to recruit c-Jun to the 
parkin promoter (lane 5-8). However, vice versa this was not the case, c-Jun was not 
able to recruit ATF4 to the parkin promoter as visualized by the reduced intensity of the 
signal. This observation suggests that c-Jun might compete with ATF4 for the 
transcriptional regulation of parkin and that it might serve as a terminator for the up-
regulation of parkin after ER stress. Of note, the recombinant c-Jun used for these 
experiments was not phosphorylated, thus it cannot be excluded that the binding of c-
Jun to the park oligo is influenced by the phosphorylation status of c-Jun. 
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Fig. 28: ER stress-induced up-regulation of parkin is increased in c-Jun-deficient cells. 
(A-D) SH-SY5Y cells were reverse transfected with c-Jun-specific or control siRNA duplexes. 
One day later cells were transfected again with siRNA duplexes and incubated with 1 µM TG for 
16 h. The cells were harvested and analyzed as described in Fig. 16 for quantitative RT-PCR 
using parkin-specific (A), c-Jun-specific (B), CHOP-specific (C) or PINK1-specific (D) primers. 
The amount of RNA of each sample was normalized with respect to β-actin. (A) Shown is the 
fold increase of parkin mRNA in response to TG treatment. (B) The efficiency of c-Jun 
downregulation was determined by quantitative RT-PCR and Western blotting using the anti-c-
Jun pAb (N) sc-45. Loading was controlled by re-probing the blots for β-actin (right panel). (C, 
D) Shown is the fold increase of CHOP mRNA (C) and PINK1 mRNA (D) in response to TG 
treatment. ** p < 0.01; n.s. = not significant. 
 
Fig. 29: ATF4 increases binding of c-Jun to the parkin promoter. Increasing amounts of 
recombinant ATF4 or c-Jun were incubated with 32P-labeled oligonucleotide comprising the 
putative ATF4-binding site of the parkin promoter (park oligo) to monitor formation of DNA-
protein complexes by EMSA. Lanes 1-4: 200, 300, 350 or 400 ng recombinant c-Jun was 
incubated with the park oligo. Lanes 5-8: 100 ng recombinant ATF4 was incubated with the 
park oligo for 15 min on ice followed by the addition of c-Jun (200, 300, 350 or 400 ng) for 
another 15 min. Lane 9-11: 100, 50 (*) or 200 ng of recombinant ATF4 was used. Lanes 12 and 
13: 350 ng recombinant c-Jun was incubated with the park oligo for 15 min on ice followed by 
the addition of ATF4 (50 and 100 ng) for another 15 min. 
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 c-Jun is regulated by the JNK (c-Jun N-terminal kinase) pathway. JNK 
phosphorylates and thereby activates c-Jun. This subfamiliy of mitogen-activated 
protein kinases (MAPK) consists of three isoforms JNK1, JNK2 and JNK3. JNK1 and 2 
are ubiquitously expressed, while JNK3 is primarily found in the brain, heart and testes. 
JNK3 has been linked to cell death in several models of neurodegeneration. To test if 
JNK3 also has an impact on parkin expression, JNK3 was cotransfected with the park-
luc construct. Indeed, overexpression of JNK3 resulted in a reduced induction of the 
park-luc construct both under ER stress and basal conditions (Fig. 30).  
 
 
 
 
 
 
 
 
 
 
3.1.4 Parkin protects cells from ER stress-induced cell death 
 Based on these results, the question arises, what are the consequences for the 
cell upon the up-regulation of parkin? The main task of the UPR is to restore ER 
function. However, additionally also the expression of pro-survival genes and genes 
which preserve cell function is induced. To test if parkin up-regulation might protect 
cells from ER stress-induced toxicity, SH-SY5Y cells transiently expressing parkin or 
pathogenic parkin mutants were treated with thapsigargin or tunicamycin.  
 Please note, for these experiments we chose SH-SY5Y cells, which show a 
reduced endogenous parkin expression due to long passage number (Fig. 31A, B).  
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Fig. 30: JNK3 decreases transcription from the park-luc reporter. HEK293T cells were co-
transfected with the park-luc reporter plasmid and JNK3 or GFP (as a control). 24 h after 
transfection, the cells were treated with 1 µM TG for 8 h. Shown is the fold induction of 
luciferase activity in JNK3-expressing cells in comparison to GFP-expressing control cells 
based on triplicates of at least three independent experiments. Expression levels of JNK3 were 
analyzed by immunoblotting using an anti-JNK pAB. Loading was controlled by re-probing the 
blots for β-actin. The Western Blot image was re-arranged by excluding one line, as indicated 
by a white line; all samples originate from one gel. (right panel). *** p < 0.001. 
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 Cells undergoing apoptosis in response to ER stress were analyzed by indirect 
fluorescence using an antibody specific for activated caspase-3. The control cells 
showed a significant increase in apoptosis in response to ER stress induced by either 
thapsigargin or tunicamycin. However, cells overexpressing parkin were protected 
against ER stress-induced cell death. Notably, the parkin mutants G430D and ΔUBL, 
which are associated with autosomal recessive parkinsonism, failed to protect the cells 
from ER stress-induced apoptosis (Fig. 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31: The level of endogenous parkin in SH-SY5Y cells changes, when the cells are 
passaged over a long period of time. Early passages of SH-SY5Y cells still contain 
considerable amounts of parkin (SH-SY5Y e), but after 30-40 passages parkin seems to be lost 
(SH-SY5Y l). Of note, parkin is expressed at very low levels in SH-SY5Y cells. (A) Parkin 
mRNA levels were analyzed as described in Fig. 16 using parkin-specific primers. The amount 
of mRNA of each sample was normalized with respect to β-actin. Shown is the fold reduction of 
parkin mRNA in SH-SY5Y e cells compared to SH-SY5Y l cells. (B) Expression levels of parkin 
were analyzed by immunoblotting using the anti-parkin PRK8 mAb. The Western Blot image 
was re-arranged by excluding one line, as indicated by a white line; all samples originate from 
one gel. (The Western Blot was kindly done by Julia Schlehe.)  
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To increase the evidence for a role of endogenous parkin in coping with ER 
stress, the consequences of a parkin knockdown induced by RNA interference were 
analyzed. First, HEK293T cells were transfected with parkin-specific siRNA duplexes, 
resulting in a >80% reduction of parkin mRNA and protein levels three days after 
transfection (Fig. 33B). Cell viability was measured with the MTT viability assay. Parkin 
knockdown cells showed a significant decrease in cell vitality after ER stress in 
comparison to control siRNA-transfected cells, indicating an increased vulnerability of 
cells to ER stress in the absence of parkin (Fig. 33A).  
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Fig. 32: Increased expression of parkin protects cells from ER stress-induced cell death. 
SH-SY5Y cells were cotransfected with EYFP (as a control) and wild-type parkin or the 
pathogenic parkin mutants G430D or ΔUBL. 24 h after transfection, cells were incubated with 10 
µM TG or 5 µg/ml TM at 37°C for 8 h, fixed, permeabilized, and then the activation of caspase-3 
was analyzed by indirect immunofluorescence using an anti-active caspase-3 pAb. For 
quantification at least three independent experiments were performed. Per experiment ≥ 300 
transfected cells were counted. Shown is the percentage of apoptotic cells among transfected 
cells. Parkin expression levels were determined by immunoblotting using the anti-parkin PRK8 
mAb. Loading was controlled by re-probing the blots for β-actin (lower panel). (Caspase assays 
were kindly counted by Kathrin Lutz.) *** p < 0.001. 
 
Fig. 33: Parkin deficiency impairs the viability of cells under ER stress. (A, B) HEK293T 
cells were transfected with parkin-specific or control siRNA duplexes. (A) Three days later the 
cells were stressed with TG (10 µM) or TM (2 µg/ml) for 16 h. Cellular viability was determined 
by the MTT assay. Shown is the relative viability of cells transfected with parkin siRNA in 
comparison to control siRNA-transfected cells treated with ER stressors based on triplicates of 
at least three independent experiments. (B) The parkin knockdown efficiency was verified by 
quantitative RT-PCR and Western blotting using the anti-parkin mAb PRK8. Loading was 
controlled by re-probing the blot for β-actin. *** p < 0.001. 
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 In addition, also the parkin knockdown in SH-SY5Y resulted in an increase of 
apoptotic cells as determined by the activated caspase 3 assay. This effect could be 
rescued by the addition of a siRNA resistant parkin wild-type construct (rescue parkin). 
The parkin rescue construct contained three silent mutations at the same site of the 
DNA recognized by the specific parkin siRNA. Because of the mutations, the siRNA 
lost its ability to bind to the construct, which would otherwise lead to its destruction (Fig. 
34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Finally, mouse embryonic fibroblast (MEF) cells derived from parkin knockout 
mice were tested for their viability after ER stress. The MEF cells were treated with 
thapsigargin overnight and analyzed by the MTT viability assay. Interestingly, the MEF 
cells derived from knockout mice were more vulnerable to ER stress than wild-type 
MEF cells (Fig. 35). (MEF cells were kindly prepared by Anita Schlierf.) 
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Fig. 34: The increased vulnerability of parkin-deficient cells to ER stress can be rescued 
by siRNA-resistant wild-type parkin. SH-SY5Y cells were transfected with parkin-specific or 
control siRNA duplexes and co-transfected with EYFP (as a control) or siRNA-resistant wild-
type parkin (rescue parkin). Three days later the cells were stressed with TG (10 µM) for 8 h 
fixed, permeabilized, and then activation of caspase-3 was analyzed by indirect 
immunofluorescence as described in Fig. 32. Parkin expression levels were determined by 
immunoblotting using the anti-parkin PRK8 mAb. Loading was controlled by re-probing the blots 
for β-actin (right panel). (Caspase assays were kindly counted by Kathrin Lutz.) *** p < 0.001. 
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3.1.5 Parkin has no direct effect on ER stress 
 The experiments above established a protective role of parkin in response to 
ER stress. To gain insight into the mechanism underlying this effect, the question was 
addressed whether parkin might have an influence on the severity of ER stress. 
Therefore, a knockdown of parkin in SH-SY5Y cells was performed (Fig. 36C) and the 
mRNA levels of the UPR target genes BIP and CHOP in response to ER stress were 
examined. After thapsigargin-induced ER stress BiP mRNA was highly up-regulated 
(15 fold compared to untreated cells). Interestingly, the knockdown of parkin had no 
significant impact on the mRNA level of the chaperone BiP under basal as well as 
under ER stress conditions (Fig. 36A). In parallel, the mRNA of the pro-apoptotic 
protein CHOP was highly up-regulated after ER stress. However, also here the 
knockdown of parkin had no influence on the level of induction (Fig. 36B).  
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Fig. 35: Mouse embryonic fibroblasts (MEFs) derived from parkin knockout mice are 
more vulnerable to ER stress than wild-type MEFs. MEFs from wild-type (WT) or parkin 
knockout (KO) mice were stressed with TG (10 µM) for 16 h and then cellular viability was 
determined by the MTT assay. Shown is the relative viability of KO MEFs in comparison to WT 
MEFs after TG treatment. Quantification is based on five independent experiments. ** p < 0.01. 
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 Additionally, MEF cells derived from parkin knockout mice were examined in 
comparison to wild-type MEFs in their capability to induce BiP mRNA after ER stress. 
In line with the findings of transient parkin knockdown cells, the parkin knockout MEFs 
also showed no significantly altered levels of BiP mRNA after thapsigargin or 
tunicamycin treatment compared to control MEFs (Fig. 37). (Experiment was kindly 
performed by Anita Schlierf.) 
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Fig. 36: The transient knockdown of parkin has no impact on the ER stress markers BiP 
and CHOP. (A-C) SH-SY5Y cells were transfected with parkin-specific or control siRNA 
duplexes. Three days later the cells were stressed with 1 µM TG for 5 h. As an indicator of ER 
stress BiP (A) and CHOP (B) mRNA levels were analyzed by quantitative RT-PCR as described 
in Fig. 16. The amount of RNA of each sample was normalized with respect to the endogenous 
housekeeping gene β-actin. Shown is the fold increase of BiP-specific mRNA (A) or CHOP-
specific mRNA (B) compared to untreated control cells. (C) To test for the efficiency of parkin 
knockdown, parkin mRNA levels were quantified in parallel. n.s. = not significant. 
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 To test whether the induced expression of parkin has an effect on the UPR, 
several reporter constructs were cloned. Given that transcriptional activation of UPR 
target genes is mediated by three signalling cascades PERK/eIF2α/ATF4, ATF6 and 
IRE1/XBP1, the reporter constructs contained different ER stress response elements in 
front of a luciferase gene, allowing to differentiate between these three pathways. 
Interestingly, especially for adaptation to chronic stress the selective activation of 
signalling through one or two of the limbs of the UPR is proposed (Rutkowski and 
Kaufman, 2007). To the different ER stress response elements one or two of the three 
known UPR transducers ATF4, ATF6 and XBP1 were able to bind (Fig. 38). The first 
luciferase construct contained the ER stress response element (ERSE), which is fully 
activated by ATF6, even in the absence of XBP1, but dependent on NF-Y (Yoshida et 
al., 1998). The second one contained the unfolded protein response element (UPRE), 
only depending on XBP1 (Wang et al., 2000). The third one, ERSE-II, allowed binding 
of ATF6 dependent on NF-Y as well as NF-Y-independent binding of XBP1 (Kokame et 
al., 2001). The last one, ATF4 response stress element (ATF4RE), contained the 
binding site for ATF4 from the promoter of the Insulin growth factor binding protein 1 
(IGFBP1) (Marchand et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3xERSE
3xUPRE
3xERSE II
ATF6NF-Y
CCAAT (N9) CCACG
XBP1 luciferase
TGACGTGG
luciferase
ATTGG - N - CCACG
luciferase
IRE1, ATF6
IRE1
IRE1, ATF6
3xARSE PERK
ATTTACATCA
luciferaseATF4
UPR transducersER stress responsive elements
XBP1
XBP1NF-Y
ATF6
ATF6
Fig. 37: The level of ER stress is not increased in mouse embryonic fibroblasts (MEFs) 
derived from parkin knockout mice. MEFs from wild-type (WT) or parkin knockout (KO) mice 
were stressed with 1 µM TG or 2 µg/ml TM for 5 h. The levels of BiP mRNA were analyzed by 
RT-PCR as described in Fig. 16. The amount of RNA of each sample was normalized with 
respect to the endogenous housekeeping gene β-actin. Shown is the fold increase of BiP-
specific mRNA compared to untreated control cells. (Experiment was kindly done by Anita 
Schlierf.) n.s. = not significant. 
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 HEK293T cells were transiently transfected with one of the ER stress reporter 
constructs and a plasmid coding for parkin or GFP as a control. To test whether parkin 
has an impact on ER stress, cells were additionally subjected to thapsigargin-induced 
ER stress (Fig. 39). Luciferase activity was clearly increased after thapsigargin 
treatment for all of the four reporter constructs. Interestingly, parkin did not significantly 
influence ER stress-dependent transcription, neither under basal conditions nor under 
ER stress. The same results were obtained in SH-SY5Y cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Besides wild-type parkin also other parkin constructs were tested for their ability 
to influence ER stress. The UPRE reporter was co-transfected with wild-type parkin, 
full-length (fl) parkin devoid of the internal initiation site, the smaller parkin species 
lacking the N-terminal UBL domain (ΔUBL) and the loss of function mutant 
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Fig. 38: ER stress luciferase reporter constructs cloned to quantify the ER stress 
response. Binding of ER stress-specific transcription factors to each construct and UPR 
transducers involved are schematically shown. ERSE: ER stress response element, UPRE: 
unfolded protein response element, ERSE II: ER stress response element II, ATF4RE: ATF4 
response element, NF-Y: nuclear factor-Y, XBP1: X-box binding protein 1, ATF6: activating 
transcription factor 6, IRE1: inositol requiring enzyme 1, ATF4: activating transcription factor 4, 
PERK: PKR (double-stranded RNA-activated protein kinase)-like ER kinase. 
 
Fig. 39: Overexpression of parkin has no influence on the ER stress level determined by 
ER stress reporter constructs. HEK293T cells were cotransfected with the ER stress reporter 
plasmids and either parkin or GFP (as a control). 24 h after transfection, the cells were treated 
with 1 µM TG for 8 h. Shown is the fold induction of luciferase activity in parkin-expressing cells 
in comparison to GFP-expressing control cells. Quantification is based on triplicates of at least 
three independent experiments. Expression levels of parkin were analyzed by immunoblotting 
using the anti-parkin pAB 2132. Loading was controlled by re-probing the blots for β-actin 
(lower panel). n.s. = not significant. 
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W453STOP. However, all parkin constructs tested showed no difference in the 
induction of the luciferase expression under basal nor under ER stress conditions (Fig. 
40A). For further evidence the ER stress reporter constructs were also tested in parkin 
deficient HEK293T cells. But also the loss of parkin did not lead to significant 
alterations in luciferase activity under ER stress as well as under normal conditions 
(Fig. 40B). 
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Fig. 40: Loss of parkin function has no impact on ER stress reporter constructs. (A) 
Parkin mutants have no influence on ER stress reporter constructs. HEK293T cells were 
cotransfected with the UPRE construct and either GFP, wild-type parkin, full-length (fl) parkin or 
the pathogenic parkin mutants ΔUBL and W453STOP. 24 h after transfection, the cells were 
treated with 1 µM TG for 8 h. Shown is the fold induction of luciferase activity in parkin-
expressing cells in comparison to GFP-expressing control cells. Quantification is based on 
triplicates of at least three independent experiments. (B) Parkin deficiency has no impact on ER 
stress reporter constructs. HEK293T cells were transfected with parkin-specific or control 
siRNA duplexes and the ER stress reporter constructs UPRE, ERSE and ERSEII. Two days 
later the cells were stressed with 1 µM TG for 8 h. Shown is the fold induction of luciferase 
activity in parkin-knockdown cells in comparison to control cells. Quantification is based on 
triplicates of at least three independent experiments. 
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 In addition, to exclude that parkin might have an influence on the induction of 
ER stress, which is not due to drug treatment rather than to protein expression, the 
Pael receptor (Pael-R) and the receptor tyrosinkinase Ret were co-expressed together 
with parkin and the reporter construct ERSE. The Pael-R is reported to be a substrate 
of parkin and when overexpressed to become unfolded and insoluble and to induce ER 
stress (Imai et al., 2001). Ret is a highly glycosylated receptor molecule at the cell 
membrane, associated with GDNF (glial cell line derived neurotrophic factor) signalling. 
Several splice variants exist, the longest one is 1114 bp long (Ret-long). 
Overexpression of Ret-long is also likely to misfold and to induce ER stress. Indeed, 
the overexpression of the Pael-R (Fig. 41A) and Ret-long (Fig. 41B) resulted in 
increased luciferase activity of ERSE-luc, indicating an induction of ER stress. 
However, also in this case the co-expression of parkin had no effect on the level of ER 
stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Parkin has an E3 ubiquitin ligase activity and was previously reported to be 
involved in the proteasomal degradation of misfolded secretory pathway proteins and 
thereby to protect the cell for toxic accumulation of parkin substrates, such as Pael-R. 
Therefore, the question was addressed whether the protective activity of parkin is 
dependent on the proteasome. To induce proteasomal inhibition, low parkin expressing 
SH-SY5Y cells were treated with a low concentration of epoxomycin. The efficiency of 
proteasome inhibition was controlled by analyzing the steady state level of the rapidly 
Fig. 41: Parkin has no influence on ER stress due to accumulating proteins in the ER. (A, 
B) HEK293T cells were cotransfected with the ERSE reporter construct and either GFP, Pael-R 
or Ret-long together with GFP or wild-type parkin. Shown is the fold induction of luciferase 
activity in Pael-expressing (A) or Ret-long-expressing (B) cells in the presence or absence of 
parkin in comparison to GFP-expressing control cells.  
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turned over transcription factor p53 and the total ubiquitin load in the cell (Fig. 42B). As 
expected, thapsigargin treatment resulted in an increase in apoptotic cells and parkin 
overexpression was able to rescue this effect. Interestingly, parkin was also protective 
in cells treated with both thapsigargin and epoxomycin, indicating that protein 
degradation via the proteasome is not required for the protective function of parkin after 
ER stress. Of note, for this experiment we used a non-toxic concentration of 
epoxomycin which was sufficient to inhibit proteasomal degradation (Fig. 42A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In addition, we tested the potential of parkin to protect cells from cell death 
induced by toxic concentrations of proteasomal inhibitors. After treatment with MG132 
for 8 hours, apoptotic SH-SY5Y cells were visualized with anti-active caspase-3 
antibody. The proteasomal block resulted in an increase of apoptotic cells, however, 
cells overexpressing parkin showed a reduced apoptotic cell rate (Fig. 43). 
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Fig. 42: The protective activity of parkin after ER stress is independent of the 
proteasome. (A, B) (A) SH-SY5Y cells were cotransfected with EYFP (as a control) and wild-
type parkin. 24 h after transfection, cells were incubated with 10 µM TG and/or 0.1 µM 
epoxomycin (epox) for 8 h, fixed, permeabilized, and then activation of caspase-3 was 
analyzed as described in Fig. 32. Parkin expression levels were determined by immunoblotting 
using the anti-parkin PRK8 mAb. Loading was controlled by re-probing the blots for β-actin 
(lower panel). (Caspase assays were kindly counted by Kathrin Lutz.) (B) Efficiency of 
proteasomal inhibition by epoxomycin was controlled by immunoblotting for p53 (mAb) and for 
ubiquitin (mAb). Loading was controlled by re-probing the blots for β-actin. *** p < 0.001, ** p < 
0.01, n.s. = not significant. 
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3.1.6 Involvement of parkin in protective signaling pathways 
 The experiments above showed a protective function for parkin after ER stress. 
In addition, previous experiments also from our group, showed that parkin is also 
protective after various other stress factors like rotenone or kainic acid. Our analysis 
demonstrated that the protective activity of parkin was not dependent on the 
proteasome as postulated recently. How does parkin mediate its protective effect? One 
hypothesis could be that parkin is influencing major anti-stress pathways. One pathway 
which is involved in the up-regulation of anti-apoptotic proteins is the NF-κB (nuclear 
factor kappa enhancer binding protein) pathway. NF-κB transcription factors regulate 
various biological processes, including apoptosis, differentiation, and immunity. The 
IκB kinase (IKK) complex, consisting of two catalytic (IKKα and IKKβ) and one 
regulatory (IKKγ/NEMO [NF-κB essential modifier]) subunit, regulates the degradation-
dependent activation of NF-κB by lysine 48 (K48)-linked ubiquitylation of the NF-κB 
inhibitor IκB. The activation of the IKK complex and other upstream located regulators 
such as TRAF2 (tumor necrosis factor [TNF] receptor associated factor 2) and TRAF6 
is dependent on the degradation independent ubiquitylation by lysine 63 (K63)-linked 
ubiquitin chains.  
 To test whether parkin could have an influence on the NF-κB pathway by 
ubiquitylating IKKγ and/or TRAF2 in a degradation-independent manner, first co-
immunoprecipitation experiments and then ubiquitylation assays were performed. Full-
length parkin and FLAG-tagged IKKγ or TRAF2 were co-expressed in HEK293T cells 
and the immunoprecipitation was performed with a polyclonal anti-IKKγ or TRAF2 
antibody. Co-precipitated proteins were subjected to SDS-PAGE and immunoblotted 
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Fig. 43: Parkin is protective against cell death induced by proteasomal inhibition. SH-
SY5Y cells were cotransfected with EYFP (as a control) and wild-type parkin. 24 h after 
transfection, cells were incubated with 5 µM MG132 for 4 h, fixed, permeabilized, and then 
activation of caspase-3 was analyzed as described in Fig. 32. 
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with a monoclonal anti-parkin antibody. IKKγ as well as TRAF2 co-immunoprecipitated 
together with parkin in a complex. The vector control and parkin transfected without 
IKKγ (Fig. 44A) or TRAF2 (Fig. 44B) did not show any complex formation. These 
findings indicate a specific interaction between IKKγ or TRAF2 and parkin in a direct or 
indirect way.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Subsequently, ubiquitylation assays were performed. Therefore, full-length 
parkin, HA-tagged ubiquitin and FLAG-tagged IKKγ or TRAF2 were co-expressed in 
HEK293T cells. The immunoprecipitation was done under denaturating conditions with 
an anti-FLAG antibody followed by Western Blot analysis using an anti-HA antibody. 
Notably, parkin was able to increase the ubiquitylation of IKKγ or TRAF2 compared to 
the vector control. Remarkably, the co-expression of the pathogenic parkin mutants 
ΔUBL and R42P showed a reduced ubiquitylation pattern for IKKγ (Fig. 45A) as well as 
for TRAF2 (Fig. 45B). In addition, also the mutant TRAF2ΔN, lacking the N-terminal 
RING domain, essential for its E3 ligase activity, was ubiquitylated by parkin, indicating 
that the increase of ubiquitylation was not due to autoubiquitylation capacity of TRAF2 
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Fig. 44: Parkin is found in a complex together with IKKγ  and TRAF2. (A, B) HEK293T cells 
were cotransfected with full-length (fl) parkin and either IKKγ (A) or TRAF2 (B). One day after 
transfection cells were harvested, lysed, and cleared by centrifugation. Equal protein amounts 
of the supernatant were incubated with a pAb against IKKγ or TRAF2 overnight at 4°C. Proteins 
present in the immunoprecipitates (IP) were resolved by SDS-PAGE and immunoblotted (IB) 
with the anti-parkin mAb PRK28. Aliquots of the supernatant were immunoblotted with 
antibodies against parkin (pAb hP1), IKKγ (mAb), TRAF2 (mAb), respectively (input controls: 
bottom panels). (This experiment was performed by Iris Henn.) 
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itself. On the other hand, the ubiquitylation of TRAF6, located upstream of IKKγ and 
also regulated by ubiquitylation, was not increased after parkin co-expresssion (Fig. 
45C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To determine the mode of ubiquitin linkage of parkin-mediated ubiquitylation of 
IKKγ, ubiquitin mutants were used. These ubiquitin mutants lack all but one lysine, K48-
Fig. 45: Parkin promotes ubiquitylation of IKKγ  and TRAF2. (A-C) Full-length (fl) parkin, 
ΔUBL parkin, or R42P, HA-tagged ubiquitin, and either FLAG-tagged IKKγ (A), TRAF2 (B), or 
TRAF6 (C) were cotransfected into HEK293T cells. At 24 h after transfection, cells were 
harvested, lysed and cleared by centrifugation. Equal protein amounts of the supernatant were 
subjected to an immunoprecipitation (IP) under denaturating conditions using an anti-FLAG 
mAb. Immunoprecipitates were resolved by SDS-PAGE and immunoblotted (IB) with the anti-
HA mAb (top panels). Aliquots of the supernatant before the immunoprecipitation were 
immunoblotted with antibodies against parkin (pAb hP1), IKKγ (mAb), TRAF2 (mAb), and 
TRAF6 (mAb) respectively (input controls: bottom panels). Molecular size markers are 
indicated as bars at the left side of the panels and represent 148, 98, and 64 kDa (A, B) or 98, 
64, and 50 kDa (C). v: vector control; b: buffer control (no lysate). (This experiment was 
performed by Iris Henn.) 
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only or K63-only, thereby allowing only the assembly of ubiquitin chains via lysine 48 or 
lysine 63, respectively. The ubiquitylation assays were performed with IKKγ as 
described above. The use of the ubiquitin mutant K48-only reduced the potential of 
parkin to ubiquitylate IKKγ. In contrast the K63-only mutant promoted ubiquitylation of 
IKKγ by parkin to a similar extent as wild-type ubiquitin. This finding indicates that 
parkin preferentially promotes ubiquitylation via K63-linked ubiquitin chains, supporting 
a non-proteolytic regulatory function of parkin (Fig. 46).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For further evidence that parkin stimulates NF-κB activation, a reporter assay 
with a NF-κB regulated inducible promoter in front of a firefly luciferase (NF-κB-luc), in 
was performed parkin-deficient cells. HEK293T cells were co-transfected with the NF-
κB-luc and control or parkin siRNA. After mild stimulation with PMA, an activator of the 
NF-κB pathway, the NF-κB dependent-expression of the luciferase construct was 
induced. However, the parkin-deficient cells showed a drastically reduced 
transcriptional activation than the control siRNA transfected cells, demonstrating that 
parkin is involved in the regulation of NF-κB activation after the stimulation with PMA 
(Fig. 47). 
 
 
 
Fig. 46: Parkin preferentially promotes K63-linked polyubiquitylation of IKKγ . Full-length 
parkin, FLAG-tagged IKKγ, and HA-tagged wild-type ubiquitin, K48-only, or K63-only ubiquitin 
mutant were cotransfected into HEK293T cells. At 24 h after transfection, cells were harvested 
and analyzed as described in Fig. 45. b: buffer control (no lysate). (This experiment was 
performed by Iris Henn.) 
IP: !"FLAG
IB: !"HA
input
HA-K48
only
HA-K63
only
b
HA-ubi
!-IKK#
!-parkin
IgG
parkin
  Results 
 69 
 
 
 
 
 
 
 
 
 
 
 
 
A possible role of NF-κB in protecting cells for ER stress induced cell death was 
supported by the finding that it is activated after ER stress (Hu et al., 2006; Pahl and 
Baeuerle, 1995). Therefore, an EMSA was performed, monitoring the NF-κB DNA 
binding affinity in response to ER stress. The induction of ER stress by thapsigargin 
lead to a slight increase of NF-κB binding to the NF-κB consensus sequence. 
Interestingly, the binding affinity of NF-κB was not influenced by parkin as 
demonstrated with parkin deficient cells. However, compared to other stressors the NF-
κB binding capacity after ER stress was quite low, either indicating only a slight 
increase of NF-κB activation to ER stress or the problematic to find the right time point 
to look at NF-κB activation, as this is possible a quite transient event. In addition, the 
NF-κB response is influenced by other factors as the signal differes between 
untransfected and control transfected cells (Fig. 48). In conclusion, a direct link of 
parkin in modulating NF-κB activation after ER stress was not dectably by this 
approach. 
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Fig. 47: Loss of parkin compromises NF-κB activation in response to stress. HEK293T 
cells co-transfected with parkin-specific or control siRNA duplexes and the NF-κB reporter 
plasmid (NF-κB-luc) were incubated 48 h after transcfection with 10 and 20 ng/ml PMA for 3 h. 
Cells were harvested and analyzed for luciferase activity 5 h later. 
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 Recent studies indicated a signalling crosstalk between JNK and NF-κB at 
various levels (Papa et al., 2004). Furthermore, JNK was shown to be activated in 
response to ER stress. In figure 26C c-Jun binding to the AP1 site was observed after 
treatment with thapsigargin, supposing an activation of upstream located c-Jun kinase 
(JNK) in response to ER stress. As we could show that parkin has a positive effect on 
the activation of the NF-κB pathway, the question arouse whether parkin would also 
have an impact on the JNK-pathway. To test this hypothesis wild-type parkin and the 
pathogenic parkin mutants ΔUBL or R42P were co-transfected with a JNK responsive 
reporter construct. Additionally, the cells were treated with thapsigargin to stimulate 
JNK activation. The JNK reporter construct was induced after ER stress, however, 
neither the expression of wild-type parkin nor the expression of the parkin mutants had 
any influence on the JNK activity under basal or under ER stress conditions (Fig. 49). 
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Fig. 48: Parkin has no impact on ER stress induced NF-κB activation. HEK293T cells 
transcfected with parkin-specific or control siRNA complexes were incubated 48 h after 
transfection with 5 µM TG or 25 ng/ml TNFα. Cells were harvested 2 h later and extracts were 
prepared and tested for binding to the 32P-labeled oligonucleotide comprising the common NF-
κB binding site by an electrophoretic mobility shift assay (EMSA).  
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 In a further approach, components of the JNK pathway were tested for their 
ability to be activated by parkin. The activation of c-Jun and JNK is regulated by 
phosphorylation, therefore phospho-specific antibodies were used to monitor the 
activation status. HEK293T cells expressing parkin were incubated under UV for 20 
min and the protein lysates were analyzed by Western blotting. JNK and c-Jun were 
phosphorylated after UV treatment, however the presence of parkin had no influence 
on the strength of the phosphorylation signal (Fig. 50). 
 
 
 
 
 
 
 
 
 Interestingly, the knockdown of parkin resulted in transcriptional up-regulation of 
the JNK suppressing protein A20 (also called tumour necrosis factor alpha induced 
protein 1), especially under ER stress conditions. This observation points to a 
compensatory mechanism of JNK suppression in the absence of parkin (Fig 51). 
 
 
 
 
 
 
 
 
 
 
Fig. 50: Parkin has no impact on c-Jun or JNK phosphorylation. HEK293T cells were 
transfected with parkin or GFP as control. The next day cells were exposed to UV light for 20 
min. Cells were lysed in cell lysis buffer containting phosphatase and protease inhibitors and 
immunoblotted using pAb against α-phospho c-Jun or α-phospho JNK. Loading was controlled 
by reprobing the blots for β-actin. 
Fig. 49: Parkin has no effect on JNK reporter assay. HEK293T cells were cotransfected with 
the JNK reporter construct and either GFP, wild-type parkin, or the parkin mutants ΔUBL or 
R42P. 8h after transfection cells were treated with 1µM thapsigargin for 14h. Shown is the fold 
induction of luciferase activity in comparison to GFP-expressing control cells.  
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 Another survival mechanism of the cell that could be influenced by parkin is the 
autophagic-lysosomal pathway. Autophagy is an intracellular, lysosome-mediated 
degradation process for damaged cellular constituents, including membranes, 
organelles, and proteins, thereby contributing to the maintenance of cellular 
homeostasis (Dice, 2007). It is also an adaptive survival mechanism that is activated in 
response to various environmental challenges (Levine, 2005; Shintani and Klionsky, 
2004). As a marker for autophagy activity, the microtuble-associated protein 1 light 
chain 3 (LC3) is used. During autophagy, the cytoplasmic form LC3-I (18kDa) is 
processed and recruited to the autophagosomes, where the smaller form LC3-II 
(16kDa) is generated by site-specific proteolysis and lipidation near the C-terminus. 
The amount of LC3-II correlates well with the number of autophagosomes, as they are 
transient structures, resulting in a short half-life for LC3-II. We were now interested 
whether parkin had an influence on autophagy after stress. As our previous 
experiments showed an up-regulation of parkin after ER stress and in addition, 
autophagy was reported to be induced after ER stress, we chose to look at LC3 levels 
after thapsigargin treatment. The autophagy inhibitor chloroquine (CQ) was used to 
analyze the autophagic flux. Chloroquine disrupts lysosomal function inhibiting the 
acid-dependent degradation of autophagosome contents, which results in the 
accumulation of autophagic vesicles that cannot be cleared. Parkin deficient HEK293T 
cells were incubated with thapsigargin or chloroquine and analyzed by immunoblotting 
for LC3. As expected, the treatment with chloroquine resulted in a strong increase of 
LC3-II, demonstrating an accumulation of autophagic vesicles containing the 
autophagosome bound LC3-II from. In parallel also the treatment with thapsigargin 
resulted in an increase of the LC3-II band, indicating an activation of autophagy after 
ER stress. However, the knockdown of parkin had only a slight influence on the ratio 
between LC3-II and LC3-I level and was not significantly changed under ER stress 
conditions (Fig. 52). Collectively, parkin does not seem to play a role for the induction 
of autophagy after ER stress.  
 
 
 
 
Fig. 51: A20 mRNA is up-regulated in parkin-deficient cells. SH-SY5Y cells were reversly 
transfected with parkin or control siRNA duplexes. Three days after transfection cells were 
treated with 1 µM thapsigargin and harvested 14 h later. Total cellular RNA was isolated and 
subjected to quantitative RT-PCR using A20-specific primers. The amount of RNA of each 
sample was normalized with respect to β-actin. Shown is the fold increase in the amount of 
A20-specific mRNA in comparison to the untreated control.  
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3.1.7 Parkin maintains mitochondrial integrity after ER stress 
 In conclusion, so far our study could not show a direct involvement of parkin in 
the activation of pro-survival pathways such as the NF-κB-pathway and the 
autophagic-lysosomal-pathway or inhibition of pro-apoptotic pathways such as the 
JNK-pathway after ER stress to mediate its protective function. Interestingly, ER stress 
was shown to lead to alterations in the morphology of mitochondria (Hom et al., 2007). 
Additionally, loss-of-parkin was demonstrated to influence mitochondria integrity (Lutz 
et al., 2009). Therefore we asked the question, whether parkin could have an impact on 
mitochondrial integrity after ER stress. The mitochondrial morphology was imaged by 
fluorescence microscopy in living SH-SY5Y cells after treatment with thapsigargin or 
tunicamycin for 6 or 15 hours. Under normal physiological conditions the majority of 
cells showed a network of tubular mitochondria, only about 30% of mitochondria are 
truncated or fragmentated. Upon ER stress the percentage of fragmented mitochondria 
was significantly increased up to 70%. Longer exposure to ER stress resulted in a 
slight increase in the amount of fragmented mitochondria. Remarkably, increased 
expression of parkin could significantly reduce ER stress-induced mitochondrial 
fragmentation (Fig. 53A,B).  
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Fig. 52: Parkin has no significant impact on autophagy after ER stress. HEK293T cells 
were transfected with control or parkin siRNA and treated after 48 h with 50 µM chloroquine 
(CQ) or 1 µM TG for 15 h. Cell lysates were lysed in 0.5% Triton X-100 and analyzed by 
immunoblotting using a pAb against LC3. The Western blot image was re-arranged by 
excluding one line, as indicated by a white line; all samples originate from one gel. 
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 The effect of parkin on mitochondrial morphology was demonstrated to be 
specific as the anti-apoptotic protein Bcl-2 failed to rescue the ER stress-induced 
fragmented mitochondria phenotype (Fig. 54A). ER stress also had an impact on the 
mitochondrial function. The cellular ATP production was drastically decreased in 
tunicamycin treated cells. Interestingly, the additional knockdown of parkin worsened 
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Fig. 53: Increased expression of parkin suppresses ER stress-induced mitochondrial 
fragmentation. (A, B) SH-SY5Y cells were transfected with parkin or mCherry (as a control). 
One day after transfection, the cells were treated with 1 µM TG or 2 µg/ml TM for 5 or 16 h. 
Mitochondria were visualized by life cell microscopy after incubating cells with the fluorescent 
dye DiOC6(3). (A) The mitochondrial morphology was classified as tubular, in case of an intact 
network of tubular mitochondria or as fragmented, when this network was disrupted and 
mitochondria appeared predominantly spherical or rod-like. Shown is the percentage of cells 
with fragmented mitochondria. Quantifications were based on three independent experiments. 
Per experiment ≥ 300 cells per coverslip of triplicate samples were assessed. Expression levels 
of parkin were analyzed by immunoblotting using the anti-parkin pAb 2132. Loading was 
controlled by re-probing the blots for β-actin (lower panel). (B) Examples of mitochondrial 
morphologies of the experiment described in (A). Treatment of cells with TG or TM cause a 
disruption of the tubular mitochondrial network, which can be suppressed by increased parkin 
expression. (The experiment was kindly done by Kathrin Lutz.) *** p < 0.001, ** p < 0.01. 
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the mitochondrial energy production after ER stress. Obviously, parkin maintains 
mitochondrial integrity and, remarkably, even under ER stress it is able to protect 
mitochondria by preventing mitochondrial morphology alterations and changes in their 
bioenergetics (Fig. 54B). (Mitochondria morphology assays and the ATP assays were 
kindly performed by Kathrin Lutz.)  
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Fig. 54: The effect of parkin on mitochondrial integrity after ER stress is specific and 
parkin deficiency increases mitochondrial dysfunction. (A) Anti-apoptotic Bcl-2 has no 
effect on ER stress-induced mitochondrial fragmentation. SH-SY5Y cells were transfected with 
Bcl-2-FLAG. One day after transfection, the cells were treated with 1 µM TG or 2 µg/ml TM for 
5 h. Mitochondria were visualized, categorized and quantified as described in Fig. 53. 
Expression level of Bcl-2 was analyzed by immunoblotting using the anti-Flag M2 mAb. 
Loading was controlled by re-probing the blots for β-actin (right panel). (B) Parkin deficiency 
increases ATP depletion in response to ER stress. SH-SY5Y cells were reversly transfected 
with either parkin or control siRNA duplexes. Three days after transfection the cells were 
treated with 2 µg/ml TM for 5 h and the steady state cellular ATP levels were measured. (The 
experiment was kindly done by Kathrin Lutz.)  *** p < 0.001. 
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3.2 REGULATION OF PD-ASSOCIATED GENES IN RESPONSE TO 
PATHOPHYSIOLOGICAL STRESS CONDITIONS 
 
3.2.1 Parkin gene expression is stress-regulated 
 Our studies showed an up-regulation of parkin in response to ER stress. We 
wondered now whether parkin is also regulated in response to other stressors 
especially as parkin has been shown to maintain neuronal integrity under various 
moderate stress conditions for example excitotoxicity, oxidative stress and proteasomal 
inhibition in different model systems. In a first attempt we used two stress conditions, 
which play a prominent pathophysiological role in PD, namely the complex-I inhibiton 
induced by rotenone and excitotoxicity induced by kainic acid. Experiments from our 
group demonstrated for both stressors a protective function of parkin (Henn et al., 
2007). SH-SY5Y cells were treated with either rotenone or kainic acid and the parkin-
specific mRNA levels were analyzed by quantitative real-time PCR (Fig. 55A). The real-
time PCR revealed that parkin mRNA levels were significantly increased in response to 
mitochondrial and excitotoxic stress with a maximal increase 5-8 hours after drug 
treatment. In parallel, the rotenone induced increase of parkin mRNA was translated 
into elevated endogenous parkin protein levels (Fig. 55B). 
 In addition, stress induction of parkin mRNA was also observed in primary 
cortical neurons derived from embryonic mouse brain after treatment with glutamate for 
6 hours. Glutamate is an excitotoxic stressor like kainic acid (Fig. 55C).  
To test whether parkin up-regulation was due to an induction of the UPR, the park-luc 
construct was tested in response to kainic acid and rotenone treatment in SH-SY5Y 
cells. Both stressors did not result in an increase in the transcriptional response of 
luciferase, indicating an ATF4 independent mechanism (data not shown).  
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 Next, dopamine was tested as a potential stressor and inducer of parkin mRNA 
expression. Dopamine is the principal neurotransmitter produced in the neurons of the 
substantia nigra. It is a highly reactive molecule that possesses a great propensity for 
oxidation to form multiple reactive oxygen species. High doses of dopamine were found 
A 
C B 
Fig. 55: Parkin is up-regulated in response to mitochondrial and excitotoxic stress. (A) 
Parkin mRNA is up-regulated in SH-SY5Y cells after excitotoxic and oxidative stress. SH-SY5Y 
cells were stressed with 50 µM kainic acid (left panel) or 1 µM rotenone (right panel) for 3 h and 
harvested 5, 8, 12 and 24 h after drug treatment, respectively and analyzed as described in Fig. 
16 for quantitative RT-PCR using parkin-specific primers. The amount of RNA of each sample 
was normalized with respect to β-actin. Shown is the fold increase in the amount of parkin-
specific mRNA in rotenone- or kainic acid-treated cells in comparison to the untreated control. 
(B) The increase of parkin mRNA was translated into elevated endogenous parkin protein 
levels. SH-SY5Y cells were treated with rotenone (1 µM, 3 h) or mock-treated, and expression 
of endogenous parkin was analyzed by Western blotting using the PRK8 mAb. (C) Parkin 
mRNA in primary neurons is up-regulated in response to excitotoxic stress. Primary cortical 
neurons derived from embryonic rat brain were incubated with glutamate (5 or 10 µM) for 6 h 
and then analyzed as described in (A). 
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to covalently modify and functionally inactivate parkin (LaVoie et al., 2005), therefore a 
low dopamine concentration was used to stimulate the cells (80 µM). SH-SY5Y cells 
treated with dopamine showed more than a 2,5-fold up-regulation of their parkin mRNA 
after 24 hours (Fig. 56A).  
 The association of parkin to the proteasome system and due to the fact that it is 
able to protect cells from cell death induced by proteasomal inhibition (Fig. 42 and 43) 
provokes the question, whether parkin expression is also regulated after proteasomal 
inhibition. The proteasome was inhibited by the treatment with MG132. Interestingly, in 
contrast to the other tested stressors proteasomal stress did not lead to an up-
regulation of parkin mRNA (Fig. 56B). 
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Fig. 56: Parkin mRNA is up-regulated in response to dopamine treatment, but not after 
protesomal inhibition. (A) Parkin mRNA expression responds to dopamine treatment. SH-
SY5Y cells were treated with 80 µM dopamine for 3 h and harvested after 5 h or 24 h and 
analyzed as described in Fig. 16 for quantitative RT-PCR using parkin-specific primers. The 
amount of RNA of each sample was normalized with respect to β-actin. Shown is the fold 
increase of parkin mRNA in response to dopamine treatment. (B) Parkin mRNA is not up-
regulated after proteasomal inhibition. SH-SY5Y cells were treated with 30 µM MG132 for 3 h 
and harvested after 5, 8, 14 or 24 h, respectively and analyzed as described in Fig. 16 for 
quantitative RT-PCR using parkin-specific primers. The amount of RNA of each sample was 
normalized with respect to β-actin. Shown is the fold increase in the amount of parkin-specific 
mRNA in MG132-treated cells in comparison to the untreated control. 
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3.2.2 PACRG is up-regulated in response to ER stress 
 The parkin co-regulated gene (PACRG) is transcribed from the same bi-
directional promoter as parkin, but on the opposite DNA strand in the opposite 
direction, suggesting some common regulatory binding motifs used for both genes. We 
were now interested whether PACRG transcription is up-regulated in response to 
stress treatment to the same extent as parkin transcription. As an example, PACRG 
expression was examined after ER stress. The treatment with thapsigargin resulted in 
a 2,7-fold increase of PACRG mRNA compared to the non-treated control (Fig. 57A). 
To exclude that parkin directly influences the expression of PACRG, PACRG mRNA 
expression in parkin deficient cells was examined. The reduced expression of parkin 
had no impact on the expression of PACRG under normal conditions (Fig. 57B) as well 
as under ER stress conditions (data not shown). 
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Fig. 57: PACRG is up-regulated in response to ER stress, but PACRG transcription is not 
dependent on parkin. (A) PACRG mRNA is up-regulated after ER stress. SH-SY5Y cells were 
treated with 1 µM TG for 14 h. Total cellular RNA was isolated and subjected to quantitative 
RT-PCR using PACRG-specific primers. The amount of RNA of each sample was normalized 
with respect to β-actin. Shown is the fold increase in the amount of PACRG-specific mRNA in 
comparison to the untreated control. (B) Parkin deficiency has no effect on PACRG mRNA 
expression. SH-SY5Y cells were reversely transfected with parkin or control siRNA duplexes. 
Three days after transfection cells were harvested and analyzed as described in A. Shown is 
the fold increase of PACRG-specific mRNA in parkin-deficient cells compared to control 
transfected cells.  
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3.2.3 α-synuclein, DJ-1, PINK1, LRRK2 and HtrA2/omi are up-regulated in 
response to ER stress 
 Besides parkin other PD-associated genes are known. At least thirteen 
chromosomal loci have been associated with monogenic familial variants of PD, among 
them the genes coding for α-synuclein, DJ-1, PINK1, LRRK2 and HtrA2/omi. As parkin 
showed an impressive up-regulation after various stressors, the question was 
addressed whether these PD-associated genes are also regulated in response to 
stress.  
 In a first attempt, the expression of these PD-associated genes was tested after 
ER stress. ER stress was induced by treatment of the cells with either thapsigargin 
(upper panel) or tunicamycin (lower panel). All PD-associated genes tested showed an 
up-regulation of their mRNA. Remarkably, for all genes, the mRNA expression was still 
increased after 24 hours (Fig. 58).  
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 The up-regulation of parkin after ER stress was shown to be specifically 
regulated by the PERK/ATF4 branch of the UPR, therefore the mRNA of α-synuclein 
(Fig. 59A), DJ-1 (Fig. 59B), PINK1 (Fig. 59C) and HtrA2/omi (Fig. 59D) was examined 
after the knockdown of ATF4. However, the quantitative RT-PCR revealed that the 
knockdown of ATF4 had no influence on the up-regulation of their mRNA after ER 
stress. In summary, in contrast to the regulation of parkin expression after ER stress 
the regulation of the PD-associated genes DJ-1, HtrA2/omi, PINK1 and α-synuclein is 
not dependent on the PERK/ATF4 branch.  
 
 
 
 
 
 
 
 
Fig. 58: α-synuclein, DJ-1, PINK1, LRRK2, and HtrA2/omi mRNA is up-regulated in 
response to ER stress. SH-SY5Y cells were incubated with 1 µM TG (upper panel) or 2 µg/ml 
TM (lower panel) for 5, 8, 12 and 24 h, respectively and analyzed as described in Fig. 16 for 
quantitative RT-PCR using α-synuclein, DJ-1, PINK1, LRKK2, HtrA2/omi and parkin-specific 
primers. The amount of RNA of each sample was normalized with respect to β-actin. Shown is 
the fold increase in the amount of mRNA in comparison to the untreated control. In addition, 
parkin mRNA in response to ER stress is shown.  
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3.2.4 The expression of α-synuclein, DJ-1, PINK1, LRRK2 and HtrA2/omi is not 
changed in response to mitochondrial stress, excitotoxicity and dopamine 
treatment 
 In a next step, SH-SY5Y cells were stressed with rotenone or kainic acid. 
Remarkably, in contrast to parkin all the other examined PD-associated genes, α-
synuclein, DJ-1, PINK1, LRRK2 and HtrA2/omi were not induced after rotenone (Fig. 
60A) or kainic acid (Fig. 60B) treatment. In addition, also the treatment with dopamine 
did not result in a significant up-regulation of their mRNA in contrast to parkin (Fig. 
60C).  
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Fig. 59: α-synuclein, DJ-1, PINK1, and HtrA2/omi are not regulated by ATF4. (A-D) SH-
SY5Y cells were reversely transfected with ATF4-specific or control siRNA duplexes. 2 days 
later cells were transfected again with siRNA duplexes and followed by incubation of 1 µM TG 
for 16 h. The cells were harvested and analyzed as described in Fig.16 for quantitative RT-PCR 
using α-synuclein, DJ-1, PINK1, or HtrA2/omi-specific primers. The amount of RNA of each 
sample was normalized with respect to β-actin. Shown is the fold increase in the amount of 
mRNA in comparison to the untreated control. 
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3.2.5 PINK1 and parkin expression are not transcriptionally linked to each other 
 Several studies with different models indicated a genetic link between parkin 
and PINK1, suggesting that parkin acts downstream of PINK1 (Clark et al., 2006; Park 
et al., 2006; Yang et al., 2006a). As PINK1 is up-regulated after ER stress similarly to 
parkin, we asked the question whether the regulation of parkin and PINK1 expression 
might be dependent of each other. Therefore, skin fibroblasts from patients with two 
different PINK1 homozygous mutations (Q126P and G309D) were examined for their 
parkin mRNA and protein levels. The mutations were shown to impair PINK1 function 
(Exner et al., 2007). From the fibroblast line carrying the mutation Q126P two different 
patients were analyzed with their respecitve controls. Unfortunately, the results were 
not consistent between the two patients. The first mutation carrier showed an increase 
in parkin expression on the mRNA (Fig. 61A) as well as on the protein level (Fig. 61B) 
compared to his age-matched control. In contrast, the second carrier did not show an 
increase in parkin expression on the mRNA and protein level, when compared to his 
age-matched control. However, comparison of this latter patient with the control 
fibroblasts matching to the first patient revealed an increase in parkin mRNA and 
protein. For the patient carrying the second PINK1 mutation, G309D, an elevated level 
of parkin mRNA as well as parkin protein was observed compared to the age-matched 
control (Fig. 61C).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 60: α-synuclein, DJ-1, PINK1, LRRK2, and HtrA2/omi mRNA is not up-regulated in 
response to mitochondrial stress, excitotoxic stress, or dopamine treatment. (A-C) SH-
SY5Y cells were incubated with 1 µM rotenone (A), 50 µM kainic acid (B) or 80 µM dopamine 
(C) for the indicated time and analyzed as described in Fig. 16 for quantitative RT-PCR using α-
synuclein, DJ-1, PINK1, LRKK2, HtrA2/omi or parkin-specific primers. The amount of RNA of 
each sample was normalized with respect to β-actin. Shown is the fold increase in the amount 
of mRNA in comparison to the untreated control. In addition, parkin mRNA in response to these 
stressors is shown. 
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 To extent our study, the brain of PINK1 knockout mice, carrying a homozygous 
truncation after exon 1 was analyzed (Morais et al., 2009). The analysis of the parkin 
mRNA by quantitative RT-PCR did not show an increase compared to wild-type mice 
(Fig. 62A). In addition, also the transient knockdown of PINK1 in SH-SY5Y cells did not 
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Fig. 61: Parkin expression in fibroblasts of PD patients carrying PINK1 mutations is not 
consistently up-regulated. (A) Different PINK1 mutation carrier differ in their parkin mRNA 
content. Fibroblasts of controls or PD patients carrying the PINK1 Q126P (left and middle panel) 
or PINK1 G309D (right panel) mutation were analyzed as described in Fig. 16 for quantitative 
RT-PCR using parkin-specific primers. The amount of RNA of each sample was normalized with 
respect to GAPDH (Glycerinaldehyde-3-phosphate-dehydrogenase). Shown is the fold increase 
in the amount of parkin-specific mRNA in fibroblasts derived from PINK1 mutation carriers in 
comparison to the age-matched control fibroblasts. Right panel: Shown is the parkin mRNA of 
the first PD patient carrying the Q126P (patient Q126P 1) mutation in comparison to his age-
matched control (control 1). Middle panel: Shown is the parkin mRNA amount of the second 
Q126P mutation carrier (patient Q126P 2) in comparison to his age-matched control (control 2), 
and to the control 1. Left panel: Shown is the parkin-specific mRNA amount in the PD patient 
carrying the G309D mutant compared to his age matched control. (B) The parkin mRNA is 
translated into corresponding parkin protein levels; different PINK1 mutation carrier differ in their 
parkin protein amount. Expression of endogenous parkin in fibroblasts of controls or PD patients 
carrying the PINK1 Q126P (left and middle panel) or PINK1 G309D (right panel) mutation were 
analyzed by Western blotting using the anti-parkin mAb PRK8. Loading was controlled by re-
probing the blots for GAPDH. Right panel: Shown is the parkin protein level of the first PD 
patient carrying the Q126P (patient 1 Q126P) mutation in comparison to his age-matched 
control (control 1 Q126P). Middle panel: Shown is the parkin protein amount of the second 
Q126P mutation carrier (patient 2 Q126P) in comparison to his age-matched control (control 2 
Q126P), and to the control 1 Q126P. Left panel: Shown is the parkin protein amount in the PD 
patient carrying the G309D mutant compared to his age matched control. 
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lead to an increase of parkin mRNA or protein (Fig. 62B). In summary, these results 
argue for a PINK1-independent regulation of parkin. The different amounts of parkin 
expression in the PINK1 and control fibroblasts could be due to individual variations in 
parkin expression and/or to variations in the isolation of fibroblasts. (PINK1 knockout 
and wild-type mice were provided by Anne Röthig; mice brains were prepared with 
experimental help of Anita Schlierf.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To test whether, parkin could have an influence on PINK1 expression, PINK1 
mRNA was quantified by RT-PCR in parkin-deficient cells. The knockdown of parkin 
did not result in a change of PINK1 mRNA expression (Fig. 63A). Subsequently, 
fibroblasts, from a patient carrying a homozygote exon two deletion of the parkin gene, 
resulting in an undetectable parkin expression (Nakaso et al., 2006), were checked for 
their PINK1 mRNA content. Also in this case no increase of PINK1 mRNA could be 
found (Fig. 63B). (Parkin fibroblast cells were provided by Kazuhiro Nakaso.) 
 
 
Fig. 62: PINK1 deficiency in mice and humans does not lead to an increase in parkin 
expression. (A) Parkin mRNA levels are not changed in PINK1 knockout mice compared to 
wild-type mice. Brains of PINK1 knockout mice and wild-type mice were homogenized, lysed in 
trizol and total cellular RNA was isolated and subjected to quantitative RT-PCR using parkin-
specific primers. The amount of RNA of each sample was normalized with respect to β-actin. 
Shown is the fold increase in the amount of parkin-specific mRNA in knock out mice in 
comparison to age-matched wild-type mice. (B) PINK1 deficiency has no impact on parkin 
mRNA amount. SH-SY5Y cells were reversely transfected with control or PINK1-specific siRNA 
duplexes. 3 days later cells were harvested and analyzed as described in Fig.16 for quantitative 
RT-PCR using parkin-specific primers. The amount of RNA of each sample was normalized 
with respect to β-actin. Shown is the fold increase in the amount of parkin mRNA in PINK1-
deficient cells in comparison to control transfected cells. 
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3.2.6 Parkin point mutations lead to misfolding 
 Accumulating evidence indicates that misfolding of pathogenic parkin mutations 
is the major mechanism of inactivation. So far, mainly C-terminal deletion mutations 
have been tested for their capacity to misfold. In this study, pathogenic parkin point 
mutations were analyzed to check whether they are likewise capable for misfolding and 
aggregation. The parkin point mutations C212Y and C289G were recently described in 
PD patients (Gu et al., 2003; Morales et al., 2002). To test if these mutations are prone 
to misfolding, the mutations were introduced by PCR into wild-type parkin and tested 
for their detergent solubility and for their cellular distribution. To analyze the folding, 
wild-type and mutant parkin were transiently transfected into N2a cells and the cells 
were lysed in detergent buffer containing 0.1% Triton X-100. The cell lysates were 
fractionated by centrifugation into detergent-soluble (supernatant) and detergent 
insoluble fraction (pellet) and analyzed by immunoblotting. In contrast to wild-type 
parkin, the pathogenic parkin mutants were mainly present in a detergent insoluble 
confirmation (Fig. 64A). The indirect immunoflourescence of transiently transfected SH-
SY5Y cells showed in contrast to wild-type parkin that the mutants are distributed in 
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Fig. 63: Parkin deficiency has no impact on PINK1 expression. (A) Downregulation of 
parkin has no influence on the PINK1 mRNA amount. SH-SY5Y cells were reversely 
transfected with control or parkin-specific siRNA duplexes. 3 days later cells were harvested 
and analyzed as described in Fig.16 for quantitative RT-PCR using PINK1-specific primers. The 
amount of RNA of each sample was normalized with respect to β-actin. Shown is the fold 
increase in the amount of PINK1 mRNA in parkin-deficient cells in comparison to control 
transfected cells. (B) Fibroblasts from PD patients carrying an exon 2 deletion of the parkin 
gene show the same PINK1 mRNA amount as age-matched control fibroblasts. Fibroblasts of 
controls or PD patients carrying the parkin exon 2 deletion were analyzed as described in Fig. 
16 for quantitative RT-PCR using PINK1-specific primers. The amount of RNA of each sample 
was normalized with respect to β-actin. Shown is the fold increase in the amount of PINK1-
specific mRNA in fibroblasts derived from a parkin deletion patient in comparison to the age-
matched control fibroblasts. 
 
  Results 
 88 
aggregates scattered throughout the cytosol. These finding indicates that also parkin 
point mutations can lead to parkin-loss of function due to misfolding and aggregation 
(Fig. 64B).  
 
 
 
 
 
 
 
 
 
Fig. 64: Pathogenic parkin point mutations lead to misfolding. (A) The parkin point 
mutations C212Y and C289G lead to misfolding. N2a cells were transiently transfected with 
wild-type parkin (wt) or the pathogenic parkin mutants C212Y and C289G, harvested, lysed in 
0.1% Triton X-100. Detergent-soluble (S) and insoluble (P) fractions were obtained by 
centrifugation and analyzed by Western blotting. Parkin was detected by the hP1 antiserum. (B) 
The parkin point mutations C212Y and C289G lead to aggregation of mutant parkin in the cell. 
SH-SY5Y cells transiently expressing wt parkin or the parkin mutants C212Y and C289G were 
analyzed by indirect immunofluorescence using the anti-parkin antiserum hP1.  
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4 Discussion 
 
4.1 PARKIN IS A TARGET OF THE UNFOLDED PROTEIN RESPONSE AND PROTECTS 
CELLS FROM ER STRESS-INDUCED MITOCHONDRIAL DAMAGE 
Parkinson’s Disease (PD) is characterized by a preferential and progressive 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The major 
question, which arises, is why are these cells particularly vulnerable, more than other 
cells and also than other neurons? Dopaminergic neurons are exposed to intrinsic 
stress, due to the enzymatic and non-enzymatic metabolism of dopamine (Maker et al., 
1981). In the course of dopamine metabolism reactive oxygen species (ROS) are 
generated, which can damage proteins, lipids and DNA, resulting in severe damage for 
the cell such as restriction in mitochondrial energy generation as well as in the 
endoplasmatic reticulum (ER) folding capacity (Raha and Robinson, 2000). But also 
other intrinsic stressors like excitoxicity have an influence on mitochondrial integrity and 
the function of the ER (Ruiz et al., 2009; Sokka et al., 2007; Yu et al., 1999). In 
addition, also extrinsic stressors like the environmental toxins MPTP, rotenone or 
paraquat were shown to damage mitochondria leading to ROS production and ER 
stress (Conn et al., 2004; Ghribi et al., 2003; Holtz and O'Malley, 2003; Holtz et al., 
2006; Holtz et al., 2005; Ryu et al., 2002; Yamamuro et al., 2006). If the damage of 
cellular processes is too severe, apoptotic pathways are activated, which result in the 
death of dopaminergic cells. Both mitochondria and the ER are crucial organelles in 
regulating these elementary pathways and therefore are playing both a major role in 
the pathology of PD.  
Accumulating evidence over the last years demonstrates parkin as an important 
regulator of cell protective processes after stress (Winklhofer, 2007), which might 
explain why dopaminergic neurons are particularly vulnerable to a loss of parkin 
function. In this study we were interested to gain more insight into the role of parkin 
after ER stress with emphasis on its protective capacity and the possible involvement 
of mitochondria.  
Our study revealed that parkin is a low abundant protein under normal 
conditions but is highly up-regulated in response to ER stress. We could show that this 
up-regulation is mediated by the binding of ATF4 (activating transcription factor 4) to 
the parkin promoter. ATF4 is a transcription factor the translation of which is induced by 
phosphorylated eIF2α (eucaryotic initiation factor 2α). eIF2α is specifically 
phosphorylated by different kinases such as the GCN2 (general control non-
derepressible-2) kinase, mainly activated by amino acid starvation, the double-stranded 
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RNA-activated protein kinase (PKR), which participates in an anti-viral defence 
mechanism, the HRI (haem regulated inhibitor) kinase that is activated by haem 
deprivation or the PKR-like ER kinase (PERK), which is activated after ER stress (Wek 
et al., 2006). We showed that ER stress induced by tunicamycin or thapsigargin as well 
as starvation results in an increase of parkin mRNA and protein levels in several cell 
lines including primary mouse neurons. Furthermore, increased expression of ATF4 
and also PERK can directly support the transcription from the parkin promoter. 
Moreover, a dominant negative mutant of ATF4 interferes with the transcriptional up-
regulation of parkin after ER stress. These findings were further supported by following 
in vivo experiments: First, the knockdown of ATF4 resulted in a reduced parkin mRNA 
induction after ER stress. Second, a ChIP (chromatin immunoprecipitation) experiment 
demonstrated an increased binding of ATF4 to the parkin promoter after ER stress.  
Moreover, our experiments revealed a second factor bound to the parkin 
promoter. We identified this transcription factor as c-Jun. However, in contrast to ATF4 
this factor reduces the activation of the parkin promoter and even more also interferes 
with the activation potential of ATF4. In agreement with these findings, the knockdown 
of c-Jun results in an increase of parkin mRNA already under normal conditions, but 
particularly after ER stress, indicating that c-Jun is a transcriptional repressor of parkin. 
What might be the physiological relevance of this observation? c-Jun could terminate 
ATF4 mediated up-regulation of parkin. This hypothesis is supported by the finding that 
ATF4 can recruit c-Jun to the parkin promoter but not vice versa. After ER stress first 
cell survival pathways are activated to restore cellular homeostasis, in case of severe 
and prolonged ER stress pro-apoptotic pathways are induced to favour the elimination 
of irreversible damaged cells (Kim et al., 2006; Szegezdi et al., 2006). Several studies 
implicate an activation of the IRE1 (inositol requiring enzyme)/TRAF2 (TNF receptor 
associated factor 2)/ASK1 (apoptosis signal-regulating kinase 1) pathway after severe 
ER stress, resulting in the activation of JNK (c-Jun N-terminal kinase) (Nishitoh et al., 
2002; Urano et al., 2002) and other pro-apoptotic factors like Bim, Bax (Bcl-2 
associated x protein) and Bak (Bcl-2 antagonist/killer) (Kim et al., 2008a; Kim et al., 
2006; Szegezdi et al., 2006). c-Jun activated by the JNK pathway could bind to the 
parkin promoter, interfere with the activation potential of ATF4 after ER stress and lead 
to the suppression of the protective protein parkin to push the cellular fate towards 
apoptosis. This hypothesis is supported by the fact that neuronal cultures from PERK 
deficient mice revealed an increased sensitivity to treatment with 6-hydroydopamine (6-
OHDA), suggesting that neurons lacking PERK were unable to mount a proper 
unfolded protein response (UPR), including the up-regulation of parkin and therefore 
were more vulnerable to 6-OHDA induced cell death (Ryu et al., 2002). The PERK 
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pathway is responsible for the early UPR response, which seems to have mainly a 
protective potential, while a sustained ER stress later through IRE1 signalling leads to 
the suppression of proteins that inhibit cell death, activation of proteins that induce cell 
death such as JNK and CHOP (C/EBP homologous protein) and to a suppression of 
the protective PERK branch by p58IPK (Kim et al., 2008a; Kim et al., 2006; Szegezdi et 
al., 2006). Of note, CHOP is also regulated by the PERK pathway, however, for its full 
pro-apoptotic function further stimuli such as modification or increased transcriptional 
activity are necessary (Harding et al., 2003; Scheuner et al., 2001; Szegezdi et al., 
2006; Wang et al., 1996). 
The involvement of the JNK-pathway in the suppression of parkin expression is 
supported by the finding that JNK3, a JNK isoform primarily found in the brain, heart 
and testes, is also able to interfere with the transcriptional up-regulation of parkin after 
ER stress. The JNK pathway is implicated in neuronal cell death and may contribute to 
the loss of neurons in neurodegenerative diseases (Bogoyevitch et al., 2004; Peng and 
Andersen, 2003; Waetzig and Herdegen, 2004). Interestingly, parkin was shown to 
suppress JNK activity in several cellular models and in studies with Drosophila 
melanogaster (Cha et al., 2005; Hasegawa et al., 2008; Jiang et al., 2004; Liu et al., 
2008; Ren et al., 2009). However, we were not able to show in preliminary experiments 
a direct impact of parkin on the JNK pathway as analyzed by phosphorylation studies 
with c-Jun and JNK as well as by a JNK-reporter assay. These negative results can be 
due to the transient activation of c-Jun and the timing and conditions of analysis. It is 
necessary to perform an in depth analysis by using different stressors in different 
concentrations and varying the stress conditions. In addition, compensatory 
mechanism could decrease the effect of parkin on JNK, as demonstrated in this study 
for A20, which is transcriptionally up-regulated in parkin deficient cells and is able to 
suppress JNK activity.  
It is therefore tempting to speculate whether there is a reciprocal interaction 
between parkin and the JNK-pathway. Dependent on the cellular context and the 
severity of stress conditions, parkin could attenuate JNK signalling and thereby shift the 
balance towards cell survival. In case JNK3 is gaining the upper hand pro-apoptotic 
pathways are induced and in parallel pro-survival pathways are suppressed, for 
example by inhibiting the protective protein parkin.  
To further support the hypothesis that parkin is a protective protein playing a 
role for pro-survival pathways, parkin was tested for its ability to protect cells from ER 
stress-induced cell death. We could clearly show that overexpression of parkin reduces 
ER stress-induced cell death, whereas a loss of parkin results in increased apoptosis in 
response to ER stress. Interestingly, the pathogenic parkin mutants fail to prevent ER 
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stress-induced cell death. These findings demonstrate that parkin is an important factor 
for the cell to switch the gear towards cell survival and that the loss of parkin and also 
mutations in the parkin gene can lead to higher vulnerability of the cell to ER stress. 
Notably, the protective function of parkin seems not to be dependent on the 
transcriptional regulation of anti-apoptotic genes, as the knockdown of parkin had no 
effect on the transcription of the anti-apoptotic proteins XIAP (x-linked inhibitor of 
apoptosis protein), Bcl2XL and MIHC (Inhibitor of apoptosis protein 1) (data not shown). 
But still the question is open how parkin mediates this protective effect for the 
cell? One possibility could be a direct impact of parkin on the severity of ER stress. As 
parkin has an E3 ubiquitin ligase activity and was reported to ubiquitylate proteins for 
proteasomal degradation parkin could play a role in the ER-associated degradation 
(ERAD) machinery, thereby reducing the amount of misfolded proteins in the ER 
resulting in a reduction of ER stress. However, our studies showed that the loss of 
parkin, neither acute nor permanent, does cause ER stress. Furthermore, also induced 
parkin expression is not able to decrease the severity of ER stress. Interestingly, the 
protective activity of parkin is independent of the proteasome, as parkin was still 
protective after ER stress when the proteasome was blocked. These findings speak 
against a role of parkin in the ERAD machinery and stand in contrast to the believed 
opinion that parkin ubiquitylates its substrates for degradation and thereby reduces the 
toxic protein load for the cell as for example reported for the PAEL-receptor (PAEL-R) 
by Y. Imai and colleagues (Imai et al., 2001). Notably, another mechanism to remove 
misfolded or unfolded proteins leading to reduced ER stress is autophagy. However, 
also for this pathway we were not able to show in preliminary experiments an influence 
of parkin. 
Which activity of parkin might then be responsible for its protective effect under 
ER stress? The pro-survival NF-κB (nuclear factor kappa enhancer binding protein) 
pathway is reported to be activated after ER stress (Deng et al., 2004; Hu et al., 2006; 
Kaneko et al., 2003). In the course of our study we could show that parkin activates the 
NF-κB pathway. Parkin is able to interact with two factors involved in the NF-κB 
signalling cascade, TRAF2 and IKKγ (IκB kinase γ or NEMO). Both proteins are 
activated by lysine 63 (K63)-linked ubiquitination. In contrast to K48-linked ubiquitin, 
which marks proteins for proteasomal degradation, K63-linked ubiquitin regulates the 
activity of proteins. Our analysis showed that parkin is able to increase K63-linked 
ubiquitiylation of IKKγ as well as TRAF2. Furthermore, the loss of parkin leads to a 
decrease of NF-κB activity after PMA (phorbol 12-myristate 13-acetate) stimulation, 
supporting a role for parkin in the activation of NF-κB. However, we were not able to 
show in preliminary experiments a direct involvement of parkin in the activation of the 
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NF-κB pathway after ER stress. This could be due to the difficulties to see NF-κB 
activation in response to ER stress in our assays. Compared to other stressors, the 
signal was quite weak, either indicating only a slight increase in the response of NF-κB 
to ER stress or difficulties in finding the right time point to look at NF-κB activation, as 
this is possibly a highly transient event. Due to the weak signal it was difficult to 
observe a difference between parkin knockdown and control cells in their activation 
potential. Yet, it is still possible that parkin might have an impact on modulating NF-κB 
activation after ER stress. Of course, our experiments need follow up studies to provide 
evidence or to rule out the possibility for a direct influence of parkin on this pro-survival 
pathway. 
 
To increase the understanding of the mechanism, which is underlying the 
protective capacity of parkin, it could be necessary to pay attention to all organells 
involved after ER stress and not only to the ER alone in an isolated manner. The ER is 
closely associated with mitochondria providing the conditions for a local and privileged 
communication between the two organelles (Pizzo and Pozzan, 2007). Specifically, we 
and others could show that ER stress leads to a disruption of mitochondrial integrity. 
The mitochondrial morphology is changed as well as their energy production reduced. 
Accumulating evidence also from our group indicates an essential role of parkin in 
maintaining mitochondrial integrity (Lutz et al., 2009). Remarkably, our study found that 
parkin is indeed able to restore mitochondrial morphology and influence cellular ATP 
production, demonstrating that parkin is able to prevent pathophysiological 
consequences of ER stress on mitochondrial integrity. Obviously, this effect is not 
mediated by an impact of parkin on the transcription of various mitochondrial proteins, 
such as the mitochondrial fusion protein Drp1 (dynamin related protein 1), NAD(P)H 
(2,4-dienoyl CoA reductase 1; DECR1), an accessory enzyme for β-oxidation and 
metabolism of unsaturated fatty enoyl-CoA esters, the ctytochrome c oxidase subunit II 
(cox2) of the mitochondrial respiratory chain, the mitochondrial chaperone mortalin 
(MOT), the ATP-dependent mitochondrial matrix protease LON and the antioxidant 
enzyme MnSOD2 (mitochondrial superoxide dismutase 2) (data not shown). 
But how is parkin able to mediate this effect? A key player in this interorganellar 
crosstalk seems to be Ca2+ (Pizzo and Pozzan, 2007; Rizzuto et al., 2009; Rizzuto and 
Pozzan, 2006). The ER acts as the intracellular calcium storage. Upon stimulation 
resident Ca2+ channels are opened, resulting in a Ca2+ efflux to the cytosol. As ER and 
mitochondria are in close contact to each other Ca2+ is ultimately taken up by the 
mitochondria. This direct Ca2+ exchange between these two organelles regulates 
various cellular processe, ranging from the induction of mitochondrial ATP production, 
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regulation of subcellular processes by Ca2+-dependent enzymes, controlling of 
mitochondrial movement and the activation of apoptotic signals (Celsi et al., 2009). 
Especially for the latter scenario mitochondria seem to play an important role. In case 
of massive and/or a prolonged accumulation of Ca2+ in the mitochondria, cell death 
pathways are activated. It is tempting to speculate that parkin could have an effect on 
the prevention of Ca2+ overload or its consequences, thereby preventing the induction 
of apoptotic pathways. This hypothesis is supported by the finding that the loss of 
PINK1, acting possibly in the same pathway, yet upstream of parkin, leads to 
mitochondrial Ca2+ overload, which results in cell death (Gandhi et al., 2009).  
Regarding the fact that cells have to adapt to increasing stress, parkin could 
also play a key role in circumventing the induction of cell death to the adaptation to 
stress. Besides the melioriation of protein folding and processing the cell needs to 
regulate the threshold for the execution of the apoptotic cascades to adapt to chronic 
stress (Lin et al., 2007; Rutkowski et al., 2003) here parkin could enter the stage for 
example by influencing JNK activity or the sensible calcium homeostasis. As chronic 
stress is also implicated to play a major role in sporadic PD and loss of parkin function 
is associated with early onset parkinsonism, it is tempting to speculate, whether parkin 
dysfunction could also have an impact on sporadic PD by loosing the adaptation 
potential of dopaminergic neurons to prolonged stress.  
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4.2  REGULATION OF PD-ASSOCIATED GENES IN RESPONSE TO 
PATHOPHYSIOLOGICAL STRESS CONDITIONS 
As mentioned above, dopaminergic neurons are exposed to a variety of intrinsic 
and extrinsic stressors. Different lines of evidence indicate exactly under those stress 
triggers, such as mitochondrial dysfunction, excitotoxicity, ER stress, proteasome 
inhibition and overexpression of tau, α-synuclein or expanded polyglutamine 
fragments, a remarkable potential of parkin to protect neuronal cells (Moore, 2006; 
Winklhofer, 2007). In line with a central role of parkin in mainting neuronal viability, the 
question arises, whether the cell includes also in its responding cell stress 
management program the induction of parkin expression? In this study different 
stressors were chosen, playing an important role in the pathogenesis of PD. First, we 
tested rotenone, a mitochondrial stressor, which can easily cross the blood brain 
barrier, and blocks complex-I of the mitochondrial electron transport chain. Inhibition of 
complex-I causes mitochondrial dysfunction associated with increased oxidative stress. 
Mitochondria dysfunction plays a central role in the pathogenesis of PD, starting with 
the early observation that the accidental toxication of young drug addicts with the 
complex-I inhibitor MPTP can cause parkinsonism (Langston et al., 1983). Second, 
excitotoxicity was induced by kainic acid. Kainic acid binds to the non-NMDA-
glutamate-receptor and stimulates the opening of cation channels, leading to the influx 
of Ca2+. Overstimulation of glutamate receptors leads to an uncontrolled influx of Ca2+, 
resulting in excitotoxicity. As glutamate is an important neurotransmitter in the brain, 
changes in the glutamate concentration, the damage of the NMDA-receptor or the 
glutamate transporter can have severe effects on the cell, reported to accompany 
neurological disorders. Third, dopamine was used to induce stress. Dopamine is the 
principal neurotransmitter produced in the neurons of the substantia nigra. It is a highly 
reactive molecule that possesses a great propensity for oxidation to form multiple 
reactive oxygen species. As fourth stressor MG132 was used, which blocks the 
proteasome. As parkin is reported to be an E3 ligase that might ubiquitinate proteins for 
degradation, this experiment was of special interest for us. In addition, the ubiquitin-
Fig. 65: Model: Parkin and ER stress. In response to ER stress parkin is transcriptionally up-
regulated via the PERK/ATF4 branch of the UPR by binding of ATF4 to a specific site within the 
parkin promoter. Increased parkin expression alleviates the cellular consequences of ER stress 
by preventing ER stress-induced mitochondrial fragmentation and ATP depletion. Activation of 
the JNK3/c-Jun pathway leads to transcriptional repression of parkin gene expression, probably 
to terminate ATF4-mediated up-regulation of parkin or to inhibit pro-survival pathways under 
conditions of severe ER stress, when cells are irreversibly damaged. 
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proteasome system is thought to play an important role in the pathogenesis of PD, for 
example the formation of Lewy bodies is seen as a failure of the cell to degrade 
misfolded or aggregated proteins (Conway et al., 2000; Miller et al., 2004; Tanaka et 
al., 2004).  
Mitochondrial stress, excitotoxicity as well as dopamine treatment resulted in an 
increase of parkin mRNA expression in a human neuroblastoma-derived cell line as 
well as in primary neurons. Please note that in the first part of this study we could 
already observe an up-regulation of parkin after ER stress in different cell lines. 
Remarkably, the up-regulation of parkin expression after treatment with kainic acid and 
rotenone was independent of ATF4 activation, as the reporter construct containing the 
ATF4-binding site of the parkin promoter was not induced in response to these 
stressors, pointing to an ER stress-independent activating pathway. These results 
demonstrate a wide response of parkin expression to neuronal stressors and point to a 
role of parkin in protecting the cell against various insults, indicating a broad protective 
capacity.  
Interestingly, parkin expression is not significantly up-regulated after the 
inhibition of the proteasome. Nevertheless, parkin is able to protect the cell for 
proteasomal stress as shown in the first part of this work. One possible explanation 
could be that proteasomal inhibition is not a normally in vivo occurring physiological 
stress and therefore the cell did not develop a specific transcriptional program in 
response to this stressor. Excitotoxicity, ER and mitochondrial stress, however, are 
stressful insults, which normally occur in the cell in vivo, therefore transcription 
responds to these stressors. 
 In the course of our study we were also interested in the transcriptional 
regulation of other PD-associated genes, such as DJ-1, PINK1, α-synuclein, HtrA2/omi 
and LRRK2 in response to different stress triggers. Notably, our analysis showed that 
only parkin gene expression is regulated by mitochondrial stress and excitotoxicity. 
These results are quite surprising, as especially PINK1, as a mitochondrially located 
kinase, is strongly associated with maintaining mitochondrial integrity (Clark et al., 
2006; Exner et al., 2007; Gandhi et al., 2009; Gegg et al., 2009; Marongiu et al., 2009; 
Morais et al., 2009; Park et al., 2006; Poole et al., 2008), and DJ-1 has been shown to 
protect cells against dopamine, MPP+ and oxidative stress-induced cell death (Canet-
Aviles et al., 2004; Kim et al., 2005; Martinat et al., 2004; Taira et al., 2004; Yokota et 
al., 2003) and is believed to be a sensor for oxidative stress (Kinumi et al., 2004). 
Additionally, HtrA2/omi was shown to protect from rotenone-induced cell death (Martins 
et al., 2004). Remarkably, all PD-associated genes studied are induced after ER 
stress, pointing to an important role of ER stress in PD. This hypothesis is supported by 
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the finding that dopaminergic neurons in the substantia nigra of sporadic PD cases 
show an increased phosphorylation of PERK and eIF2α, indicating an activation of the 
UPR in these patients (Hoozemans et al., 2007). Futhermore, the observation suggests 
also a possible involvement of all or at least a part of the examined familial PD genes in 
common pathways, as already demonstrated for parkin and PINK1 (further discussed 
below). However, in contrast to parkin, DJ-1, HtrA2/omi, PINK1 and α-synuclein 
expression is not regulated by the PERK/ATF4 pathway, indicating a different 
mechanism for the transcriptional up-regulation in response to ER stress. 
Nevertheless, the analysis of the PINK1 promoter could not reveal a binding site for 
another ER stress induced transcription factor.  
Several lines of evidence also from our group indicate that parkin and PINK1 
function in a common genetic pathway. Parkin is able to compensate for the PINK1 
loss-of-function phenotype in Drosophila and different cellular models but not vice 
versa, implying that parkin acts downstream of PINK1 (Clark et al., 2006; Exner et al., 
2007; Lutz et al., 2009; Yang et al., 2006a). In contrast to the functional link, our study 
revealed that the transcriptional regulation and expression of parkin works 
independently of PINK1 and vice versa. So was the transcriptional up-regulation of 
parkin in fibroblasts of PD patients carrying homozygous PINK1 mutations not 
consitently up-regulated. Also PINK1 knockout mice and the transient knockdown of 
PINK1 did not lead to an increase in the parkin mRNA level. Vice versa in fibroblasts 
derived from PD patients carrying a deletion in the parkin gene and in parkin-deficient 
cells the level of PINK1 mRNA was not changed.  
 
Up to date no mutations in the parkin promoter as well as in the relatively 
uncharacterized promoters of the other PD-associated genes were described. Only one 
single nucleotide polymorphismus at bp -258 was reported to influence the transcription 
of parkin and to increase the risk factor in elderly PD patients (Sutherland et al., 2007; 
Tan et al., 2005; West et al., 2001; West et al., 2002). It is possible that due to the 
nucleotide exchanged the binding of a nuclear protein expressed in the substantia 
nigra to this site is influenced, resulting in transcriptional alterations (West et al., 2002). 
Furthermore another binding protein n-myc was reported to bind to the parkin promoter 
and to negatively influence parkin transcription. This finding implicates parkin function 
in cell cycle and neuronal differentiation (West et al., 2004). The studies of Shuichi 
Asakawa and Andrew West as well as our analysis of the parkin promoter revealed 
auxiliary potential transcription factor binding sites such as SP-1, AP-4, NF-1, STATx, 
HSF1, HSF2, GATA-1 and of course AP1/CREB (Asakawa et al., 2001; West et al., 
2001). Interestingly, the GATA-1 transcription factor was also associated with the 
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transcriptional regulation of α-synuclein in the substantia nigra (Scherzer et al., 2008). 
In addition, the expression of GATA-1 seems to be influenced by age (Budovskaya et 
al., 2008), indicating a probably role in PD.  
Further screening of the first intron of parkin could not identify special 
transcription factor binding sites. However, the length of the promoter (up to 5 kb [core 
promoter: 250 bp]) and the large introns (first intron: 284 kb) makes a detection of 
further potential transcription regulatory elements very difficult.  
The length and the yet relatively uncharacterized structure are probably the 
reason why still no mutation in the promoter or intron has been described to count for 
parkin-associated parkinsonism. Therefore it is possible that heterozygous carriers, 
which still develop PD, late onset but also early onset cases are reported (Farrer et al., 
2001; Foroud et al., 2003; Khan et al., 2003), have an additional mutation in the non-
coding region of the parkin promoter or intron. This complementary mutation could be 
responsible for their increased risk to develop PD (Abbas et al., 1999; Lucking et al., 
2000).  
Interestingly, the parkin co-regulated gene (PACRG), sharing with parkin the 
same promoter but transcribed on the opposite strand in an opposite orientation 
showed also an up-regulation of its mRNA after ER stress (Wang et al., 2007b), 
indicating that parkin and PACRG share some regulatory binding sites. Both proteins 
demonstrate overlapping but not identical tissue expression profiles (West et al., 
2003b). How interleaving their regulation is has to be further investigated. PACRG and 
parkin were shown to interact (Imai et al., 2003). However, in our study we could not 
show that a reduced expression of parkin resulted in any regulatory changes for 
PACRG transcription. Whether PACRG contributes to the pathogenesis of PD for 
example by influencing the function of parkin has still to be elucidated. 
Immunostainings of post mortem brains of PD patients as well as of multiple system 
atrophy (MSA) and progressive supranuclear palsy (PSP) patients revealed PACRG in 
areas of neurodegeneration (Taylor et al., 2007) yet, a significant link between single 
nucleotide exchanges and early onset PD could not be demonstrated so far (Deng et 
al., 2005b). 
 
Of all examined PD-associated genes, parkin expression seems to be the most 
sensitive one for a wide spectrum of different stressors. Additionally, parkin was shown 
to protect cells against several different stressors, supporting the assumption that 
parkin plays an important role for the cell to handle cellular stress and to maintain 
cellular integrity. This observation also seems to be of pathological relevance to 
sporadic PD as elevated parkin levels were found in the substantia nigra of sporadic 
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PD patients (Moran et al., 2007). Drawing the circle back to familiar PD, also here the 
loss of parkin function due to pathogenic mutations in the parkin gene seems to result 
in difficulties for the dopaminergic neurons to cope with cellular stress, as the patients 
suffer from early onset parkinsonism. Notably, different lines of evidence indicate that 
parkin can be inactivated by misfolding and aggregation of the pathogenic parkin 
mutations (Cookson et al., 2003; Gu et al., 2003; Henn et al., 2005; Schlehe et al., 
2008; Sriram et al., 2005; Wang et al., 2005b; Winklhofer et al., 2003). Yet, even wild-
type parkin is prone to misfolding especially under high-level oxidative stress, resulting 
in a loss of function (LaVoie et al., 2007; LaVoie et al., 2005; Wang et al., 2005a; 
Winklhofer et al., 2003; Wong et al., 2007). On the other hand, parkin is postulated to 
play a remarkably protective role under stress. How can this discrepancy be explained? 
This finding makes sense in a physiological context. Parkin is functional under mild and 
moderate stress conditions, whereas under severe stress, which irreversibly might 
damage neurons parkin is inactivated by misfolding. When cellular stress exceeds a 
critical threshold, the damage for the cell will be irreversible, reaching a point of no 
return, cell-survival programs will be shut down, and pro-apoptotic pathways induced, 
resulting in the death of the cell. As sporadic PD cases are usually late onset cases, 
age is considered as the major risk factor. Aging neurons are compromised in their 
capability to cope with stress, for example it could be that constant stress levels may 
impair parkin up-regulation. In addition, dopaminergic neurons are characterized by a 
high oxidative burden. Over the time reactive oxygen species are able to accumulate 
particularly in the metabolism of dopamine, which then may lead to misfolding and 
inactivation of parkin. This observation may explain why dopaminergic neurons are 
particularly vulnerable in sporadic PD.  
 The analysis of parkin and the other PD-associated genes gives us significant 
new insights into the molecular mechanisms underlying hereditary PD, but also 
sporadic PD. The discovery of pathways, dependent on parkin or other PD-associated 
gene regulation may serve as a basis for the development of drugs, which could halt or 
delay the disease progression. 
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5 Methods 
 
5.1 CELL CULTURE METHODS 
5.1.1 Cell culture 
 All used cells lines and primary cell cultures (fibroblasts) grew as adherent 
monolayers. Cells were cultivated in 25 or 75 cm2 tissue culture flasks, maintained at 
37°C with 5% CO2. For cultivating, confluent grown cells were washed once with PBS 
(Phosphate Buffered Saline) followed by incubation with 0.5 g/l trypsin with EDTA 
(Invitrogen, GIBCO) for some minutes at room temperature. Cells were then taken up 
into fresh media and passaged into new culture flasks. For transfection, cells were 
counted and plated in the desired confluency in cell culture dishes. All cell lines and 
their desired medium are listed in Table 3. 
Table 3: List of cell lines. 
Cell line Organism / cell type Culture medium 
HEK 293T human embryonic 
kidney; ATCC-Nr. CRL-
1573 
DMEM (Dulbecco’s Modified Eagle’s Medium), 
10% FCS (fetal calf serum), penicillin (50 U/ml) 
/streptomycin (50 µg/ml) 
N2a murine neuroblastoma; 
ATCC-Nr. CCL 131 
MEM (Minimal Essential Medium), 10% FCS, 
penicillin/streptomycin 
SH-SY5Y human neuroblastoma; 
DSMZ-Nr. ACC 209 
DMEM/Ham’s F12, 15% FCS, 1% non-
essential amino acids, penicillin/streptomycin  
SH-SY5Y l human neuroblastoma 
with reduced parkin 
expression 
DMEM plus pyruvate, 10% FCS, 2 mM 
glutamate, penicillin/streptomycin 
 
5.1.2 Preparation and cultivation of mouse embryonic fibroblasts 
 Primary mouse fibroblasts were isolated from parkin knockout and wild-type 
mice (Itier et al., 2003). Embryos at embryonic stage 12.5 days post coitum were 
extracted and all inner organs were removed. The remaining tissue was washed 5 
times with PBS before incubation with trypsin for 20 min at 37°C. The cells were 
dissociated by passing several times through a pipette and spun down at 1000 rpm for 
5 min. The pellet was resuspended and plated into complete DMEM media (10% FCS, 
Pen/Strep). 
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5.1.3 Preparation and cultivation of mouse and rat primary cortical neurons 
 Cortices were removed from the brains of embryonic wild-type day 18 rats or 
day 14.5 mice. Cells were dissociated by mild trypsination and trituration. The 
dissociated neurons were plated onto polyethyleneimine-coated dishes and grown in 
neurobasal medium (Invitrogen) supplemented with 5 mM HEPES, 1.2 mM glutamine, 
B27 supplement (20 ml/L; Invitrogen) and gentamicin (0.1 mg/ml). All experimental 
treatments were performed on 8 to 10 day old cultures. To induce glutamate 
excitotoxicity rat neurons were exposed to 5 and 10 µM glutamate in EBSS medium 
(6800 mg/l NaCl, 400 mg/l KCl, 264 mg/l CaCl2, 200 mg/l MgCl2, 2200 mg/l NaHCO3 
and 140 mg/l NaH2PO4 pH 7.2) with 10 mM glucose. After the indicated time cells were 
harvested for RNA extraction. To induce ER stress, mouse neurons were exposed to 1 
µM thapsigargin or 2 µg/ml tunicamycin. After 12 h cells were harvested for RNA 
extraction as described below.  
 
5.1.4 Transient transfection 
 Cells were plated 24 h before transfection; HEK 293T cells were plated 0.6 x 
106, SH-SY5Y cells 0.3 x 106 and N2a 1 x 106. For transient transfection, DNA was 
mixed with Lipofectamine and Plus (Invitrogen) in Opti-MEM medium (Invitrogen) 
according to the manufacturers instructions. The incubation was conducted for 3-5 
hours in the transfection mix and Opti-MEM, which was than replaced by normal 
growth medium.  
 
5.1.5 RNA interference 
 For RNA interference the Stealth small interfering RNA (siRNA) from Invitrogen 
was used. Stealth siRNA is a chemical modified dsRNA, able to reduce the induction of 
cellular stress response pathways. Reverse transfection showed the highest knock 
down efficiency. This method works as follows: HEK293T cells were transfected with 
Lipofectamine 2000 (Invitrogen). First, 5 µl Lipofectamine 2000 and likewise the 
appropriate amount of siRNA (indicated below) were diluted separately in 250 µl Opti-
MEM medium. After 15 min incubation at room temperature siRNA and Lipofectamine 
dilution were combined and incubated for another 15 min at room temperature to allow 
complex formation. The mixture was transferred into poly-L-lysine coated 6-wells and 
0.3 x 106 HEK 293T cells in 1.5 ml Opti-MEM were added on top. The next day 2 ml 
growth medium without antibiotics was added to the cells. 
 The transfection of SH-SY5Y was performed with 5 µl Lipofectamine RNAiMAX 
incubated directly with the appropriate amount of siRNA (indicated below) in 500 µl 
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Opti-MEM for 15 min at room temperature followed by the transfer to a 6-well dish and 
the addition of 0.2 x 106 SH-SY5Y cell–suspension in 1.5 ml Opti-MEM. The next day 2 
ml growth medium without antibiotics was added to the cells.  
 For endogenous parkin knock down the Stealth siRNA duplex 1 (PARK2-
HSS107593) was the most efficient one followed by duplex 2 (PARK2-HSS107594). 
For one 6-well dish 100 pmol (5 µl of 20 µM stock) of parkin siRNA was used. The 
highest knock down efficiency was achieved at day 4 after transfection.  
For the ATF4 knock down the best siRNA was duplex 3 (ATF4-HSS141299) followed 
by duplex 1 (ATF4-HSS141297). For an efficient knock down 100 pmol siRNA was 
used. To interfere with the up-regulation of the ATF4 mRNA after induction of ER 
stress, the cells were again transfected 3 days after the first transfection with the same 
siRNA. Therefore, siRNA was incubated for 15 min with RNAiMAX, before added 
directly on top of the Opti-MEM washed cells. 5 h later cells were stressed and 
harvested 14 h later. 
 The best siRNA for c-Jun knock down was duplex 2 (Jun-HSS105641) and 
duplex 3 (Jun-HSS105642). To get acceptable knockdown efficiency 200 pmol of 
siRNA was used per 6-well dish. 1 day after the first transfection the cells were again 
transfected with the same amount of siRNA, stressed, and harvested as described for 
the ATF4 knock down.  
 As control the negative control duplex siRNA (medium GC-content) from 
Invitrogen was used. 
 
5.1.6 Starvation of cells 
 For starvation assays cells were plated with medium containing dialysed FCS. 
To starve the cells L-histidinol (2 mM) was added, which blocks the charging of the 
amino acid histidine to its tRNA. The cells were harvested after 16 h of incubation. 
 
 
5.2 NUCLEIC ACID BIOCHEMISTRY  
5.2.1 Polymerase chain reaction (PCR) 
 DNA fragments were amplified by PCR (Saiki et al., 1988). The reaction was 
performed in a 50 µl reaction volume containing 100 ng template, 10 pmol of each 
primer (used primers are listed below), 0.25 mM dNTPs (dATP, dCTP, dGTP and 
dTTP), 1 x PCR reaction buffer and 2.5 units of DNA Polymerase. For amplification the 
following program was applied: step 1 (denaturation): 5 min at 95°C; step 2 
(denaturation): 50 sec at 95°C; step 3 (primer annealing): 50 sec at 50 - 60°C 
  Material and Methods 
 103 
(dependent on the calculated melting temperature); step 4 (elongation): 2 min / kilo 
base pair of to be amplified DNA at 72°C; step 5 (final elongation): 5 min at 72°C; step 
6 (end): 4°C. Steps 2 - 4 were repeated for a total of 28 - 30 cycles.  
 
Two step PCR 
 To substitute single amino acids, a two step PCR strategy was used: the first 
PCRs were performed using forward and reverse primers containing the desired 
mutations, and the respective flanking primers at the 5’ and 3’ end of the cDNA. The 
PCR products were isolated and purified. Aliquots of the PCR products were used as 
templates fort the second PCR, together with the outermost primer pair.  
 
5.2.2 Agarose-gelelectrophoresis 
 To analyze the resulting PCR products or to separate linearized DNA fragments 
from supercoiled DNA, the DNA was loaded onto a 1% (w/v) agarose gel in 1x TBE 
buffer containing 0,1 µg/ml Ethidium Bromide. The appropriate volume of 6x DNA 
loading buffer was added to the DNA, and gels were run at a constant voltage (10 
V/cm) until sufficient separation of the fragments. To determine the different size of the 
DNA fragments 1 kB or 100 Bp marker was loaded in parallel.  
 
5.2.3 Isolation and purification of DNA fragments from agarose gels 
 The right sized DNA fragments, verified under the UV lamp, were cut out from 
the agarose gel and purified with the Nucleo Spin Extract kit (Macherey-Nagel) 
according to the manufacturer’s instructions.  
 
5.2.4 Restriction digest  
 All analytical and preparative restriction digests were performed in total volumes 
of 20-50 µl, using 10 U restriction enzyme and the appropriate amount of the 
respective 10x reaction buffer. The reaction was incubated at 37°C for several hours or 
over night, unless otherwise noted in the manufacturer’s direction. DNA fragments 
were purified as described above. 
 
5.2.5 Ligation 
 To insert DNA fragments into the appropriate linearized vector, fragment and 
vector were incubated in a 1:3 ratio in final reaction volume of 20 µl, buffered with 5x 
T4 ligation buffer and including 1U of T4 Ligase. The mixture was incubated either for 3 
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h at room temperature or overnight at 4°C, before used to transform competent 
bacteria. 
 
5.2.6 Preparation of competent bacteria 
 For competent Escherichia coli (E.coli) cells, the cell membrane was 
destabilized by divalent cations (Sambrook et al, 1989) to make the cell compatible to 
take up plasmid-DNA. An overnight culture of DH5α in 3 ml Luria Broth (LB)-Medium 
without antibiotics was used to inoculate 200 ml LB. Bacteria were grown to a density 
of 0.3-0.6 at 600 nm (OD600 = 0.3 – 0.6) at 37°C. Cells were chilled on ice for 10 min 
and centrifugated at 5000 rpm for 10 min. The pellet was resuspended in 100 ml of 
transformation buffer (50 mM CaCl2, 15% Glycerol, 10 mM PIPES-buffer; pH 6.6), 
incubated for 20 min on ice, centrifugated as before and resuspended in 10 ml 
transformation buffer. 100 µl aliquots were shock frozen in liquid nitrogen and stored at 
-80°C.  
 
5.2.7 Transformation of competent E.coli  
 50 µl competent DH5α were thawed on ice, mixed gently with DNA and 
incubated for 30 min on ice. As next step the cells were heat shocked by placing the 
reaction tube for 90 sec into a 42°C heat block and immediately chilled on ice for 3min. 
Afterwards 400 µl of antibiotic free LB media was added followed by incubation at 37°C 
for 60min. Subsequently, in case of a ligation the transformed cells were shortly 
centrifugated, the pellet resuspended in 50 µl of LB and then plated on LB-agar plates 
containing the respective antibiotic to select positive clones. In case of a re-
transformation an aliquot of 50 µl was plated directly on an agar plate. LB-agar plates 
were incubated at 37°C over night, single clones were analyzed as described below.  
 
5.2.8 Plasmid DNA preparation 
 Single clones were used to inoculate LB-medium for small-scale DNA 
preparation (Macherey-Nagel), which was performed according to the manufacturers 
instructions. Large-scale DNA-preparation (Midi Macherey-Nagel) was used to obtain 
higher amounts of DNA according to the manufacturer’s instructions. To obtain 
endotoxin free DNA samples the Endofree Plasmid Maxi Kit (Qiagen) was used 
according to the manufacturer’s instructions. DNA amounts and purity were determined 
by measuring absorbance at 260/280 nm. 
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5.2.9 Sequencing 
 For sequencing purified DNA samples were analyzed by GATC Biotech AG 
(Konstanz, Germany).  
 
5.2.10 Generation of DNA constructs 
5.2.10.1 ER stress reporter constructs 
 The luciferase reporter constructs were cloned by subcloning the unfolded 
protein response element (UPRE), the ER stress response element (ERSE), the ER 
stress response element II (ERSEII), the ATF4 binding site of the IGFBP-1 promoter 
(ATF4RE) or the ATF4 binding element of the parkin promoter (Park) into the pGL3 
vector (Promega). The oligonucleotides were synthesized containing the binding site in 
triplicates separated by nine random nucleotides and flanked by NheI and BglII 
restriction sites (oligonucleotides are listed below). The oligonucleotides (100 pmol of 
each) were annealed by boiling for 3 min in TE. After cooling them down they were 
directly inserted by ligation into the digested pGL3 vector. 
 
5.2.10.2 Generation of the renilla luciferase construct 
 To generate the renilla luciferase construct, the SV40 promoter from the pGL3 
vector was subcloned into the phRL-SV40 vector (Promega) by digestion with BglII and 
HindIII, thereby replacing the SV40 early enhancer/promoter. 
 
5.2.10.3 Generation of hP rescue (siRNA resistant parkin) 
 Into human parkin wild type four silent mutations were introduced into the parkin 
siRNA1 (Invitrogen) target sequence (1035-1059 bp). Following base pairs were 
mutated: C 1038 to T, G 1044 to A, C 1053 to A and A 1059 to G. The PCR fragment 
of the hP rescue construct was subcloned into pcDNA3.1/Zeo(+) by using the 
restriction enzymes HindIII and NotI and the primer pairs listed below. 
 
5.2.10.4 Generation of parkin mutants 
 To clone parkin mutants, the cDNA of human wild-type parkin in 
pcDNA3.1/Zeo(+) was used. The pathogenic point mutations C212Y and C289G were 
inserted into the wild-type parkin cDNA using the primer pairs listed below and the 
PCR fragment was ligated via the restriction sites HindIII and NotI into 
pcDNA3.1/Zeo(+). 
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5.2.10.5 Generation of c-Jun constructs 
 The human c-Jun cDNA in the pMT35 vector (Krappmann et al., 1996) was 
subcloned into the pcDNA3.1(-) vector by digestion with BamHI and HindIII (name: c-
Jun His), into the pcDNA3.1(-) vector using the primer pairs Flag c-Jun XhoI F and Flag 
c-Jun HindIII listed below, where the N-terminal primer contains a Flag-Tag, and the 
restriction sites XhoI and HindIII (name: Flag c-Jun) and into the pcDNA3.1(-) vector 
using the primer pairs Kozak c-Jun EcoRI F and Flag c-Jun HindIII R listed below, 
where the N-terminal primer contains a Kozak sequence, and the restriction sites 
EcoRI and HindIII (name: Kozak c-Jun; with experimental help of V. Palmisano). 
 
5.2.10.6 Generation of ATF4 constructs 
 The human ATF4 cDNA (Tanabe et al., 2003) was subcloned into the pCMV-
HA vector using the primer pairs HA ATF4 EcoRI F and HA ATF4 NotI R listed below 
and the restriction sites EcoRI and NotI (name: pCMV HA-ATF4, with experimental 
help of V. Palmisano), into the pcDNA6 V5/His vector using the primer pairs ATF4 V5 
BamHI F and ATF4 V5 XbaI R listed below and the restriction sites BamHI and XbaI 
(name: ATF4 V5/His), into the pcDNA3.1(-) vector using the primer pairs Flag ATF4 
XhoI F and Flag ATF4 HindIII R listed below, where the N-terminal primer contains a 
Flag-Tag, and the restriction sites XhoI and HindIII (name: Flag-ATF4), into the pCMV-
TAG (Flag) vector the primer pairs Flag ATF4 BamHI F and Flag ATF4 HindIII R listed 
below and the restriction sites BamHI and HindIII (name: pCMV-Flag ATF4) and into 
the pcDNA3.1(-) vector using the primer pairs Kozak ATF4 XhoI F and Flag ATF4 
HindIII R listed below, where the N-terminal primer contains a Kozak sequence, and 
the restriction sites XhoI and HindIII (name: Kozak ATF4; with experimental help of V. 
Palmisano). 
 
5.2.11 RNA preparation from cells 
 For analysis of mRNA induction under various stress conditions, SH-SY5Y 
cells, mouse embryonic fibroblasts or mouse/rat neurons were incubated with 1 µM 
thapsigargin, 2 µg/ml tunicamycin, 1 µM rotenone, 50 µM kainic acid, 30 µM MG123 or 
80 µM dopamine for the indicated time. Total cellular RNA was isolated and treated 
with DNaseI according to manufacturer’s instructions (RNaesy mini kit, QIAGEN). 
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5.2.12 RNA preparation from mouse brain 
 To prepare RNA from mouse brain, brains were pesteled in liquid nitrogen and 
total RNA was isolated using the RNaesy lipid tissue kit (QIAGEN) according to 
manufacturer’s instructions. 
 
5.2.13 cDNA synthesis  
 cDNA was synthesized from 1 µg of total RNA using iScript cDNA Synthesis Kit 
(Bio-Rad). 
 
5.2.14 Real-time RT-PCR 
 Each quantitative PCR reaction (final volume 20 µl) included 0.5–2 µl cDNA 
solution, 10 µl PCR Master Mix and 0.5 µl of each primer. For the quantification of 
human parkin or PINK1 mRNA the TaqMan Gene Expression Assay (parkin: 
Hs00247755_m1; PINK1: Hs02330592_s1, β-actin: P/N 4326315E; GAPDH: P/N 
4326317E; 18sRNA: P/N 4319413E) (Applied Biosystems) was used. For all other 
mRNA quantifications, PCR reactions were performed with 2x Power SYBR Green 
PCR Master Mix (Applied Biosystems) and 1 µM of each primer pair (listed below). 
Quantification was performed with 7500 Fast Real Time System (Applied Biosystems) 
based on triplicates per primer set. The mid-linear range was used to establish the 
threshold for each oligonucleotide set. Gene expression was normalized with respect 
to endogenous housekeeping control genes, β-actin, glyceraldehyde phosphate 
dehydrogenase (GAPDH) and 18sRNA, which were determined not to have 
significantly changed under the different conditions. Relative expression was calculated 
for each gene using the ΔΔCT method. 
 
 
5.3 PROTEIN BIOCHEMISTRY  
5.3.1 Lysate preparation 
 For parkin detection cells were lysed in detergent buffer containing 0.1% Triton 
X-100 in PBS supplemented with protease inhibitor cocktail for 5 min on ice, followed 
by centrifugation for 10 min at 13,000 rpm.  
 For detection with phospho-antibodies the cells were lysed using a lysis buffer 
containing phosphatase inhibitors (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerolphosphate, 1 mM sodium orthovanadate, 1 µg/ml leupeptin, phosphatase 
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inhibitor and protease inhibitor) likewise for 5 min on ice. To disturb nuclear envelope 
and DNA cells were sonicated for 5 sec 5 times and cell debris were pelleted by 
centrifugation (16,000 x g, 10 min). The cleared supernatants were transferred to a 
new tube.  
 For detection of ATF4, c-Jun and PERK urea lysis buffer was used to lyse the 
cells (6 M urea, 50 mM HEPES pH 8.0, 0.5% SDS and protease inhibitor cocktail) for 
10 min on ice. To disrupt DNA the cells were needled about ten times on ice.  
 For electrophoretic mobility shift assays the cells were lysed in hypotonic cell 
lysis buffer (20 mM HEPES (pH 7.9), 10 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 0.1% 
Triton-x 100, 20% glycerol, add before use protease inhibitor and 2 mM DTT) to obtain 
cytoplasmic cell extract. To obtain nuclear extracts cell pellets of step one were 
resuspended in hypotonic cell lysis buffer plus 380 mM NaCl. 
 Protein concentration was determined by BCA protein assay (Uptima). 
 
5.3.2 Detergent solubility assay 
 Transfected cells were harvested and lysed in detergent buffer (0,1% Triton X-
100 in PBS). After centrifugation at 16,000x g for 20 min at 4°C, supernatant and pellet 
fraction were separated. The pellet fraction was washed with lysis buffer and 
resuspended in Laemmli sample buffer in a volume equal to the supernatant. To 
compare the relative distribution of the protein of interest, equal amounts of detergent-
soluble and – insoluble fractions were analyzed by Western blot.  
 
5.3.3 SDS-PAGE 
 Proteins were separated by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) (Laemmli, 1970). Samples were boiled for 5 min in the 
presence of 4x SDS-PAGE-loading buffer. Equal amounts of protein were run on 8, 10 
or 12% SDS-PAGE gels, depending on the size of the protein. The electrophoresis was 
made using the minigel system (BIORAD). The gels were run at constant current of 25 
mA per gel. 
 
5.3.4 Western Blot 
 After electrophoresis, proteins were electro-transferred from the SDS-gel onto a 
polyvinylidenfluorid (PVDF) membrane (Millipore) using the minigel system (BIO RAD) 
(Towbin et al., 1979). Membranes were blocked directly in 5% nonfat dry milk or 5% 
BSA in TBS containing 0.1% Tween-20 (TBS-T) for 1 h at room temperature and then 
probed with the primary antibody in TBS-T with 5% milk or 5% BSA for 2 h at RT or 
overnight at 4°C with gentle agitation. After extensive washing with TBS-T, the 
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membranes were incubated with HRP-conjugated secondary antibody. After washing 
again with TBS-T, the antigens were detected with the enhanced chemoluminescence 
detection system (Amersham Biosciences) or the Immobilon Western 
chemoluminiscent HRP substrate (Millipore).  
 
5.3.5 Co-immunoprecipitation 
 HEK293T cells were co-transfected with full-length parkin and FLAG-IKKγ or 
FLAG-TRAF2. The next day, cells were washed twice with cold PBS, scraped off the 
plate, pelleted by centrifugation, and lysed in cold lysis buffer (0.1% Triton X-100 in 
PBS, supplemented with protease inhibitor cocktail). Cell lysates were cleared by 
centrifugation (16,000 x g, 20 min, 4°C), and pre-cleared with immobilized protein A for 
1 h at 4°C. Equal amounts of protein of the detergent-soluble fraction were incubated 
overnight at 4°C with the antibody indicated. The antigen-antibody complexes were 
captured by the addition of protein A agarose for 90 min. Prior to immunoblotting, the 
beads were washed three times with lysis buffer and boiled in 2x Laemmli sample 
buffer in order to release the precipitated proteins.  
 
5.3.6 Ubiquitylation assay 
 Parkin or parkin mutants, HA-tagged ubiquitin or the ubiquitin mutants HA-
K48only-ubiquitin, HA-K63only–ubiquitin and either FLAG-IKKγ, FLAG-TRAF2, FLAG-
TRAF2ΔN or FLAG-TRAF6 were co-transfected into HEK293T cells. One day after 
transfection, protein lysates were prepared in denaturing lysis buffer (50 mM Tris/HCl 
pH 7.4, 5 mM EDTA, 1% SDS, 15 U/ml DNase I, and protease inhibitor cocktail) and 
boiled for 5 min at 95°C. Protein extracts were diluted 1:10 with nondenaturing lysis 
buffer (50 mM Tris/HCl pH 7.4, 300 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 
protease inhibitor cocktail), and immunoprecipitation was performed with FLAG-M2 
agarose (Sigma). Proteins present in the immunoprecipitates were analyzed by 
Western blotting using an anti-HA antibody. 
 
5.3.7 Luciferase assay 
 Luciferase and renilla reporter plasmids (0.3 µg / 6-well) and the indicated DNA 
construct (0.5 - 1µg / 6-well) were cotransfected in HEK293T or SH-SY5Y cells. 8 h or 
24 h later, the cells were treated with 1 µM of thapsigargin or 10 to 20 ng/ml PMA for 8 
h or 14 h. Luciferase activity of cell lysates was determined luminometrically using an 
LB96V luminometer (Berthold Technologies) by the dual luciferase assay system 
(Promega) as specified by the manufacturer. The measured values were analyzed with 
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WinGlow Software (Berthold Technologies). Quantification was based on at least three 
independent experiments. Per experiment, each transfection was performed at least in 
dublicates. 
 
5.3.8 Immunocytochemistry and fluorescence microscopy 
 SH-SY5Y cells were grown on glass coverslips. 24 h after transfection cells 
were fixed and permeabilized in ice cold methanol for 10 min, followed by incubation 
with the primary antibody (diluted 1:200 in PBS, 1% BSA) for 1 h at room temperature. 
After washes with PBS, the coverslips were incubated with fluorescently labelled Alexa 
555-conjugated secondary antibody (diluted 1:200 in PBS, 1% BSA) for 30 min at room 
temperature. Finally, cells were embedded in Mowiol mounting medium (Calbiochem) 
supplemented with 4’, 6-diamidimo-2-phenylindole (DAPI; Sigma) to stain the nuclei. 
Images were obtained on a Zeiss LSM 510 microscope. 
 
5.3.9 Apoptosis and cell viability assays 
Active caspase-3 
 SH-SY5Y cells were grown on glass coverslips. 24 h after transfection (for 
parkin knockdown three days later), cells were incubated with thapsigargin (10 µM), 
tunicamycin (5 µg/ml) and/or epoxomycin (0.1 µM) for 8 h. The cells were then fixed 
with 3% paraformaldehyde (PFA) for 20 min, permeabilized with 0.2% Triton X-100 in 
PBS for 10 min at room temperature and blocked with 1% BSA in PBS for 1 h at room 
temperature. Fixed cells were incubated with anti-active caspase-3 antibody overnight 
at 4°C, washed, and incubated with Alexa 555-conjugated secondary antibody for 1 h 
at room temperature. After extensive washing, cells were mounted onto glass slides 
and examined by fluorescence microscopy using a Zeiss Axioscope 2 plus microscope 
(Carl Zeiss). To detect cells undergoing apoptosis, the number of activated caspase-3-
positive cells out of at least 300 transfected cells was determined. Quantifications were 
based on triplicates of at least three independent experiments.  
 
Vybrant MTT Cell Proliferation Assay  
 For the cell viability test equal numbers of HEK293T cells or mouse embryonic 
fibroblasts were plated into 12-well plates. The HEK293T cells were reversely 
transfected with parkin or control siRNA. 2 days later the cells were stressed with 
tunicamycin (2 µg/ml) or thapsigargin (10 µM) for 16 h and the Vybrant MTT Cell 
Proliferation Assay was performed according to manufacturer’s instructions 
(Invitrogen). 
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5.3.10 Electrophoretic mobility shift assay (EMSA) 
Oligonucleotide annealing 
 Oligonucleotides (1.25 µg of each oligonucleotide) were annealed by boiling for 
10 min in 50 µl 100 mM KCl. 
Preparation of shift probe 
 The DNA probe was 32P end-labeled with γ32P-ATP (50 µCi) by using the T4 
ploynucleotide kinase (Promega). To purify the labeled oligonucleotides the 
ProbeQuant G-50 columns were used, according to the manufacturer’s direction.  
EMSA  
 For the binding reaction 10 µg of extracts or the indicated amount of 
recombinant protein were incubated with binding buffer (10 mM HEPES (pH 7.9), 50 
mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 5% glycerol), 2 mM DTT, 10 µg BSA, 2 µg 
poly(dI-dC) and 0.2 ng (20,000 cpm) of 32P-labeled, double-stranded park 
oligonucleotide (5’-CCC CGG TGA CGT AAG ATT GC-3’), ATF4RE oligonucleotide 
(ATF4 binding site from the IGFBP1 promoter) (5’-AGA TTT ACA TCA TCC CCT G-3’) 
or AP1 oligonucleotide (5’-CGC TTG ATG AGT CAG CCG GAA-3’) in a final volume of 
20 µl. For supershift assays 0.2 µg of the ATF4 antibody or 2 µg of the c-Jun(N)X 
antibody, for competition experiments 50 ng (100 x) of cold oligonucleotide was added 
to the binding reaction. After binding on ice for 30 min, mixtures were loaded onto 
nondenaturating 4% polyacrylamide gels in 0.5 x TBE (45 mM Tris borate and 1 mM 
EDTA). Gels were electrophoresed at 4°C for 4 h at 160V, dried, and exposed for 
autoradiography at -80°C. 
 
5.3.11 Chromatin immunoprecipitation (ChIP) 
 HEK293T cells were seeded at 1.5 x 107 / 150-mm dish with complete medium 
and grown for 24 h. Cells were replenished with fresh medium to ensure that the cells 
were in the basal state, 12 h before transfer to either complete medium or medium 
containing 300 nM thapsigargin. Protein-DNA was cross-linked by adding 
formaldehyde directly to the culture medium to a final concentration of 1% and then 
stopped 10 min later by adding 2 M glycine to a final concentration of 0.125 M. Cross-
linked chromatin was solubilised by sonication using a Sonic Dismembrator (Model 60, 
Fisher Scientific Co) for five bursts of 40 sec at power 10 with 2-min cooling on ice 
between each burst. To monitor ATF4 binding the extracts from 1 x 107 cells was 
incubated with 2 µg of rabbit polyclonal ATF4 antibody (Cocalico Biologicals). A rabbit 
anti-chicken IgG was used as the nonspecific antibody control. The antibody-bound 
complex was precipitated by protein A-Sepharose beads (Amersham Biosciences). 
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cross-linking at 65°C for 5 h and purified using a QIAquick PCR purification kit 
(Qiagen). Purified, immunoprecipitated DNA was analyzed by quantitative real time 
PCR. A 5 µl aliquot of DNA was mixed with 62.5 pmol of each PCR primer (F: 5’-GTT 
GCT AAG CGA CTG GTC AA-3’, R: 5’-CAG CCC CCC ACC GCC GCC-3’) and 12.5 µl 
of SYBR Green PCR master mix (Applied Biosystems) in a 25 µl total volume. The 
real-time PCR was performed with a DNA Engine Opticon 3 system (Bio-Rad). The 
reaction mixtures were incubated at 95°C for 15 min, followed by amplification at 95°C 
for 15 sec and 60°C for 60 sec for 35 cycles. All experiments were performed in 
triplicate and each sample was subjected to PCR in duplicate.  
 
5.3.12 Fluorescent staining of mitochondria  
 SH-SY5Y cells were grown on 15 mm glas coverslips, and were fluorescently 
labeled with 0.1 µM DiOC6(3) in cell culture medium for 15 min, before replacing them 
for 30 min in normal medium. The coverslips with the living cells were analyzed for 
mitochondrial morphology by fluorescence microscopy using a Leica DMRB 
microscope. Cells were categorized in two classes according to their mitochondrial 
morphology: tubular or fragmented. Cells displaying an intact network of tubular 
mitochondria were classified as tubular. When this network was disrupted and 
mitochondria appeared predominantly spherical or rod-like they were classified as 
fragmented. Quantifications were based on three independent experiments. Per 
experiment the mitochondrial morphology of more than 300 transfected cells per 
coverslip of triplicate samples was assessed. 
 
5.3.13 Measurement of cellular ATP levels 
 Cellular steady state ATP levels were measured using the ATP 
Bioluminescence Assay Kit HS II (Roche) according to the manufacturer’s instructions. 
This kit uses the ATP dependency of the light-emitting luciferase catalyzed oxidation of 
luciferin for the measurement of extremely low concentrations of ATP. The quantitative 
determination of ATP was done in SH-SY5Y cells, reversely transfected with parkin or 
control siRNA. 24 hours prior to harvesting cells, the culture medium was replaced 
containing 3 mM glucose, 5 hours before the measurement cells were treated with 2 
µg/ml tunicamycin. Cells were washed twice with PBS, scraped off the plate and lysed 
according to the provided protocol. ATP content of the samples was determined using 
an LB96V luminometer (Berthold technologies), analyzed with WinGlow Software 
(Berthold technologies) and normalized to total protein levels. Quantification was based 
on at least three independent experiments. Per experiment, each transfection was 
performed at least in triplicates. 
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5.3.14 Statistical analysis 
 Data were expressed as means ± SE. Statistical analysis among groups was 
carried out using ANOVA. P-values are as follows: *p < 0.05, **p < 0.01, ***p < 0.001. 
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6 Material 
 
6.1 TECHNICAL DEVICES AND FURTHER EQUIPMENT 
Autoclave (Tuttnauer 3850 EL)  Systec 
Camera (CCD Video Camera Module)  Raiser 
Cell counter chamber, Neubauer Labor Optik 
Cell culture dish (60x15 mm, 100x17 mm, 24 well, 12 
well)  
Nunc 
Cell culture flasks Nunc 
Cell homogenisator 1 ml  B.Braun  
Cell scraper Corning Inc. 
Centrifuge (J-20XP) Rotors: Type JA10 Beckman 
Centrifuge for Eppendorf tubes (Biofuge pico)  Heraeus, Kendro 
Centrifuge for Eppendorf tubes/4°C (Biofuge pico)  Heraeus, Kendro 
Centrifuge/4°C/ swing rotor (Megafuge 1.0R)  Heraeus, Kendro 
Centrifuge/4°C/ swing rotor (Multifuge 3L-R)  Heraeus, Kendro 
Clean bench (Hera Safe HS12)  Heraeus, Kendro 
CO2-Incubator (Hera cell)  Heraeus, Kendro 
Disposable cuvette (10x4x45 mm)  Sarstedt 
Electrophoresis chamber Hoefer SE600 with Power 
Supply EPS 
Pharmacia Biotech 
Electrophoresis chamber: Mini-PROTEAN 3 
electrophoresis cell  
Bio-Rad 
Eppendorf tubes (200 µl, 1,5 ml, 2 ml) Eppendorf 
Falcon tubes (15 ml; 50 ml)  Genaxxon 
Freezer -20°C  Elektrolux/Liebherr 
Freezer -80°C (HFU 86-450)  Heraeus, Kendro 
Fridge +4°C  Elektrolux / Siemens 
Gas burner (Gas profi 1scs)  WLD-Tec 
Gel dryer SGD300 Savant 
Gel running chamber  PeqLab technologies 
Heatblock  Liebisch 
Incubator 37°C (Function line)  Heraeus 
Incubator 56°C  Heraeus 
LB96V luminometer Berthold Technologies 
Luminometer WinGlow Software Berthold Technologies 
Magnet stirler (IKAMAG REO)  IKA Labortechnik 
MicroAmp optical 96-well plate Applied Biosystems 
Microscope (Wilovert S 10x 4/10/20)  Hund 
Microscope cover glasses (∅ 15 mm) Marienfeld 
Microscope Zeiss Axioscope 2 plus  Carl Zeiss  
Microscopic slide (76 x 26 mm) Thermo scientific 
Microwave  Bosch 
Pasteur pipettes  VWR International 
PCR Real Time System 7500 Fast Applied Biosystems 
PCR-machine Master Cycler Eppendorf 
pH-Meter (Inolab pH Level 1)  WTW 
Photometer (SmartSpecTM 3000)  Bio-Rad 
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Pipette tips (2 µl, 20 µl, 200 µl, 1 ml)  Sarstedt 
Pipette tips with sterile filter (2 µl, 20 µl, 200 µl, 1 ml)  Sarstedt 
Pipettes (P2, P20, P200, P1000)  Gilson 
Pipettes sterile (2 ml, 5 ml 10 ml, 25 ml)  Sarstedt 
Pipett-boy (Accu-Jet)  Brand 
Pipetts disposable (2 ml, 5 ml, 10 ml, 25 ml)  Sarstedt 
Power supply (Power Pac 300)  Bio-Rad 
Printer (p91)  Mitsubishi 
Quarz cuvette (10x10x45 mm)  Hellma 
Rotator (Rotator shaker genie 2)  Scientific Industries 
Scale (Analytical +200 g - 0.0001 g)  Ohaus 
Scale (Standard 2000 g - 0.01 g)  Ohaus 
Shaker (KM2)  Edmund Buhler 
Shaker 37°C (Certomat BS-1) B. Braun Biotech International 
Thermomixer 5439 compact Eppendorf 
Tumbler Heidolph 
UV-Lamp (White/Ultraviolet Transilluminator)  UVP 
Vortex apparatus (Vortex Genie 2)  Scientific Industries 
Water bath (Typ 1002; Typ 1003)  GFL 
Water deionizing machine (Milli-Q academic)  Millipore 
 
 
6.2 MATERIAL, SOLUTIONS AND BUFFER FOR CELL CULTURE 
 
6.2.1 Material 
B27 supplement Invitrogen 
DMEM plus pyruvate  Gibco Invitrogen 
DMEM/Ham’s F12  Lonza  
Dulbecco’s Modified Eagle’s Medium (DMEM)  Gibco Invitrogen  
dialysed FCS (Fetal Calf Serum) Gibco Invitrogen 
Fetal Calf Serum (FCS) Gibco Invitrogen  
gentamicin Gibco Invitrogen 
glucose Gibco Invitrogen 
glutamate  Gibco Invitrogen 
glutamine Gibco Invitrogen 
Lipofectamine/Plus  Invitrogen  
Lipofectamine 2000 Invitrogen 
Neurobasal medium Invitrogen 
non-essential amino acids  Gibco Invitrogen  
Opti-MEM Gibco Invitrogen  
PBS (Phosphate buffered saline) Gibco Invitrogen  
Penicillin/Streptomycin (Pen/Strep)  Invitrogen  
Poly-L-lysine hydrobromide (10 mg/ml) Sigma 
RNAiMAX Invitrogen 
Stealth small interfering RNA Invitrogen 
Trypan Blue Invitrogen 
Trypsin-EDTA  Gibco Invitrogen  
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Table 4: List of inhibitors and drugs 
chloroquine Sigma 
dopamine Sigma 
epoxomycin Calbiochem 
glutamate Sigma 
kainic acid  Calbiochem  
L-histidinol Sigma 
MG132  Merck 
PMA Sigma 
rotenone Sigma 
thapsigargin Sigma 
TNFα Biomol 
tunicamycin Fluka/Sigma 
Table 5: Stealth siRNA/control (Invitrogen) 
negative control duplex medium GC-content 
parkin  
duplex 1 PARK2-HSS107593 
duplex 2 PARK2-HSS107594 
duplex 3 PARK2-HSS107595 
c-Jun  
duplex 1 Jun-HSS105640 
duplex 2 Jun-HSS105641 
duplex 3 Jun-HSS105642 
ATF4  
duplex 1 ATF4-HSS141297 
duplex 2 ATF4-HSS141298 
duplex 3 ATF4-HSS141299 
 
6.2.2 Solutions and buffer  
EBSS medium  
6800 mg/l NaCl, 400 mg/l KCl, 264 mg/l CaCl2, 200 mg/l MgCl2, 2200 mg/l NaHCO3 
and 140 mg/l NaH2PO4 pH 7.2,  
 
 
6.3 MATERIAL, SOLUTIONS AND BUFFER FOR NUCLEIC ACID BIOCHEMISTRY 
 
6.3.1 Material 
Agarose  Serva 
DNA preparation kit mini/midi Macherey-Nagel 
dNTPs Sigma 
EndoFree Plasmid Maxi kit Qiagen 
Ethidium Bromide Sigma 
iScript cDNA Synthesis Kit Bio-Rad 
Nucleo spin extract kit Macherey-Nagel 
Pfu-polymerase and 10x buffer Promega 
Power SybrGreen PCR Master Mix (2x) Applied Biosystems 
Pre-stained protein standard: 1kB, 100Bp  NEB 
QIAquick PCR purification kit  Qiagen  
QIAshredder  Qiagen 
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Restriction enzymes and buffers NEB/Fermentas 
RNaesy mini kit Qiagen 
RNase-free DNase set Qiagen 
T4 ligase and buffer Roche 
TaqMan Fast Real-time PCR universal Master Mix 
(2x) 
Applied Biosystems 
TaqMan Gene expression assay Applied Biosystems 
Primer/oligo Thermo Scientific 
Bacteria  
DH5α Genotyp: supE44, Δlac169, 
(Φ80lacZΔM15), hsdR17, 
recA1, gyrA96, thi-1, relA1 
Source: Hanahan, 1983 
Table 6: List of DNA constructs 
name source 
parkin human wild-type (Winklhofer et al., 2003) 
parkin mutant ΔUBL  (Henn et al., 2005) 
parkin mutant G430D (Henn et al., 2005) 
parkin mutant C212Y See Methods 
parkin mutant C289G See Methods 
ATF4 (Tanabe et al., 2003) 
pcMV HA-ATF4 See Methods 
ATF4-V5/His See Methods 
Flag-ATF4 See Methods 
pcMV-Flag-ATF4 See Methods 
Kozak-ATF4 See Methods 
ATF4ΔN (Steinmuller and Thiel, 2003) 
PERK (Harding et al., 1999) 
c-Jun His (pMT35) (Krappmann et al., 1996) 
c-Jun His See Methods 
Flag c-Jun See Methods 
Kosak-c-Jun See Methods 
JNK3 (Waetzig and Herdegen, 2003) 
Bcl-2-Flag (Rambold et al., 2006) 
mCherry (Shaner et al., 2004) 
Parkin siRNA resistant (hP rescue) See Methods 
EYFP Clontech 
cGFP Clontech 
3x UPRE-luc See Methods 
3x ERSE-luc See Methods 
3x ERSEII-luc See Methods 
3x ATF4RE-luc See Methods 
3x Park-luc See Methods 
1x ERSE-luc See Methods 
Renilla See Methods 
pGL3 vector Promega 
Flag-TRAF6 (Rothe et al., 1995) 
Flag-TRAF2 (Krappmann et al., 2000) 
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HA-ubiquitin (Krappmann et al., 1996) 
HA-K63R-ubiquitin, HA-K48R-ubiquitin (Evans et al., 2004) 
PAEL-R (Imai et al., 2001) 
Ret (Wang et al., 2004a) 
Flag-IKKγ (Tegethoff et al., 2003) 
IRE1 (Kaneko et al., 2003) 
NF-κB-luc (Krappmann et al., 2001) 
pcDNA3.1/Zeo(+) Invitrogen 
pcDNA3.1/Zeo(-) Invitrogen 
Flag-TRAF2ΔN (Rothe et al., 1995) 
pCMV-HA Clontech 
phRL-SV40 vector Promega 
Table 7: List of Primers 
name sequence 
1x ERSE F 5’-GAT CCT TCA CCA ATC GGC GGC CTC CAC GAC GGA-3’ 
1x ERSE R 5’-GAT CTC CGT CGT GGA GGC CGC CGA TTG GTG AAG-3’ 
1x ERSEII F 5’-GAT CCG CCG ATT GGG CCA CGT TGG GAG AA-3’ 
1x ERSEII R 5’-GAT CTT CTC CCA ACG TGG CCC AAT CGG CG-3’ 
1x UPRE F 5’-GAT CCG TGC TGA CGT GGC GAT A-3’ 
1x UPRE R 5’-GAT CTA TCG CCA CGT CAG CAC G-3’ 
ATF4RE R 5’-GAT CTC AGG GGA TGA TGT AAA TCT CAG GGG ATG ATG 
TAA ATC TCA GGG GAT GAT GTA AAT CTG CGG GAT CCA TGA 
CCG AAA TGA GC-3’ 
ATFRE F 
 
5’-CTA GCA GAT TTA CAT CAT CCC CTG AGA TTT ACA TCA TCC 
CCT GAG ATT TAC ATC ATC CCC TGA-3’ 
Park-Luc F 5’-CTA GCC CCG GTG ACG TAA GAT TGC CCC GGT GAC GTA 
AGA TTG CCC CGG TGA CGT AAG ATT GCA-3’ 
Park-Luc R 5’-GAT CTG CAA TCT TAC GTC ACC GGG GCA ATC TTA CGT 
CAC CGG GGC AAT CTT ACG TCA CCG GG-3’ 
3x ERSE F 5’-CTA GCT TCA CCA ATC GGC GGC CTC CAC GAC GGT TCA 
CCA ATC GGC GGC CTC CAC GAC GGT TCA CCA ATC GGC GGC 
CTC CAC GAC GGA-3’ 
3x ERSE R 5’-GAT CTC CGT CGT GGA GGC CGC CGA TTG GTG AAC CGT 
CGT GGA GGC CGC CGA TTG GTG AAC CGT CGT GGA GGC 
CGC CGA TTG GTG AAG-3’ 
3x ERSEII F 5’-CTA GCT GCC GAT TGG GCC ACG TTG GGA GAG CCG ATT 
GGG CCA CGT TGG GAG AGC CGA TTG GGC CAC GTT GGG 
AGA A-3’ 
3x ERSEII R 5’-GAT CTC TCC CAA CGT GGC CCA ATC GGC TCT CCC AAC 
GTG GCC CAA TCG GCT CTC CCA ACG TGG CCC AAT CGG 
CAG-3’ 
3x UPRE F 5’-CTA GCT CGT GCT GAC GTG GCG ATC GTG CTG ACG TGG 
CGA TCG TGC TGA CGT GGC GAT A-3’ 
3x UPRE R 5’-GAT CTA TCG CCA CGT CAG CAC GAT CGC CAC GTC AGC 
ACG ATC GCC ACG TCA GCA CGA G-3’ 
ATF4 V5 BamHI F 5’-CGG GAT CCA TGA CCG AAA TGA GC-3’ 
ATF4 V5 XbaI R 5’-CGT CTA GAG GGG ACC CTT TTC TTC C-3’ 
Flag ATF4 BamHI F  5’-GGC GGA TCC ACC GAA ATG AGC TTC-3’ 
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Flag ATF4 HindIII R 5’-CGA TAA GCT TCT AGG GGA CCC TTT CTT-3’ 
Flag ATF4 XhoI F 5’-GAC CTC GAG ATG GAT TAC AAG GAT GAC GAC GAT AAG 
ACC GAA ATG AGC TTC C-3’ 
Kozak ATF4 XhoI F 5’-GAC CTC GAG GCC ACC ATG ACC GAA ATG AGC TTC C-3’ 
HA ATF4 EcoRI F 5’-GGA ATT CGG ACC GAA ATG AGC TTC C-3’ 
HA ATF4 NotI R 5’-TAT TCT TAC GCC GGC GCT AGG GGA CCC-3’ 
Flag c-Jun HindIII R  5’-CGA TAA GCT TTC AGA ATG TTT GCA ACT GCT GCG T-3’ 
Flag c-Jun XhoI F 5’-GAC CTC GAG ATG GAT TAC AAG GAT GAC GAC GAT AAG 
ACT GCA AAG ATG GAA ACG-3’ 
Kozak c-Jun EcoRI F 5’-GGA ATT CGC CAC CAT GAC TGC AAA GAT GGA AAC-3’ 
hP C212Y F 5’-TTT TTC TTT AAA TAT GGA GCA CAC CCC-3’ 
hP C212Y R 5’-GGG GTG TGC TCC ATA TTT AAA GAA AAA-3’ 
hP C289G F 5’-GGC TAC TCC CTG CCT GGT GTG GCT GGC TGT CC-3’ 
hP C289G F 5’-GGA CAG CCA GCC ACA CCA GGC AGG GAG TAG CC-3’ 
hP siRNA resc. F  5’-TGC CGG AGC CTG ATC AGA GAA AAG TCA CAT GCG AGG 
GGG GCA ATG-3’ 
hP siRNA resc. R  5’-CAT TGC CCC CCT CGC ATG TGA CTT TTC TCT GAT CAG GCT 
CCG GCA-3’ 
Table 8: List of EMSA oligonucleotides 
name sequence 
park oligo 5’-CCC CGG TGA CGT AAG ATT GC-3’ 
park mut oligo  5’-CCC CGG TGA GCG CAC ATT GC-3’ 
ATF4RE oligo (IGFBP1) 5’-AGA TTT ACA TCA TCC CCT G-3’ 
NF-κB oligo 5’-AGT TGA GGG TTT CCC AGG C-3’ 
Oct1 oligo 5’-TGT CGS ATG CAA ATC ACT AGA A-3’ 
AP1 oligo 5’-CGC TTG ATG AGT CAG CCG GAA-3’ 
Table 9: List of Real time PCR Primers 
M=mouse; h=human; r=rat; F=forward; R=reverse 
name sequence 
hA20 F 5’-TCC TCC TCT CCT ACC AAG CA-3’ 
hA20 R 5’-CAC GCG ACT TGT GTG TCT TT-3’ 
hactin-β F 5‘-TGG ACT TCG AGC AAG AGA TG-3‘  
hactin-β R 5‘-AGG AAG GAA GGC TGG AAG AG-3‘  
hATF4 F 5’-CCC TTC ACC TTC TTA CAA CCT C-3’  
hATF4 R 5’-GTC TGG CTT CCT ATC TCC TTC A-3’  
hBcl2A1 F 5’-TCT CAG CAC ATT GCC TCA AC-3’ 
hBcl2A1 R 5’-GTC CTG AGC CAG CCT GTA A-3’ 
hBcl2L1 F 5’-CCT CTC CCG ACC TGT GAT A-3’ 
hBcl2L1 R 5’-ACT GAG TCT CGT CTC TGG TTA GTG-3’ 
hBiP F 5’-GCT CGA CTC GAA TTC CAA AG-3’  
hBiP R 5’-GAT CAC CAG AGA GCA CAC CA-3’ 
hc-Jun F 5’-CGC CTG ATA ATC CAG TCC A-3’ 
hc-Jun R 5’-CCT GCT CAT CTG TCA CGT TC-3’ 
hChop F 5’-CCC TTG GTC TTC CTC TCT T-3’ 
hChop R 5’-CCT CTC TGG CTT GGC TGA CT-3’ 
hcox2 F 5’-TCG ATGCTG TGG AGC TGT AT-3’ 
hcox2 R 5’-GCT TCC AGT AGG CAG GAG AA-3’ 
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hDJ-1 F: 5’-CTG GCT AAA GGA GCA GAG GA-3’ 
hDJ-1 R: 5’-ATG ACC ACA TCA CGG CTA CA-3’ 
hDrp1 F 5’-ACA GGC AAC TGG AGA GGA AT-3’ 
hDrp1 R 5’-GCA ACA GGA ACT GGC ACA T-3’ 
hFTHC1 (Ferritin heavy polypeptide) F 5’-TGG AGC TCT ACG CCT CCT AC-3’ 
hFTHC1 R 5’-AGC ATG TTC CCT CTC CTC AT-3’ 
hFTMT (ferritin mitochondrial) F 5’-GAA CAG GAC GAC TGG GAA AG-3’ 
hFTMT R 5’-CCA GCA ACG ACT GGT TCA-3’ 
hGadd45b1 F 5’-ACC CAT GAA CTC CCA GTT TG-3’ 
hGadd45b1 F 5’-CTT CCC ATC TCG CTC TCA GT-3’ 
hGAPDH F 5‘-ATG GGT GTG AAC CAT GAG AA-3‘ 
hGAPDH R 5‘-GTG CTA AGC AGT TGG TGG TG-3‘) 
hHsp72 F 5’-CAA GAT CAC CAT CAC CAA CG-3’ 
hHsp72 R 5’-TCG TCC TCC GCT TTG TAC TT-3’ 
hIRF1 F (interferon regulatory factor 1) 5’-AGC TCA GCT GTG CGA GTG TA-3’ 
hIRF1 R 5’-CCT CTT GGC CTT GCT CTT A-3’ 
hLon P1 F 5’-CCT TAT GTC GGC GTC TTT CT-3’ 
hLon P1 R 5’-CCC CGT GTG GTA GAT TTC AT-3’ 
hLRRK2 F: 5’-CCT TCT TGG CTT GGT CCT T-3’ 
hLRRK2 R: 5’-AGG CTG TTC CTT CTT CCA CA-3’ 
hMIHC F (inhibitor of apoptosis protein 1) 5’-GAG GAG ACA GTC CTA CTG AAA AGC-3’ 
hMIHC R 5’-GGA AAA GTA GGC TGA GAG GTA GC-3’ 
hmot2 / mito. Hsp70 F 5’-GAA GGA CTA TCG CTC CAT GC-3’ 
hmot2 / mito. Hsp70 R 5’-GCC ACC CAC AAG AAT CAC TT-3’ 
hmyc F (v-myc myelocytomatosis viral 
oncogene homolog) 
5’-GAA CAG CTA CGG AAC TCT TGT G-3’ 
hmyc R 5’-AGT CTC AAG ACT CAG CCA AGG T-3’ 
hNAD(P)H F 5’-AAA GGA CCC TTC CGG AGT AA-3’ 
hNAD(P)H R 5’-GTG GAT CCC TTG CAG AGA GT-3’ 
hNFKBIA F 5’-ATG CTC AGG AGC CCT GTA AT-3’ 
hNFKBIA R 5’-GGT GAG CTG GTA GGG AGA ATA G-3’ 
hp53 F 5’-GGA AGA GAA TCT CCG CAA GA-3’ 
hp53 R 5’-GGA GAG GAG CTG GTG TTG TT-3’ 
hPACRG F 5’-AAC AAA TGC CCA GAC AAG ATG-3’ 
hPACRG R 5’-TGT GAA ACC CTC AGA AAC CA-3’ 
hParkin F 5’-CGA CCC TCA ACT TGG CTA CT-3’ 
hParkin R 5’-GAC ACA CTC CTC TGC ACC ATA C-3’ 
hPINK1 F: 5’-CCA ACA GGC TCA CAG AGA AG-3’ 
hPINK1 R: 5’-AGC GTT TCA CAC TCC AGG TT-3’ 
hSOD2 F (superoxide dismutase 2) 5’-AAG GAA CGG GGA CAC TTA CA-3’ 
hSOD2 R 5’-ATC CCC AGC AGT GGA ATA AG-3’ 
hTau F 5’-CCA AAG CCA AGA CAG ACC A-3’ 
hTau R 5’-TGG AGG AGA CAT TGC TGA GA-3’ 
hTH (Thyrosin Hydroxylase) F 5’-GCA GTT CTC GCA GGA CAT T-3’ 
hTH R 5’-CTG CTT ACA CAG CCC GAA-3’ 
hXIAP F 5’-ATG CTC ACC TAA CCC CAA GA-3’ 
hXIAP R 5’-AGG AAA GTG TCG CCT GTG TT-3’ 
hα-syn F: 5’-AAC CAA GGA GGG AGT GGT G-3’  
hα-syn R: 5’-TGT CTT CTG GGC TAC TGC TG-3’  
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LUC F 5’-AAA CGC TGG GCG TTA ATC-3’ 
LUC R 5’-GTC TTC GTC CCA GTA AGC TAT G-3’ 
m/ractin-β R 5’-GGT CTT TAC GGA TGT CAA CG-3’ 
mactin-β F 5’-AGC CTT CCT TCT TGG GTA TG-3’  
mBiP F 5’-GCC TCA TCG GAC GCA CTT-3’ 
mBiP R 5’-GGG GCA AAT GTC TTG GTT-3’  
mGAPDH F 5’-CAT CAA GAA GGT GGT GAA GC-3’ 
mGAPDH R 5’-AGG TGG AAG AGT GGG AGT TG-3’ 
mparkin F 5’-AAA CCG GAT GAG TGG TGA GT-3’ 
mparkin R 5’-AGC TAC CGA CGT GTC CTT GT-3’  
ractin-β F 5’-CTC TCT TCC AGC CTT CCT TC-3’ 
rGAPDH F 5’-ACT CTA CCC ACG GCA AGT TC-3’ 
rGAPDH R 5’-TAC TCA GCA CAG CAT CAC C-3’ 
rparkin F 5’-AGA CAA GCA ACC CTC ACC TT-3’ 
rparkin R 5’-TGG CAC TCT CCA CTC ATC C-3’ 
Table 10: TaqMan gene expression assay (Applied biosystems) 
hparkin Hs00247755_m1  
hPINK1 Hs02330592_s1 
hβ-actin P/N 4326315E 
hGAPDH P/N 4326317E  
h18sRNA P/N 4319413E 
 
6.3.2 Solutions and buffer  
LB-Medium  
1% Tryptone, 0.5% NaCl, 0.5 % yeast extract in dH2O pH 7.0; autoclaved; Ampicillin 
100 µg/ml or Kanamycin 30 µg/ml  
LB-Agar  
1.5% Agar in LB-Medium, autoclaved; Ampicillin 100 µg/ml or Kanamycin 30 µg/ml  
TBE  
9 mM Tris-borate, 2 mM EDTA in dH2O 
Transformation buffer  
50 mM CaCl2, 15% glycerol, 10 mM PIPES pH 6.6 
6x DNA sample buffer 
0.25% (w/v) bromphenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol 
TE 
10 mM Tris-Cl, pH 8,0, 1 mM EDTA, pH 8,0 
 
 
6.4 MATERIAL, SOLUTIONS AND BUFFER FOR PROTEIN BIOCHEMISTRY 
 
6.4.1 Material 
4’,6’-Diamidino-2-phenylindole (DAPI) Sigma 
Amplify  Amersham  
Biomax MR film (autoradiography) Kodak 
Bovine serum Albumine (BSA; 2mg/ml) New England Biolabs 
Complete protease inhibitor (PI) Roche 
Dual luciferase assay system Promega 
ECL Amersham  Amersham  
Goat serum  Sigma-Aldrich  
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Immobilon Western ECL  Millipore  
Mito-tracker green DIOC6(3) Invitrogen 
Mowiol 4-88 Calbiochem 
Na-Deoxycholate  Sigma  
PBS +/+ Mg2+/Ca2+ Invitrogen  
PFA  Sigma  
Protein A Sepharose  Pierce  
PVDF-membrane  Millipore  
recombinant full-length ATF4 Abnova 
recombinant full-length c-Jun Sigma 
See BluePlus2 Invitrogen 
Super RX film (chemiluminescence)  Fuji  
Vybrant MTT cell proliferation Assay kit Molecular Probes 
Whatman paper  Schleicher & Schüll  
Table 11: List of Antibodies 
name source 
PRK8, monoclonal Millipore 
PRK28, monoclonal (Pawlyk et al., 2003) 
Parkin #2132, polyclonal Cell Signaling Technology 
hP1, polyclonal (Winklhofer et al., 2003) 
Actin, monoclonal Sigma 
CREB2 (ATF4) C-20, polyclonal Santa Cruz Biotechnology 
Myc 9E10, monoclonal  Sigma 
TRAF6 H274, polyclonal Santa Cruz Biotechnology 
c-Jun (N) sc45, polyclonal Santa Cruz Biotechnology 
c-Jun (N) sc45X, polyclonal (EMSA) Santa Cruz Biotechnology 
SAPK/JNK, polyclonal Cell Signaling Technology 
p53, monoclonal Calbiochem/Merck 
Ubiquitin P4D1, polyclonal Cell Signaling Technology 
IKKγ (B-3), monoclonal Santa Cruz Biotechnology 
IKKγ (FL-419), polyclonal Santa Cruz Biotechnology 
TRAF2 (C-20), polyclonal Santa Cruz Biotechnology 
TRAF2 (33a1293), monoclonal Santa Cruz Biotechnology 
Phospho-c-Jun (Ser63) II, polyclonal Cell Signaling Technology 
Phospho-c-Jun (Ser73), polyclonal Upstate 
Phospho-JNK (Thr183/Tyr185), polyclonal Cell Signaling Technology 
LC3, monoclonal nanoTools 
GAPDH, monoclonal Ambion 
Active-caspase-3, polyclonal Promega 
Flag M2, monoclonal Sigma 
Alexa 555-conjugated goat anti rabbit Sigma 
Horseradish peroxidase-conjugated anti 
mouse IgG 
Promega 
Horseradish peroxidase-conjugated anti 
rabbit IgG 
Promega 
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6.4.2 Solutions and buffer  
PBS  
3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl pH 7.4  
TBS  
25 mM Tris / HCl, 150 mM NaCl pH 7.2  
TBS-T 
TBS containing 0.1% Tween-20  
Denaturing lysis buffer  
50 mM Tris / HCl pH 7.4, 5 mM EDTA, 1% SDS, 15 U/ml DNAse, protease inhibitor 
cocktail 
Non-denaturing lysis buffer  
50 mM Tris/HCl pH 7.4, 300 mM NaCl, 5 mM EDTA, 1% Triton X-100, protease 
inhibitor cocktail 
Detergent buffer 
0.1% Triton X-100 in PBS, protease inhibitor 
Phosphatase inhibitor lysis buffer 
20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium orthovanadate, 1 
µg/ml leupeptin, 1 mM phenylmethylsulfonylfluorid (PMSF) 
Urea lysis buffer 
6 M urea, 50 mM HEPES pH 8.0, 0.5% SDS and protease inhibitor cocktail 
Laemmli sample buffer 4x 
240 mM Tris / HCl pH 6.8, 4% SDS, 40 % glycerol, 2% bromophenol blue, 4% β-
mercaptho-ethanol 
APS 
10% ammoniumperoxodisulfate in PBS 
Lower Tris Buffer for SDS-PAGE 
0.5 M Tris/HCl pH 6.8, 0.4% SDS  
Upper Tris Buffer for SDS-PAGE 
1.5M Tris/HCl pH 8.8, 0.4% SDS  
Running Buffer for SDS-PAGE 
25 mM Tris/HCl, 190 mM glycine, 0.1% SDS 
Blotting buffer 
25 mM Tris, 20 mM glycine 
Blocking buffer 
5% nonfat dry milk or 5% BSA in TBS-T 
Stripping buffer 
70 mM Tris pH 6.7, 2% SDS add 350 µl β-ME to 50 ml buffer before use 
Hypotonic cell lysis buffer 
20 mM HEPES (pH 7.9), 10 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 0.1% Triton-x 100, 
20% glycerol, add before use protease inhibitor, 2 mM DTT  
EMSA binding buffer 
10 mM HEPES (pH 7.9), 50 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 5% glycerol 
Blocking buffer (caspase assay) 
5% goat serum, 0.1% Tween 20 in PBS 
Mowiol mounting medium 
3.26 M glycerine, 2.72 M mowiol 4-88, 0.12 M Tris pH8.5 in UPW, add 0.5 µl DAPI/ml 
Mowiol before use 
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